PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
19772353-0	2009	The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling.	Niclosamide	20-31	Wnt family member 3A	Homo sapiens	41-44
19772353-0	2009	The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling.	Niclosamide	20-31	frizzled class receptor 1	Homo sapiens	45-54
19772353-5	2009	We now report that the anti-helminthic niclosamide, a drug used for the treatment of tapeworm, promotes Frizzled1 endocytosis, downregulates Dishevelled-2 protein, and inhibits Wnt3A-stimulated beta-catenin stabilization and LEF/TCF reporter activity.	Niclosamide	39-50	frizzled class receptor 1	Homo sapiens	104-113
19772353-5	2009	We now report that the anti-helminthic niclosamide, a drug used for the treatment of tapeworm, promotes Frizzled1 endocytosis, downregulates Dishevelled-2 protein, and inhibits Wnt3A-stimulated beta-catenin stabilization and LEF/TCF reporter activity.	Niclosamide	39-50	Wnt family member 3A	Homo sapiens	177-182
19772353-5	2009	We now report that the anti-helminthic niclosamide, a drug used for the treatment of tapeworm, promotes Frizzled1 endocytosis, downregulates Dishevelled-2 protein, and inhibits Wnt3A-stimulated beta-catenin stabilization and LEF/TCF reporter activity.	Niclosamide	39-50	catenin beta 1	Homo sapiens	194-206
19772353-6	2009	Additionally, following niclosamide-mediated internalization, the Frizzled1 receptor colocalizes in vesicles containing transferrin and agonist-activated beta(2)-adrenergic receptor.	Niclosamide	24-35	frizzled class receptor 1	Homo sapiens	66-75
19772353-6	2009	Additionally, following niclosamide-mediated internalization, the Frizzled1 receptor colocalizes in vesicles containing transferrin and agonist-activated beta(2)-adrenergic receptor.	Niclosamide	24-35	transferrin	Homo sapiens	120-131
19772353-7	2009	Therefore, niclosamide may serve as a negative modulator of Wnt/Frizzled1 signaling by depleting upstream signaling molecules (i.e., Frizzled and Dishevelled) and moreover may provide a valuable means of studying the physiological consequences of Wnt signaling.	Niclosamide	11-22	Wnt family member 3A	Homo sapiens	60-63
19772353-7	2009	Therefore, niclosamide may serve as a negative modulator of Wnt/Frizzled1 signaling by depleting upstream signaling molecules (i.e., Frizzled and Dishevelled) and moreover may provide a valuable means of studying the physiological consequences of Wnt signaling.	Niclosamide	11-22	frizzled class receptor 1	Homo sapiens	64-73
19772353-7	2009	Therefore, niclosamide may serve as a negative modulator of Wnt/Frizzled1 signaling by depleting upstream signaling molecules (i.e., Frizzled and Dishevelled) and moreover may provide a valuable means of studying the physiological consequences of Wnt signaling.	Niclosamide	11-22	Wnt family member 3A	Homo sapiens	247-250
19771169-6	2009	mTORC1 inhibition and autophagosome accumulation induced by perhexiline, niclosamide or rottlerin were rapidly reversed upon drug withdrawal whereas amiodarone inhibited mTORC1 essentially irreversibly.	Niclosamide	73-84	CREB regulated transcription coactivator 1	Mus musculus	0-6
19160421-6	2009	Using this system, we found that the luciferase activity of CBF1-dependent reporter gene was activated by baicalin and baicalein but suppressed by niclosamide in both dose- and time-dependent manners.	Niclosamide	147-158	recombination signal binding protein for immunoglobulin kappa J region	Homo sapiens	60-64
18454287-2	2008	Currently, only one chemical molluscicide, niclosamide, which is used as 50% wettable powder of niclosamide ethanolamine salt (WPN), is commercially available for field snail control in China.	Niclosamide	43-54	snail family transcriptional repressor 1	Homo sapiens	169-174
19160421-0	2009	The autonomous notch signal pathway is activated by baicalin and baicalein but is suppressed by niclosamide in K562 cells.	Niclosamide	96-107	notch receptor 1	Homo sapiens	15-20
33774344-0	2021	Discovery of N-substituted sulfamoylbenzamide derivatives as novel inhibitors of STAT3 signaling pathway based on Niclosamide.	Niclosamide	114-125	signal transducer and activator of transcription 3	Homo sapiens	81-86
15296091-0	2004	Physical transformation of niclosamide solvates in pharmaceutical suspensions determined by DSC and TG analysis.	Niclosamide	27-38	desmocollin 3	Homo sapiens	92-95
15296091-1	2004	This study reports the preparation of four niclosamide solvates and the determination of the stability of the crystal forms in different suspension vehicles by DSC and TG analysis.	Niclosamide	43-54	desmocollin 3	Homo sapiens	160-163
14557374-3	2003	Several potent heteroactivators of CYP2C9-mediated 7-methoxy-4-trifluoromethyl-coumarin metabolism are marketed drugs or endogenous compounds (amiodarone, niclosamide, liothyronine, meclofenemate, zafirlukast, estropipate, and dichlorphenamide, yielding 150% control reaction velocity at 0.04, 0.09, 0.5, 1, 1.2, 1.5, and 2.5 microM, respectively).	Niclosamide	155-166	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	35-41
11124226-5	2001	Niclosamide had substrate-dependent contrasting effects on CYP2C9 activity with an apparent activation (400%) of 7-methoxy-4-trifluoromethylcoumarin demethylase activity and potent inhibition (K(i) = 6.00 microM) of diclofenac 4-hydroxylase activity.	Niclosamide	0-11	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	59-65
11124226-6	2001	Potent inhibitors of CYP1A2 were artemisinin, dihydroartemisinin, thiabendazole, primaquine, and niclosamide (K(i) = 0.43, 3.67, 1.54, 0.22, and 2.70 microM, respectively).	Niclosamide	97-108	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	21-27
2128985-6	1990	Beginning in 1986 niclosamide was applied focally wherever infected snails were found and the monthly snail surveillance continued until 1989.	Niclosamide	18-29	snail family transcriptional repressor 1	Homo sapiens	68-73
33774344-2	2021	Herein, we designed and synthesized a series of N-substituted Sulfamoylbenzamide STAT3 inhibitors based on small-molecule STAT3 inhibitor Niclosamide.	Niclosamide	138-149	signal transducer and activator of transcription 3	Homo sapiens	81-86
33774344-2	2021	Herein, we designed and synthesized a series of N-substituted Sulfamoylbenzamide STAT3 inhibitors based on small-molecule STAT3 inhibitor Niclosamide.	Niclosamide	138-149	signal transducer and activator of transcription 3	Homo sapiens	122-127
34929248-3	2022	Niclosamide is known to have multiple cellular targets including the inhibition of STAT3 and NFkappaB signaling pathways.	Niclosamide	0-11	signal transducer and activator of transcription 3	Homo sapiens	83-88
32795515-3	2020	We hypothesized that niclosamide, a STAT3 inhibitor, would reduce vascular remodeling in an established pulmonary arterial hypertension model, thus enhancing cardiac function.	Niclosamide	21-32	signal transducer and activator of transcription 3	Rattus norvegicus	36-41
34913075-13	2022	Furthermore, niclosamide upregulated protein expression of cleaved caspase-3 and LC3B, while downregulated those of Bcl-2 and p62, in a dose-dependent manner in both Jurkat and CCRF-CEM cells.	Niclosamide	13-24	caspase 3	Homo sapiens	67-76
34913075-13	2022	Furthermore, niclosamide upregulated protein expression of cleaved caspase-3 and LC3B, while downregulated those of Bcl-2 and p62, in a dose-dependent manner in both Jurkat and CCRF-CEM cells.	Niclosamide	13-24	microtubule associated protein 1 light chain 3 beta	Homo sapiens	81-85
34913075-13	2022	Furthermore, niclosamide upregulated protein expression of cleaved caspase-3 and LC3B, while downregulated those of Bcl-2 and p62, in a dose-dependent manner in both Jurkat and CCRF-CEM cells.	Niclosamide	13-24	BCL2 apoptosis regulator	Homo sapiens	116-121
34913075-13	2022	Furthermore, niclosamide upregulated protein expression of cleaved caspase-3 and LC3B, while downregulated those of Bcl-2 and p62, in a dose-dependent manner in both Jurkat and CCRF-CEM cells.	Niclosamide	13-24	nucleoporin 62	Homo sapiens	126-129
34913075-14	2022	The in vivo results showed that niclosamide treatment significantly suppressed tumor growth and the disease progression in T-ALL xenograft mice by activating cleaved caspase-3 and LC3B.	Niclosamide	32-43	caspase 3	Mus musculus	166-175
34913075-14	2022	The in vivo results showed that niclosamide treatment significantly suppressed tumor growth and the disease progression in T-ALL xenograft mice by activating cleaved caspase-3 and LC3B.	Niclosamide	32-43	microtubule-associated protein 1 light chain 3 beta	Mus musculus	180-184
34929248-3	2022	Niclosamide is known to have multiple cellular targets including the inhibition of STAT3 and NFkappaB signaling pathways.	Niclosamide	0-11	nuclear factor kappa B subunit 1	Homo sapiens	93-101
34929248-7	2022	By targeting NFkappaB signaling, we further revealed its role in mediating the anti-HEV action of niclosamide.	Niclosamide	98-109	nuclear factor kappa B subunit 1	Homo sapiens	13-21
34929248-8	2022	These results demonstrated that niclosamide potently inhibits HEV replication by inhibiting NFkappaB signaling but independent of STAT3.	Niclosamide	32-43	nuclear factor kappa B subunit 1	Homo sapiens	92-100
34736968-7	2021	At the concentrations more than 0.1 muM, niclosamide reduced the increased interleukin- 6 (IL-6) mRNA expression in lipopolysaccharide (LPS)-stimulated RAW264.7 and THP-1 derived macrophages.	Niclosamide	41-52	interleukin 6	Mus musculus	75-89
34736968-7	2021	At the concentrations more than 0.1 muM, niclosamide reduced the increased interleukin- 6 (IL-6) mRNA expression in lipopolysaccharide (LPS)-stimulated RAW264.7 and THP-1 derived macrophages.	Niclosamide	41-52	interleukin 6	Mus musculus	91-95
34736968-8	2021	In cultured primary cardiomyocytes and cardiac fibroblasts, niclosamide (more than 0.1 muM) suppressed IL-6- and phenylephrine-induced cardiomyocyte hypertrophy, and inhibited collagen secretion from cardiac fibroblasts.	Niclosamide	60-71	interleukin 6	Mus musculus	103-107
34736968-9	2021	In conclusion, niclosamide attenuates heart failure in mice and the underlying mechanisms include enhancing mitochondrial respiration of cardiomyocytes, inhibiting collagen secretion from cardiac fibroblasts, and reducing the elevated serum inflammatory mediator IL-6.	Niclosamide	15-26	interleukin 6	Mus musculus	263-267
34429248-0	2021	Niclosamide affects intracellular TDP-43 distribution in motor neurons, activates mitophagy, and attenuates morphological changes under stress.	Niclosamide	0-11	TAR DNA binding protein	Homo sapiens	34-40
34736968-5	2021	Oral administration of niclosamide reduced TAC-induced increase of serum IL-6 in heart failure mice.	Niclosamide	23-34	interleukin 6	Mus musculus	73-77
34482191-4	2021	Here in this work, we formulated poly ethylene glycol (PEG) coated bovine serum albumin (BSA) stabilized Niclosamide (NIC) nanoparticles (NPs) (~BSA-NIC-PEG NPs) as an effective injectable formulation.	Niclosamide	105-116	albumin	Homo sapiens	74-87
34482191-4	2021	Here in this work, we formulated poly ethylene glycol (PEG) coated bovine serum albumin (BSA) stabilized Niclosamide (NIC) nanoparticles (NPs) (~BSA-NIC-PEG NPs) as an effective injectable formulation.	Niclosamide	118-121	albumin	Homo sapiens	74-87
34429248-6	2021	Furthermore, niclosamide activated mitophagy via the PINK1-parkin-ubiquitin pathway.	Niclosamide	13-24	PTEN induced kinase 1	Homo sapiens	53-58
34429248-5	2021	STAT3 inhibitors, such as niclosamide, prevented TDP-43 mislocalization and degraded TDP-43 aggregates, and attenuated morphological changes under stress.	Niclosamide	26-37	signal transducer and activator of transcription 3	Homo sapiens	0-5
34429248-5	2021	STAT3 inhibitors, such as niclosamide, prevented TDP-43 mislocalization and degraded TDP-43 aggregates, and attenuated morphological changes under stress.	Niclosamide	26-37	TAR DNA binding protein	Homo sapiens	49-55
34429248-5	2021	STAT3 inhibitors, such as niclosamide, prevented TDP-43 mislocalization and degraded TDP-43 aggregates, and attenuated morphological changes under stress.	Niclosamide	26-37	TAR DNA binding protein	Homo sapiens	85-91
34807278-0	2022	Niclosamide downregulates LOX-1 expression in mouse vascular smooth muscle cells and changes the composition of atherosclerotic plaques in ApoE-/- mice.	Niclosamide	0-11	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	26-31
34807278-0	2022	Niclosamide downregulates LOX-1 expression in mouse vascular smooth muscle cells and changes the composition of atherosclerotic plaques in ApoE-/- mice.	Niclosamide	0-11	apolipoprotein E	Mus musculus	139-143
34807278-4	2022	The expression of the S100A4 protein is upregulated in synthetic VSMCs and inhibited by niclosamide on metastatic progression in colon cancer.	Niclosamide	88-99	S100 calcium binding protein A4	Mus musculus	22-28
34807278-7	2022	Oral administration of niclosamide changed 4-week-old plaques to collagen-rich and less-necrotic core phenotypes and downregulated the expression of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in vivo.	Niclosamide	23-34	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	206-211
34807278-8	2022	In vitro analysis indicated that niclosamide reduced LOX-1 expression in VSMCs in a concentration-dependent and S100A4-independent manner.	Niclosamide	33-44	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	53-58
34807278-8	2022	In vitro analysis indicated that niclosamide reduced LOX-1 expression in VSMCs in a concentration-dependent and S100A4-independent manner.	Niclosamide	33-44	S100 calcium binding protein A4	Mus musculus	112-118
34807278-9	2022	The inhibitory effect of niclosamide on LOX-1 and collagen type I was associated with the inactivation of the nuclear factor-kappaB signaling pathway.	Niclosamide	25-36	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	40-45
34807278-10	2022	We demonstrated that the administration of niclosamide reduced LOX-1 expression and altered the composition of murine carotid plaques.	Niclosamide	43-54	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	63-68
34831024-1	2021	Repurposing Niclosamide for Targeting Pancreatic Cancer by Inhibiting Hh/Gli Non-Canonical Axis of Gsk3beta.	Niclosamide	12-23	GLI family zinc finger 1	Homo sapiens	73-76
34831024-1	2021	Repurposing Niclosamide for Targeting Pancreatic Cancer by Inhibiting Hh/Gli Non-Canonical Axis of Gsk3beta.	Niclosamide	12-23	glycogen synthase kinase 3 alpha	Homo sapiens	99-107
34638761-3	2021	Previously, we reported that niclosamide targets a metabolic vulnerability in p53-deficient tumours, providing a basis for patient stratification and personalised treatment strategies.	Niclosamide	29-40	tumor protein p53	Homo sapiens	78-81
34638761-8	2021	Notably, quantitative scoring of drug sensitivity suggests that elimination of its nitro group enhanced the target selectivity of niclosamide against p53 deficiency.	Niclosamide	130-141	tumor protein p53	Homo sapiens	150-153
34572856-0	2021	Niclosamide and Pyrvinium Are Both Potential Therapeutics for Osteosarcoma, Inhibiting Wnt-Axin2-Snail Cascade.	Niclosamide	0-11	axin 2	Homo sapiens	91-96
34572856-0	2021	Niclosamide and Pyrvinium Are Both Potential Therapeutics for Osteosarcoma, Inhibiting Wnt-Axin2-Snail Cascade.	Niclosamide	0-11	snail family transcriptional repressor 1	Homo sapiens	97-102
34572856-5	2021	In this study, we show that both niclosamide and pyrvinium target Axin2, resulting in the suppression of EMT by the inhibition of the Wnt/Snail axis in osteosarcoma cells.	Niclosamide	33-44	axin 2	Homo sapiens	66-71
34572856-5	2021	In this study, we show that both niclosamide and pyrvinium target Axin2, resulting in the suppression of EMT by the inhibition of the Wnt/Snail axis in osteosarcoma cells.	Niclosamide	33-44	snail family transcriptional repressor 1	Homo sapiens	138-143
34386088-0	2021	Anthelminthic niclosamide inhibits tumor growth and invasion in cisplatin-resistant human epidermal growth factor receptor 2-positive breast cancer.	Niclosamide	14-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-124
34386088-4	2021	However, the specific function and underlying mechanism of action of niclosamide in chemoresistant human epidermal growth factor receptor 2 (HER2)-positive breast cancer remain unknown.	Niclosamide	69-80	erb-b2 receptor tyrosine kinase 2	Homo sapiens	141-145
34386088-5	2021	The present study aimed to determine whether niclosamide can inhibit cell proliferation, invasion and epithelial-to-mesenchymal transition, as well as the stem-like phenotype in cisplatin-resistant HER2-positive breast cancer.	Niclosamide	45-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	198-202
34386088-8	2021	The results from the present study demonstrated that niclosamide inhibited the resistance of HER2-positive breast cancer to cisplatin both in vitro and in vivo.	Niclosamide	53-64	erb-b2 receptor tyrosine kinase 2	Homo sapiens	93-97
34386088-10	2021	The inhibitory effect of niclosamide was mediated by apoptosis induction and Bcl-2 downregulation.	Niclosamide	25-36	BCL2 apoptosis regulator	Homo sapiens	77-82
34386088-11	2021	Taken together, the results of the present study suggested that niclosamide combined with cisplatin may be considered as a novel treatment for chemoresistant HER2-positive breast cancer.	Niclosamide	64-75	erb-b2 receptor tyrosine kinase 2	Homo sapiens	158-162
34166727-6	2021	Molecular signaling data by western blotting also indicated that niclosamide-loaded lithocholic acid tryptophan conjugate nanomicelle interfered with the EphA2 receptor signaling and inhibition of the Wnt/beta-catenin pathway and resulted in the synergistic anticancer activity compared to niclosamide pure drug.	Niclosamide	65-76	EPH receptor A2	Homo sapiens	154-159
34434118-10	2021	Treatment with niclosamide (STAT3 inhibitor) or protein tyrosine phosphatase-1B (PTP1B) overexpression blocked the TRIM18 induced EMT, inflammation and fibrosis.	Niclosamide	15-26	signal transducer and activator of transcription 3	Homo sapiens	28-33
34434118-10	2021	Treatment with niclosamide (STAT3 inhibitor) or protein tyrosine phosphatase-1B (PTP1B) overexpression blocked the TRIM18 induced EMT, inflammation and fibrosis.	Niclosamide	15-26	midline 1	Mus musculus	115-121
34360618-7	2021	In contrast, niclosamide, an inhibitor of TMEM16A, blocked mucus production and mucus secretion in vivo and in vitro.	Niclosamide	13-24	anoctamin 1, calcium activated chloride channel	Mus musculus	42-49
34360618-8	2021	Treatment of airway epithelial cells with niclosamide strongly inhibited expression of the essential transcription factor of Th2-dependent inflammation and goblet cell differentiation, SAM pointed domain-containing ETS-like factor (SPDEF).	Niclosamide	42-53	SAM pointed domain containing ets transcription factor	Mus musculus	185-230
34360618-8	2021	Treatment of airway epithelial cells with niclosamide strongly inhibited expression of the essential transcription factor of Th2-dependent inflammation and goblet cell differentiation, SAM pointed domain-containing ETS-like factor (SPDEF).	Niclosamide	42-53	SAM pointed domain containing ets transcription factor	Mus musculus	232-237
34166727-6	2021	Molecular signaling data by western blotting also indicated that niclosamide-loaded lithocholic acid tryptophan conjugate nanomicelle interfered with the EphA2 receptor signaling and inhibition of the Wnt/beta-catenin pathway and resulted in the synergistic anticancer activity compared to niclosamide pure drug.	Niclosamide	65-76	catenin beta 1	Homo sapiens	205-217
34298652-0	2021	Metformin and Niclosamide Synergistically Suppress Wnt and YAP in APC-Mutated Colorectal Cancer.	Niclosamide	14-25	Yes1 associated transcriptional regulator	Homo sapiens	59-62
34298652-0	2021	Metformin and Niclosamide Synergistically Suppress Wnt and YAP in APC-Mutated Colorectal Cancer.	Niclosamide	14-25	APC regulator of WNT signaling pathway	Homo sapiens	66-69
34300711-0	2021	Bovine Serum Albumin-Coated Niclosamide-Zein Nanoparticles as Potential Injectable Medicine against COVID-19.	Niclosamide	28-39	albumin	Homo sapiens	13-20
34300711-6	2021	(2) Methods: Here we deployed a simple self-assembling technique through which Zein nanoparticles were successfully used to encapsulate NIC, which was then coated with bovine serum albumin (BSA) in order to improve the drugs" stability, injectablity, and selectivity towards the virus-infected cells.	Niclosamide	136-139	albumin	Homo sapiens	175-188
34206370-0	2021	Repurposing Niclosamide for Targeting Pancreatic Cancer by Inhibiting Hh/Gli Non-Canonical Axis of Gsk3beta.	Niclosamide	12-23	GLI family zinc finger 1	Homo sapiens	73-76
34206370-0	2021	Repurposing Niclosamide for Targeting Pancreatic Cancer by Inhibiting Hh/Gli Non-Canonical Axis of Gsk3beta.	Niclosamide	12-23	glycogen synthase kinase 3 alpha	Homo sapiens	99-107
34206370-7	2021	Further, Nic treatment resulted in Gsk3beta inactivation by phosphorylating its Ser-9 residue leading to upregulation of Sufu and Gli3, thereby negatively impacting hedgehog signaling and cell survival.	Niclosamide	9-12	glycogen synthase kinase 3 alpha	Homo sapiens	35-43
34206370-7	2021	Further, Nic treatment resulted in Gsk3beta inactivation by phosphorylating its Ser-9 residue leading to upregulation of Sufu and Gli3, thereby negatively impacting hedgehog signaling and cell survival.	Niclosamide	9-12	SUFU negative regulator of hedgehog signaling	Homo sapiens	121-125
34206370-7	2021	Further, Nic treatment resulted in Gsk3beta inactivation by phosphorylating its Ser-9 residue leading to upregulation of Sufu and Gli3, thereby negatively impacting hedgehog signaling and cell survival.	Niclosamide	9-12	GLI family zinc finger 3	Homo sapiens	130-134
34155207-8	2021	Targeting of autophagic pathways by exogenous administration of the polyamines spermidine and spermine, the selective AKT1 inhibitor MK-2206, and the BECN1-stabilizing anthelmintic drug niclosamide inhibit SARS-CoV-2 propagation in vitro with IC50 values of 136.7, 7.67, 0.11, and 0.13 muM, respectively.	Niclosamide	186-197	beclin 1	Homo sapiens	150-155
34249437-0	2021	Niclosamide exerts anticancer effects through inhibition of the FOXM1-mediated DNA damage response in prostate cancer.	Niclosamide	0-11	forkhead box M1	Homo sapiens	64-69
34249437-4	2021	Niclosamide significantly increased the number of gammaH2AX- and 53BP1-positive cells.	Niclosamide	0-11	BP1	Homo sapiens	67-70
34249437-6	2021	Bioinformatics analysis using TCGA data set revealed that FOXM1 is an important target of niclosamide.	Niclosamide	90-101	forkhead box M1	Homo sapiens	58-63
34249437-9	2021	Taken together, our results suggest that niclosamide exerts anticancer activity through inhibition of the FOXM1-mediated DNA damage response in CRPC.	Niclosamide	41-52	forkhead box M1	Homo sapiens	106-111
34204596-13	2021	Molecules such as galiellalactone or niclosamide have an inhibitory effect on both androgen receptor and STAT-3 pathways.	Niclosamide	37-48	androgen receptor	Homo sapiens	83-100
34118929-0	2021	Targeting S100A4 with niclosamide attenuates inflammatory and profibrotic pathways in models of amyotrophic lateral sclerosis.	Niclosamide	22-33	S100 calcium binding protein A4	Homo sapiens	10-16
34118929-4	2021	METHODS: Here, we employed fibroblasts derived from ALS patients harboring the C9orf72 hexanucleotide repeat expansion and ALS patients with no mutations in known ALS-associated genes and we downregulated S100A4 using siRNA or the S100A4 transcriptional inhibitor niclosamide.	Niclosamide	264-275	S100 calcium binding protein A4	Homo sapiens	205-211
34204596-13	2021	Molecules such as galiellalactone or niclosamide have an inhibitory effect on both androgen receptor and STAT-3 pathways.	Niclosamide	37-48	signal transducer and activator of transcription 3	Homo sapiens	105-111
34118929-4	2021	METHODS: Here, we employed fibroblasts derived from ALS patients harboring the C9orf72 hexanucleotide repeat expansion and ALS patients with no mutations in known ALS-associated genes and we downregulated S100A4 using siRNA or the S100A4 transcriptional inhibitor niclosamide.	Niclosamide	264-275	S100 calcium binding protein A4	Homo sapiens	231-237
34118929-9	2021	CONCLUSION: Our findings show that S100A4 has a role in ALS-related mechanisms, and that drugs such as niclosamide which are able to target inflammatory and fibrotic pathways could represent promising pharmacological tools for ALS.	Niclosamide	103-114	S100 calcium binding protein A4	Mus musculus	35-41
35344901-1	2022	Niclosamide, a widely-used anthelmintic drug, inhibits SARS-CoV-2 virus entry through TMEM16F inhibition and replication through autophagy induction, but the relatively high cytotoxicity and poor oral bioavailability limited its application.	Niclosamide	0-11	anoctamin 6	Homo sapiens	86-93
34107998-15	2021	Specifically, niclosamide ethanolamine salt could reduce the over expression of autophagy-related proteins, including p-AMPK (Thr172), FoxO3a, p-ULK1 (Ser555), LC3B II, and p-p38 in gastrocnemius muscle of the type 1 diabetes mice.	Niclosamide	14-43	forkhead box O3	Mus musculus	135-141
34107998-15	2021	Specifically, niclosamide ethanolamine salt could reduce the over expression of autophagy-related proteins, including p-AMPK (Thr172), FoxO3a, p-ULK1 (Ser555), LC3B II, and p-p38 in gastrocnemius muscle of the type 1 diabetes mice.	Niclosamide	14-43	unc-51 like kinase 1	Mus musculus	145-149
34107998-15	2021	Specifically, niclosamide ethanolamine salt could reduce the over expression of autophagy-related proteins, including p-AMPK (Thr172), FoxO3a, p-ULK1 (Ser555), LC3B II, and p-p38 in gastrocnemius muscle of the type 1 diabetes mice.	Niclosamide	14-43	microtubule-associated protein 1 light chain 3 beta	Mus musculus	160-164
34107998-15	2021	Specifically, niclosamide ethanolamine salt could reduce the over expression of autophagy-related proteins, including p-AMPK (Thr172), FoxO3a, p-ULK1 (Ser555), LC3B II, and p-p38 in gastrocnemius muscle of the type 1 diabetes mice.	Niclosamide	14-43	mitogen-activated protein kinase 14	Mus musculus	175-178
35460941-0	2022	Low doses of niclosamide and quinacrine combination yields synergistic effect in melanoma via activating autophagy-mediated p53-dependent apoptosis.	Niclosamide	13-24	tumor protein p53	Homo sapiens	124-127
35460941-5	2022	The results showed, briefly, an exposure to niclosamide and quinacrine led to an increased apoptosis-related protein p53, cleaved caspase-3 and cleaved PARP and autophagy-related protein LC3B expression, and a decreased expression of autophagy-related protein p62, finally leading to cell apoptosis and autophage.	Niclosamide	44-55	tumor protein p53	Homo sapiens	117-120
35460941-5	2022	The results showed, briefly, an exposure to niclosamide and quinacrine led to an increased apoptosis-related protein p53, cleaved caspase-3 and cleaved PARP and autophagy-related protein LC3B expression, and a decreased expression of autophagy-related protein p62, finally leading to cell apoptosis and autophage.	Niclosamide	44-55	caspase 3	Homo sapiens	130-139
35460941-5	2022	The results showed, briefly, an exposure to niclosamide and quinacrine led to an increased apoptosis-related protein p53, cleaved caspase-3 and cleaved PARP and autophagy-related protein LC3B expression, and a decreased expression of autophagy-related protein p62, finally leading to cell apoptosis and autophage.	Niclosamide	44-55	collagen type XI alpha 2 chain	Homo sapiens	152-156
35460941-5	2022	The results showed, briefly, an exposure to niclosamide and quinacrine led to an increased apoptosis-related protein p53, cleaved caspase-3 and cleaved PARP and autophagy-related protein LC3B expression, and a decreased expression of autophagy-related protein p62, finally leading to cell apoptosis and autophage.	Niclosamide	44-55	microtubule associated protein 1 light chain 3 beta	Homo sapiens	187-191
35460941-5	2022	The results showed, briefly, an exposure to niclosamide and quinacrine led to an increased apoptosis-related protein p53, cleaved caspase-3 and cleaved PARP and autophagy-related protein LC3B expression, and a decreased expression of autophagy-related protein p62, finally leading to cell apoptosis and autophage.	Niclosamide	44-55	nucleoporin 62	Homo sapiens	260-263
35460941-8	2022	To sum up, we developed a new, safe strategy for melanoma treatment by using low doses of niclosamide and quinacrine to treat melanoma; and found a novel mechanism by which the combination application of low doses of niclosamide and quinacrine exerts an efficient anti-melanoma effect through activation of autophagy-mediated p53-dependent apoptosis.	Niclosamide	90-101	tumor protein p53	Homo sapiens	326-329
35460941-8	2022	To sum up, we developed a new, safe strategy for melanoma treatment by using low doses of niclosamide and quinacrine to treat melanoma; and found a novel mechanism by which the combination application of low doses of niclosamide and quinacrine exerts an efficient anti-melanoma effect through activation of autophagy-mediated p53-dependent apoptosis.	Niclosamide	217-228	tumor protein p53	Homo sapiens	326-329
35344901-4	2022	Fluorescence microscopy revealed that compound 5 exhibited better activity in the reduction of phosphatidylserine externalization compared to niclosamide, which was related to TMEM16F inhibition.	Niclosamide	142-153	anoctamin 6	Homo sapiens	176-183
35344901-5	2022	The AI-predicted protein structure of human TMEM16F protein was applied for molecular docking, revealing that 4"-NO2 of 5 formed hydrogen bonding with Arg809, which was blocked by 2"-Cl in the case of niclosamide.	Niclosamide	201-212	anoctamin 6	Homo sapiens	44-51
35548329-9	2022	Additionally, niclosamide suppressed cell proliferation and induced cell death mainly by triggering ER stress and autophagy, whilst CPT induced cell apoptosis mainly through p53-mediated mitochondrial dysfunction and activation of the MAPK (ERK/JNK) pathways.	Niclosamide	14-25	mitogen-activated protein kinase 8	Homo sapiens	245-248
35440080-0	2022	Correction: The anthelmintic drug niclosamide induces GSK-beta-mediated beta-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression.	Niclosamide	34-45	catenin beta 1	Homo sapiens	72-84
35276090-0	2022	Niclosamide induces miR-148a to inhibit PXR and sensitize colon cancer stem cells to chemotherapy.	Niclosamide	0-11	microRNA 148a	Homo sapiens	20-28
35276090-0	2022	Niclosamide induces miR-148a to inhibit PXR and sensitize colon cancer stem cells to chemotherapy.	Niclosamide	0-11	nuclear receptor subfamily 1 group I member 2	Homo sapiens	40-43
35276090-5	2022	We then develop a fluorescent reporter screen for miR-148a activators and identify the anti-helminthic drug niclosamide as an inducer of miR-148a expression.	Niclosamide	108-119	microRNA 148a	Mus musculus	50-58
35276090-5	2022	We then develop a fluorescent reporter screen for miR-148a activators and identify the anti-helminthic drug niclosamide as an inducer of miR-148a expression.	Niclosamide	108-119	microRNA 148a	Mus musculus	137-145
35276090-6	2022	Consequently, niclosamide decreased PXR expression and CSC numbers in colorectal cancer patient-derived cell lines and synergized with chemotherapeutic agents to prevent CSC chemoresistance and tumor recurrence in vivo.	Niclosamide	14-25	nuclear receptor subfamily 1 group I member 2	Homo sapiens	36-39
35453613-0	2022	The PINK1 Activator Niclosamide Mitigates Mitochondrial Dysfunction and Thermal Hypersensitivity in a Paclitaxel-Induced Drosophila Model of Peripheral Neuropathy.	Niclosamide	20-31	PTEN-induced putative kinase 1	Drosophila melanogaster	4-9
35453613-4	2022	In this study, we show that the small-molecule PINK1 activator niclosamide exhibits therapeutic potential for paclitaxel-induced peripheral neuropathy.	Niclosamide	63-74	PTEN-induced putative kinase 1	Drosophila melanogaster	47-52
35453613-5	2022	Specifically, niclosamide cotreatment significantly ameliorated the paclitaxel-induced thermal hyperalgesia phenotype in Drosophila larvae in a PINK1-dependent manner.	Niclosamide	14-25	PTEN-induced putative kinase 1	Drosophila melanogaster	144-149
35453613-8	2022	In addition, niclosamide suppressed paclitaxel-induced mitochondrial dysfunction in human SH-SY5Y cells in a PINK1-dependent manner.	Niclosamide	13-24	PTEN induced kinase 1	Homo sapiens	109-114
35169791-2	2022	Their modulators with therapeutic potential include 1PBC, a potent inhibitor with anti-tumoral properties, and the FDA-approved drug niclosamide that targets TMEM16F to inhibit syncytia formation induced by SARS-CoV-2 infection.	Niclosamide	133-144	anoctamin 6	Homo sapiens	158-165
35169791-3	2022	Here, we report cryo-EM structures of TMEM16F associated with 1PBC and niclosamide, revealing that both molecules bind the same drug binding pocket.	Niclosamide	71-82	anoctamin 6	Homo sapiens	38-45
35115509-0	2022	The anthelmintic drug niclosamide induces GSK-beta-mediated beta-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression.	Niclosamide	22-33	catenin (cadherin associated protein), beta 1	Mus musculus	60-72
35115509-6	2022	Mechanistically, niclosamide exerted these therapeutic effects via targeting beta-catenin.	Niclosamide	17-28	catenin (cadherin associated protein), beta 1	Mus musculus	77-89
35115509-8	2022	Moreover, niclosamide induced beta-catenin phosphorylation and protein degradation.	Niclosamide	10-21	catenin (cadherin associated protein), beta 1	Mus musculus	30-42
35115509-9	2022	Interestingly, niclosamide also induced GSK-3beta phosphorylation, which is involved in the ubiquitination degradation of beta-catenin.	Niclosamide	15-26	glycogen synthase kinase 3 alpha	Mus musculus	40-49
35115509-9	2022	Interestingly, niclosamide also induced GSK-3beta phosphorylation, which is involved in the ubiquitination degradation of beta-catenin.	Niclosamide	15-26	catenin (cadherin associated protein), beta 1	Mus musculus	122-134
35115509-10	2022	Pharmacological activation of beta-catenin by methyl vanillate and beta-catenin overexpression abolished the inhibitory effects of niclosamide.	Niclosamide	131-142	catenin (cadherin associated protein), beta 1	Mus musculus	30-42
35115509-10	2022	Pharmacological activation of beta-catenin by methyl vanillate and beta-catenin overexpression abolished the inhibitory effects of niclosamide.	Niclosamide	131-142	catenin (cadherin associated protein), beta 1	Mus musculus	67-79
35115509-11	2022	Furthermore, niclosamide potentiated the antitumor effect of the chemotherapy drug gemcitabine and reduced the ability of cancer immune evasion by downregulating the expression levels of PD-L1, which is involved in T cell immunity.	Niclosamide	13-24	CD274 antigen	Mus musculus	187-192
35115509-12	2022	Thus, our study indicated that niclosamide induces GSK-beta-mediated beta-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability, and suppress pancreatic cancer progression.	Niclosamide	31-42	catenin (cadherin associated protein), beta 1	Mus musculus	69-81
35159160-0	2022	Niclosamide Ethanolamine Salt Alleviates Idiopathic Pulmonary Fibrosis by Modulating the PI3K-mTORC1 Pathway.	Niclosamide	0-29	CREB regulated transcription coactivator 1	Mus musculus	94-100
35145418-6	2022	We show compounds Niclosamide, Panobinostat, and Candesartan Celexitil increased AQP5 abundance, and show that Niclosamide has favorable cellular toxicity profiles.	Niclosamide	18-29	aquaporin 5	Homo sapiens	81-85
35145418-6	2022	We show compounds Niclosamide, Panobinostat, and Candesartan Celexitil increased AQP5 abundance, and show that Niclosamide has favorable cellular toxicity profiles.	Niclosamide	111-122	aquaporin 5	Homo sapiens	81-85
35145418-7	2022	We determine that AQP5 levels are regulated in part by ubiquitination and proteasomal degradation in lung epithelial cells, and mechanistically Niclosamide increases AQP5 levels by reducing AQP5 ubiquitination and proteasomal degradation.	Niclosamide	144-155	aquaporin 5	Homo sapiens	18-22
35145418-7	2022	We determine that AQP5 levels are regulated in part by ubiquitination and proteasomal degradation in lung epithelial cells, and mechanistically Niclosamide increases AQP5 levels by reducing AQP5 ubiquitination and proteasomal degradation.	Niclosamide	144-155	aquaporin 5	Homo sapiens	166-170
35145418-7	2022	We determine that AQP5 levels are regulated in part by ubiquitination and proteasomal degradation in lung epithelial cells, and mechanistically Niclosamide increases AQP5 levels by reducing AQP5 ubiquitination and proteasomal degradation.	Niclosamide	144-155	aquaporin 5	Homo sapiens	190-194
35145418-8	2022	Functionally, Niclosamide stabilized AQP5 levels in response to hypotonic stress, a stimulus known to reduce AQP5 levels.	Niclosamide	14-25	aquaporin 5	Homo sapiens	37-41
35145418-8	2022	Functionally, Niclosamide stabilized AQP5 levels in response to hypotonic stress, a stimulus known to reduce AQP5 levels.	Niclosamide	14-25	aquaporin 5	Homo sapiens	109-113
35145418-9	2022	In complementary assays, Niclosamide increased endogenous AQP5 in both A549 cells and in primary, polarized human bronchial epithelial cells compared to control-treated cells.	Niclosamide	25-36	aquaporin 5	Homo sapiens	58-62
35145418-11	2022	Niclosamide-treated A549 cell volume changes occurred more rapidly compared to control-treated cells, suggesting that increased Niclosamide-mediated increases in AQP5 expression affects functional water transport.	Niclosamide	0-11	aquaporin 5	Homo sapiens	162-166
35145418-11	2022	Niclosamide-treated A549 cell volume changes occurred more rapidly compared to control-treated cells, suggesting that increased Niclosamide-mediated increases in AQP5 expression affects functional water transport.	Niclosamide	128-139	aquaporin 5	Homo sapiens	162-166
35145418-13	2022	We validated the effects of Niclosamide on endogenous AQP5 levels and in regulating cell-volume changes in response to tonicity changes.	Niclosamide	28-39	aquaporin 5	Homo sapiens	54-58
35008910-0	2022	Niclosamide Suppresses Migration and Invasion of Human Osteosarcoma Cells by Repressing TGFBI Expression via the ERK Signaling Pathway.	Niclosamide	0-11	transforming growth factor beta induced	Homo sapiens	88-93
35127876-7	2021	Niclosamide, an FDA-improved anthelmintic drug, markedly inhibited calcification along with reduced alkaline phosphatase activity and CROT mRNA expression.	Niclosamide	0-11	carnitine O-octanoyltransferase	Homo sapiens	134-138
35127876-10	2021	In addition, niclosamide improved features of fatty liver, including decreased cholesterol levels along with decreased Crot expression, while plasma total cholesterol levels did not change.	Niclosamide	13-24	carnitine O-octanoyltransferase	Homo sapiens	119-123
35127876-11	2021	Proteomic analysis of aortic samples demonstrated that niclosamide affected wingless/integrated (Wnt) signaling pathway and decreased runt-related transcription factor 2 (Runx2) expression, an essential factor for calcification.	Niclosamide	55-66	RUNX family transcription factor 2	Homo sapiens	134-169
35127876-11	2021	Proteomic analysis of aortic samples demonstrated that niclosamide affected wingless/integrated (Wnt) signaling pathway and decreased runt-related transcription factor 2 (Runx2) expression, an essential factor for calcification.	Niclosamide	55-66	RUNX family transcription factor 2	Homo sapiens	171-176
35163010-5	2022	The potential of encapsulated niclosamide to inhibit TMEM16A whole-cell Cl- currents and intracellular Ca2+ signalling was assessed in airway epithelial cells in vitro.	Niclosamide	30-41	anoctamin 1, calcium activated chloride channel	Mus musculus	53-60
35008910-0	2022	Niclosamide Suppresses Migration and Invasion of Human Osteosarcoma Cells by Repressing TGFBI Expression via the ERK Signaling Pathway.	Niclosamide	0-11	mitogen-activated protein kinase 1	Homo sapiens	113-116
35008910-7	2022	The results indicated that niclosamide, at concentrations of up to 200 nM, inhibited the migration and invasion of human osteosarcoma U2OS and HOS cells and repressed the transforming growth factor beta-induced protein (TGFBI) expression of U2OS cells, without cytotoxicity.	Niclosamide	27-38	transforming growth factor beta induced	Homo sapiens	220-225
35008910-9	2022	Moreover, niclosamide significantly decreased the phosphorylation of ERK1/2 in U2OS cells and the combination treatment of the MEK inhibitor (U0126) and niclosamide resulted in the intensive inhibition of the TGFBI expression and the migratory ability in U2OS cells.	Niclosamide	10-21	mitogen-activated protein kinase 3	Homo sapiens	69-75
35008910-9	2022	Moreover, niclosamide significantly decreased the phosphorylation of ERK1/2 in U2OS cells and the combination treatment of the MEK inhibitor (U0126) and niclosamide resulted in the intensive inhibition of the TGFBI expression and the migratory ability in U2OS cells.	Niclosamide	10-21	transforming growth factor beta induced	Homo sapiens	209-214
35008910-9	2022	Moreover, niclosamide significantly decreased the phosphorylation of ERK1/2 in U2OS cells and the combination treatment of the MEK inhibitor (U0126) and niclosamide resulted in the intensive inhibition of the TGFBI expression and the migratory ability in U2OS cells.	Niclosamide	153-164	mitogen-activated protein kinase 3	Homo sapiens	69-75
35008910-9	2022	Moreover, niclosamide significantly decreased the phosphorylation of ERK1/2 in U2OS cells and the combination treatment of the MEK inhibitor (U0126) and niclosamide resulted in the intensive inhibition of the TGFBI expression and the migratory ability in U2OS cells.	Niclosamide	153-164	mitogen-activated protein kinase kinase 7	Homo sapiens	127-130
35008910-9	2022	Moreover, niclosamide significantly decreased the phosphorylation of ERK1/2 in U2OS cells and the combination treatment of the MEK inhibitor (U0126) and niclosamide resulted in the intensive inhibition of the TGFBI expression and the migratory ability in U2OS cells.	Niclosamide	153-164	transforming growth factor beta induced	Homo sapiens	209-214
35008910-10	2022	Therefore, TGFBI derived from osteosarcoma cells via the ERK pathway contributed to cellular migration and invasion and niclosamide inhibited these processes.	Niclosamide	120-131	transforming growth factor beta induced	Homo sapiens	11-16
35008910-10	2022	Therefore, TGFBI derived from osteosarcoma cells via the ERK pathway contributed to cellular migration and invasion and niclosamide inhibited these processes.	Niclosamide	120-131	mitogen-activated protein kinase 1	Homo sapiens	57-60
3704470-5	1986	Bayluscide was applied in two different ways depending on snail distribution within the sites.	Niclosamide	0-10	snail family transcriptional repressor 1	Homo sapiens	58-63
3509190-5	1987	SRB was used in a concentration of 6.25 kg per 1.000 m3 water, to achieve 1.0 ppm Bayluscide concentration according to the producer"s instruction in Massachussett-USA.	Niclosamide	82-92	chaperonin containing TCP1 subunit 4	Homo sapiens	0-3
7386719-3	1980	Treatment with drugs (thiabendazole, niclosamide, niridazole) which are effective in suppressing the infection also prevents the rise, or causes an early decline, in the titers of phospholipase B appearing in the excreta.	Niclosamide	37-48	phospholipase B1	Mus musculus	180-195
33961984-0	2021	The ameliorative effect of niclosamide on bile duct ligation induced liver fibrosis via suppression of NOTCH and Wnt pathways.	Niclosamide	27-38	notch receptor 2	Rattus norvegicus	103-108
33961984-0	2021	The ameliorative effect of niclosamide on bile duct ligation induced liver fibrosis via suppression of NOTCH and Wnt pathways.	Niclosamide	27-38	Wnt family member 5B	Rattus norvegicus	113-116
33961984-3	2021	This study was conducted to investigate the hepatoprotective effect of niclosamide as a NOTCH inhibitor and on the Wnt pathway against cholestatic liver fibrosis (CLF) which was experimentally induced by bile duct ligation (BDL).	Niclosamide	71-82	notch receptor 2	Rattus norvegicus	88-93
33961984-8	2021	niclosamide (5 and 10 mg/kg) significantly reduced liver enzymes levels, oxidative stress, inflammation and phosphorylated signal transducer and activator of transcription3 (p-STAT3).	Niclosamide	0-11	signal transducer and activator of transcription 3	Rattus norvegicus	123-172
33961984-8	2021	niclosamide (5 and 10 mg/kg) significantly reduced liver enzymes levels, oxidative stress, inflammation and phosphorylated signal transducer and activator of transcription3 (p-STAT3).	Niclosamide	0-11	signal transducer and activator of transcription 3	Rattus norvegicus	176-181
33961984-9	2021	Niclosamide (5 and 10 mg/kg) also significantly reduced NOTCH pathway (Jagged1, NOTCH2, NOTCH3, HES1, SOX9), Wnt pathway (Wnt5B, and Wnt10A), and fibrosis (transforming growth factor-beta1 (TGF-beta1), alpha smooth muscle actin (alpha-SMA) and collagen deposition with more prominent effect of the higher dose 10 mg/kg.	Niclosamide	0-11	notch receptor 2	Rattus norvegicus	56-61
33961984-9	2021	Niclosamide (5 and 10 mg/kg) also significantly reduced NOTCH pathway (Jagged1, NOTCH2, NOTCH3, HES1, SOX9), Wnt pathway (Wnt5B, and Wnt10A), and fibrosis (transforming growth factor-beta1 (TGF-beta1), alpha smooth muscle actin (alpha-SMA) and collagen deposition with more prominent effect of the higher dose 10 mg/kg.	Niclosamide	0-11	jagged canonical Notch ligand 1	Rattus norvegicus	71-78
33961984-9	2021	Niclosamide (5 and 10 mg/kg) also significantly reduced NOTCH pathway (Jagged1, NOTCH2, NOTCH3, HES1, SOX9), Wnt pathway (Wnt5B, and Wnt10A), and fibrosis (transforming growth factor-beta1 (TGF-beta1), alpha smooth muscle actin (alpha-SMA) and collagen deposition with more prominent effect of the higher dose 10 mg/kg.	Niclosamide	0-11	notch receptor 2	Rattus norvegicus	80-86
33961984-9	2021	Niclosamide (5 and 10 mg/kg) also significantly reduced NOTCH pathway (Jagged1, NOTCH2, NOTCH3, HES1, SOX9), Wnt pathway (Wnt5B, and Wnt10A), and fibrosis (transforming growth factor-beta1 (TGF-beta1), alpha smooth muscle actin (alpha-SMA) and collagen deposition with more prominent effect of the higher dose 10 mg/kg.	Niclosamide	0-11	notch receptor 3	Rattus norvegicus	88-94
33961984-9	2021	Niclosamide (5 and 10 mg/kg) also significantly reduced NOTCH pathway (Jagged1, NOTCH2, NOTCH3, HES1, SOX9), Wnt pathway (Wnt5B, and Wnt10A), and fibrosis (transforming growth factor-beta1 (TGF-beta1), alpha smooth muscle actin (alpha-SMA) and collagen deposition with more prominent effect of the higher dose 10 mg/kg.	Niclosamide	0-11	hes family bHLH transcription factor 1	Rattus norvegicus	96-100
33961984-9	2021	Niclosamide (5 and 10 mg/kg) also significantly reduced NOTCH pathway (Jagged1, NOTCH2, NOTCH3, HES1, SOX9), Wnt pathway (Wnt5B, and Wnt10A), and fibrosis (transforming growth factor-beta1 (TGF-beta1), alpha smooth muscle actin (alpha-SMA) and collagen deposition with more prominent effect of the higher dose 10 mg/kg.	Niclosamide	0-11	SRY-box transcription factor 9	Rattus norvegicus	102-106
33961984-9	2021	Niclosamide (5 and 10 mg/kg) also significantly reduced NOTCH pathway (Jagged1, NOTCH2, NOTCH3, HES1, SOX9), Wnt pathway (Wnt5B, and Wnt10A), and fibrosis (transforming growth factor-beta1 (TGF-beta1), alpha smooth muscle actin (alpha-SMA) and collagen deposition with more prominent effect of the higher dose 10 mg/kg.	Niclosamide	0-11	Wnt family member 5B	Rattus norvegicus	109-112
33961984-9	2021	Niclosamide (5 and 10 mg/kg) also significantly reduced NOTCH pathway (Jagged1, NOTCH2, NOTCH3, HES1, SOX9), Wnt pathway (Wnt5B, and Wnt10A), and fibrosis (transforming growth factor-beta1 (TGF-beta1), alpha smooth muscle actin (alpha-SMA) and collagen deposition with more prominent effect of the higher dose 10 mg/kg.	Niclosamide	0-11	Wnt family member 5B	Rattus norvegicus	122-127
33961984-9	2021	Niclosamide (5 and 10 mg/kg) also significantly reduced NOTCH pathway (Jagged1, NOTCH2, NOTCH3, HES1, SOX9), Wnt pathway (Wnt5B, and Wnt10A), and fibrosis (transforming growth factor-beta1 (TGF-beta1), alpha smooth muscle actin (alpha-SMA) and collagen deposition with more prominent effect of the higher dose 10 mg/kg.	Niclosamide	0-11	Wnt family member 10A	Rattus norvegicus	133-139
33961984-9	2021	Niclosamide (5 and 10 mg/kg) also significantly reduced NOTCH pathway (Jagged1, NOTCH2, NOTCH3, HES1, SOX9), Wnt pathway (Wnt5B, and Wnt10A), and fibrosis (transforming growth factor-beta1 (TGF-beta1), alpha smooth muscle actin (alpha-SMA) and collagen deposition with more prominent effect of the higher dose 10 mg/kg.	Niclosamide	0-11	transforming growth factor, beta 1	Rattus norvegicus	156-188
33961984-9	2021	Niclosamide (5 and 10 mg/kg) also significantly reduced NOTCH pathway (Jagged1, NOTCH2, NOTCH3, HES1, SOX9), Wnt pathway (Wnt5B, and Wnt10A), and fibrosis (transforming growth factor-beta1 (TGF-beta1), alpha smooth muscle actin (alpha-SMA) and collagen deposition with more prominent effect of the higher dose 10 mg/kg.	Niclosamide	0-11	transforming growth factor, beta 1	Rattus norvegicus	190-199
33961984-9	2021	Niclosamide (5 and 10 mg/kg) also significantly reduced NOTCH pathway (Jagged1, NOTCH2, NOTCH3, HES1, SOX9), Wnt pathway (Wnt5B, and Wnt10A), and fibrosis (transforming growth factor-beta1 (TGF-beta1), alpha smooth muscle actin (alpha-SMA) and collagen deposition with more prominent effect of the higher dose 10 mg/kg.	Niclosamide	0-11	actin gamma 2, smooth muscle	Rattus norvegicus	202-227
34038481-6	2021	Treatment of normal myotubes with niclosamide did not activate mTOR, a major regulator of muscle protein synthesis, and increased the expression of atrogin-1, which is induced in catabolic states.	Niclosamide	34-45	F-box protein 32	Homo sapiens	148-157
33772737-10	2021	Phosphorylation of eNOS and VASP in aortic tissues was significantly reduced in diabetic rats, which were markedly increased by Nic treatment (p < 0.05).	Niclosamide	128-131	nitric oxide synthase 3	Rattus norvegicus	19-23
33772737-10	2021	Phosphorylation of eNOS and VASP in aortic tissues was significantly reduced in diabetic rats, which were markedly increased by Nic treatment (p < 0.05).	Niclosamide	128-131	vasodilator-stimulated phosphoprotein	Rattus norvegicus	28-32
34038481-7	2021	Niclosamide treatment also inhibited myogenesis in muscle precursor cells, enhanced the expression of myoblast markers Pax7 and Myf5, and downregulated the expression of differentiation markers MyoD, MyoG and Myh2.	Niclosamide	0-11	paired box 7	Homo sapiens	119-123
34038481-7	2021	Niclosamide treatment also inhibited myogenesis in muscle precursor cells, enhanced the expression of myoblast markers Pax7 and Myf5, and downregulated the expression of differentiation markers MyoD, MyoG and Myh2.	Niclosamide	0-11	myogenic factor 5	Homo sapiens	128-132
34038481-7	2021	Niclosamide treatment also inhibited myogenesis in muscle precursor cells, enhanced the expression of myoblast markers Pax7 and Myf5, and downregulated the expression of differentiation markers MyoD, MyoG and Myh2.	Niclosamide	0-11	myogenic differentiation 1	Homo sapiens	194-198
34038481-7	2021	Niclosamide treatment also inhibited myogenesis in muscle precursor cells, enhanced the expression of myoblast markers Pax7 and Myf5, and downregulated the expression of differentiation markers MyoD, MyoG and Myh2.	Niclosamide	0-11	myogenin	Homo sapiens	200-204
34038481-7	2021	Niclosamide treatment also inhibited myogenesis in muscle precursor cells, enhanced the expression of myoblast markers Pax7 and Myf5, and downregulated the expression of differentiation markers MyoD, MyoG and Myh2.	Niclosamide	0-11	myosin heavy chain 2	Homo sapiens	209-213
33961950-4	2021	The binding potency of NIC with ERalpha, ERbeta and ERRgamma were determined by fluorescence competitive binding assays, which shows an IC50 (the concentration of NIC needed to displace 50% of the probe from the receptor) of 90 +- 4.1, 10 +- 1.7 nM and 0.59 +- 0.07 nM respectively.	Niclosamide	23-26	estrogen receptor 1	Homo sapiens	32-39
33961950-4	2021	The binding potency of NIC with ERalpha, ERbeta and ERRgamma were determined by fluorescence competitive binding assays, which shows an IC50 (the concentration of NIC needed to displace 50% of the probe from the receptor) of 90 +- 4.1, 10 +- 1.7 nM and 0.59 +- 0.07 nM respectively.	Niclosamide	23-26	estrogen receptor 1	Homo sapiens	41-47
33961950-4	2021	The binding potency of NIC with ERalpha, ERbeta and ERRgamma were determined by fluorescence competitive binding assays, which shows an IC50 (the concentration of NIC needed to displace 50% of the probe from the receptor) of 90 +- 4.1, 10 +- 1.7 nM and 0.59 +- 0.07 nM respectively.	Niclosamide	23-26	estrogen related receptor gamma	Homo sapiens	52-60
33961950-4	2021	The binding potency of NIC with ERalpha, ERbeta and ERRgamma were determined by fluorescence competitive binding assays, which shows an IC50 (the concentration of NIC needed to displace 50% of the probe from the receptor) of 90 +- 4.1, 10 +- 1.7 nM and 0.59 +- 0.07 nM respectively.	Niclosamide	163-166	estrogen receptor 1	Homo sapiens	32-39
33961950-4	2021	The binding potency of NIC with ERalpha, ERbeta and ERRgamma were determined by fluorescence competitive binding assays, which shows an IC50 (the concentration of NIC needed to displace 50% of the probe from the receptor) of 90 +- 4.1, 10 +- 1.7 nM and 0.59 +- 0.07 nM respectively.	Niclosamide	163-166	estrogen receptor 1	Homo sapiens	41-47
33961950-4	2021	The binding potency of NIC with ERalpha, ERbeta and ERRgamma were determined by fluorescence competitive binding assays, which shows an IC50 (the concentration of NIC needed to displace 50% of the probe from the receptor) of 90 +- 4.1, 10 +- 1.7 nM and 0.59 +- 0.07 nM respectively.	Niclosamide	163-166	estrogen related receptor gamma	Homo sapiens	52-60
33860549-8	2021	Niclosamide also inhibits aberrant inflammation in the PF, ELL, pelvic organs (uterus and vagina) and dorsal root ganglion (DRG), as well as MPhi infiltration, vascularization and innervation in the ELL.	Niclosamide	0-11	elongation factor for RNA polymerase II	Homo sapiens	59-62
33860549-8	2021	Niclosamide also inhibits aberrant inflammation in the PF, ELL, pelvic organs (uterus and vagina) and dorsal root ganglion (DRG), as well as MPhi infiltration, vascularization and innervation in the ELL.	Niclosamide	0-11	elongation factor for RNA polymerase II	Homo sapiens	199-202
33860549-9	2021	PF from ELL mice stimulated DRG outgrowth in vitro, whereas the PF from niclosamide-treated ELL mice lacked the strong stimulatory nerve growth response.	Niclosamide	72-83	elongation factor RNA polymerase II	Mus musculus	92-95
33855343-8	2021	Furthermore, FXR1 or IGF2BP2 deficient ovarian cancer cells exhibited reduced response to most doses of niclosamide showing greater cell viability than those with intact RBPs.	Niclosamide	104-115	FMR1 autosomal homolog 1	Homo sapiens	13-17
33855343-8	2021	Furthermore, FXR1 or IGF2BP2 deficient ovarian cancer cells exhibited reduced response to most doses of niclosamide showing greater cell viability than those with intact RBPs.	Niclosamide	104-115	insulin like growth factor 2 mRNA binding protein 2	Homo sapiens	21-28
33855343-9	2021	These results suggest that FXR1 and IGF2BP2 are direct targets of niclosamide and could have critical activities that drive multiple oncogenic pathways in ovarian cancer.	Niclosamide	66-77	FMR1 autosomal homolog 1	Homo sapiens	27-31
33855343-9	2021	These results suggest that FXR1 and IGF2BP2 are direct targets of niclosamide and could have critical activities that drive multiple oncogenic pathways in ovarian cancer.	Niclosamide	66-77	insulin like growth factor 2 mRNA binding protein 2	Homo sapiens	36-43
33827113-8	2021	One of the most effective molecules was Niclosamide, which markedly blunted calcium oscillations and membrane conductances in Spike-expressing cells by suppressing the activity of TMEM16F/Anoctamin6, a calcium-activated ion channel and scramblase responsible for phosphatidylserine exposure on the cell surface.	Niclosamide	40-51	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	126-131
33939112-7	2021	RESULTS: We identified Auranofin, Colchicine, Monensin, Niclosamide, Podophyllotoxin, Quinacrine and Thiostrepton as efficient inhibitors of invasive growth of 2nd line HER2 inhibitor lapatinib resistant breast cancer spheroids and ovarian cancer organoids.	Niclosamide	56-67	erb-b2 receptor tyrosine kinase 2	Homo sapiens	169-173
33476693-8	2021	Although a disruption of the mechanistic target of rapamycin complex 1 (mTORC1) pathway by niclosamide was previously hypothesized as a mechanism against pH-independent viruses like RSV, using a chemical mTORC1 inhibitor, temsirolimus, and a chemical mTORC1 agonist, MHY1485 (MHY), we show here that the mechanism of RSV inhibition by niclosamide was mTORC1 independent.	Niclosamide	91-102	CREB regulated transcription coactivator 1	Mus musculus	72-78
33476693-8	2021	Although a disruption of the mechanistic target of rapamycin complex 1 (mTORC1) pathway by niclosamide was previously hypothesized as a mechanism against pH-independent viruses like RSV, using a chemical mTORC1 inhibitor, temsirolimus, and a chemical mTORC1 agonist, MHY1485 (MHY), we show here that the mechanism of RSV inhibition by niclosamide was mTORC1 independent.	Niclosamide	91-102	CREB regulated transcription coactivator 1	Mus musculus	204-210
33476693-8	2021	Although a disruption of the mechanistic target of rapamycin complex 1 (mTORC1) pathway by niclosamide was previously hypothesized as a mechanism against pH-independent viruses like RSV, using a chemical mTORC1 inhibitor, temsirolimus, and a chemical mTORC1 agonist, MHY1485 (MHY), we show here that the mechanism of RSV inhibition by niclosamide was mTORC1 independent.	Niclosamide	91-102	CREB regulated transcription coactivator 1	Mus musculus	204-210
33476693-8	2021	Although a disruption of the mechanistic target of rapamycin complex 1 (mTORC1) pathway by niclosamide was previously hypothesized as a mechanism against pH-independent viruses like RSV, using a chemical mTORC1 inhibitor, temsirolimus, and a chemical mTORC1 agonist, MHY1485 (MHY), we show here that the mechanism of RSV inhibition by niclosamide was mTORC1 independent.	Niclosamide	91-102	CREB regulated transcription coactivator 1	Mus musculus	204-210
33476693-8	2021	Although a disruption of the mechanistic target of rapamycin complex 1 (mTORC1) pathway by niclosamide was previously hypothesized as a mechanism against pH-independent viruses like RSV, using a chemical mTORC1 inhibitor, temsirolimus, and a chemical mTORC1 agonist, MHY1485 (MHY), we show here that the mechanism of RSV inhibition by niclosamide was mTORC1 independent.	Niclosamide	335-346	CREB regulated transcription coactivator 1	Mus musculus	72-78
33476693-9	2021	Indeed, our data indicated that niclosamide hindered RSV infection via proapoptotic activity by a reduction of AKT prosurvival protein, activation of cleaved caspase-3 and PARP (poly ADP-ribose polymerase), and an early apoptosis induction.	Niclosamide	32-43	AKT serine/threonine kinase 1	Homo sapiens	111-114
33476693-9	2021	Indeed, our data indicated that niclosamide hindered RSV infection via proapoptotic activity by a reduction of AKT prosurvival protein, activation of cleaved caspase-3 and PARP (poly ADP-ribose polymerase), and an early apoptosis induction.	Niclosamide	32-43	caspase 3	Homo sapiens	158-167
33476693-9	2021	Indeed, our data indicated that niclosamide hindered RSV infection via proapoptotic activity by a reduction of AKT prosurvival protein, activation of cleaved caspase-3 and PARP (poly ADP-ribose polymerase), and an early apoptosis induction.	Niclosamide	32-43	poly(ADP-ribose) polymerase 1	Homo sapiens	172-176
33476693-9	2021	Indeed, our data indicated that niclosamide hindered RSV infection via proapoptotic activity by a reduction of AKT prosurvival protein, activation of cleaved caspase-3 and PARP (poly ADP-ribose polymerase), and an early apoptosis induction.	Niclosamide	32-43	poly(ADP-ribose) polymerase 1	Homo sapiens	178-204
33827113-8	2021	One of the most effective molecules was Niclosamide, which markedly blunted calcium oscillations and membrane conductances in Spike-expressing cells by suppressing the activity of TMEM16F/Anoctamin6, a calcium-activated ion channel and scramblase responsible for phosphatidylserine exposure on the cell surface.	Niclosamide	40-51	anoctamin 6	Homo sapiens	180-187
33827113-8	2021	One of the most effective molecules was Niclosamide, which markedly blunted calcium oscillations and membrane conductances in Spike-expressing cells by suppressing the activity of TMEM16F/Anoctamin6, a calcium-activated ion channel and scramblase responsible for phosphatidylserine exposure on the cell surface.	Niclosamide	40-51	anoctamin 6	Homo sapiens	188-198
33713017-0	2021	Quinacrine and Niclosamide Promote Neurite Growth in Midbrain Dopaminergic Neurons Through the Canonical BMP-Smad Pathway and Protect Against Neurotoxin and alpha-Synuclein-Induced Neurodegeneration.	Niclosamide	15-26	bone morphogenetic protein 1	Homo sapiens	105-108
33605496-9	2021	The gene perturbation correlation method showed that niclosamide, an antiparasitic drug, suppressed PDAC growth by inhibition of ASAP2 expression.	Niclosamide	53-64	ArfGAP with SH3 domain, ankyrin repeat and PH domain 2	Homo sapiens	129-134
33605496-11	2021	Furthermore, niclosamide was identified as a repositioned therapeutic agent for PDAC possibly targeting ASAP2.	Niclosamide	13-24	ArfGAP with SH3 domain, ankyrin repeat and PH domain 2	Homo sapiens	104-109
33713017-0	2021	Quinacrine and Niclosamide Promote Neurite Growth in Midbrain Dopaminergic Neurons Through the Canonical BMP-Smad Pathway and Protect Against Neurotoxin and alpha-Synuclein-Induced Neurodegeneration.	Niclosamide	15-26	synuclein alpha	Homo sapiens	157-172
33713017-7	2021	In this study, we investigated the neurotrophic potential of two FDA-approved drugs, quinacrine and niclosamide, that are modulators of BMP2 signalling.	Niclosamide	100-111	bone morphogenetic protein 2	Homo sapiens	136-140
33482272-5	2021	Here, we show that CD44v6-targeted polymeric micelles (PM) loaded with niclosamide (NCS), a drug against CSC, is a good therapeutic strategy against colorectal CSC and circulating tumor cells (CTC) in vivo.	Niclosamide	71-82	CD44 molecule (Indian blood group)	Homo sapiens	19-23
33713017-8	2021	We report that quinacrine and niclosamide, like BMP2, significantly increased neurite length, as a readout of neurotrophic action, in SH-SY5Y cells and dopaminergic neurons in primary cultures of rat ventral mesencephalon.	Niclosamide	30-41	bone morphogenetic protein 2	Homo sapiens	48-52
33713017-9	2021	We also show that these effects of quinacrine and niclosamide require the activation of BMP-Smad signalling.	Niclosamide	50-61	bone morphogenetic protein 1	Homo sapiens	88-91
33713017-10	2021	Finally, we demonstrate that quinacrine and niclosamide are neuroprotective against degeneration induced by the neurotoxins, MPP+ and 6-OHDA, and by viral-mediated overexpression of alpha-synuclein in vitro.	Niclosamide	44-55	synuclein alpha	Homo sapiens	182-197
33482272-5	2021	Here, we show that CD44v6-targeted polymeric micelles (PM) loaded with niclosamide (NCS), a drug against CSC, is a good therapeutic strategy against colorectal CSC and circulating tumor cells (CTC) in vivo.	Niclosamide	84-87	CD44 molecule (Indian blood group)	Homo sapiens	19-23
33571320-0	2021	Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae.	Niclosamide	50-61	lysozyme	Homo sapiens	62-70
33524445-1	2021	Activation of NLRP3 inflammasome is implicated in varieties of pathologies, the aim of the present study is to characterize the effect and mechanism of mitochondrial uncouplers on NLRP3 inflammasome activation by using three types of uncouplers, niclosamide, CCCP and BAM15.	Niclosamide	246-257	NLR family pyrin domain containing 3	Homo sapiens	14-19
33524445-1	2021	Activation of NLRP3 inflammasome is implicated in varieties of pathologies, the aim of the present study is to characterize the effect and mechanism of mitochondrial uncouplers on NLRP3 inflammasome activation by using three types of uncouplers, niclosamide, CCCP and BAM15.	Niclosamide	246-257	NLR family pyrin domain containing 3	Homo sapiens	180-185
33524445-2	2021	Niclosamide, CCCP and BAM15 inhibited LPS plus ATP-induced increases of NLRP3 protein and IL-1beta mRNA levels in RAW264.7 macrophages and THP-1 derived macrophages.	Niclosamide	0-11	NLR family pyrin domain containing 3	Homo sapiens	72-77
33524445-2	2021	Niclosamide, CCCP and BAM15 inhibited LPS plus ATP-induced increases of NLRP3 protein and IL-1beta mRNA levels in RAW264.7 macrophages and THP-1 derived macrophages.	Niclosamide	0-11	interleukin 1 alpha	Homo sapiens	90-98
33524445-2	2021	Niclosamide, CCCP and BAM15 inhibited LPS plus ATP-induced increases of NLRP3 protein and IL-1beta mRNA levels in RAW264.7 macrophages and THP-1 derived macrophages.	Niclosamide	0-11	GLI family zinc finger 2	Homo sapiens	139-144
33524445-3	2021	Niclosamide, CCCP and BAM15 inhibited LPS plus ATP-induced increase of NFkappaB (P65) phosphorylation, and inhibited NFkappaB (P65) nuclear translocation in RAW264.7 macrophages.	Niclosamide	0-11	nuclear factor kappa B subunit 1	Homo sapiens	71-79
33524445-3	2021	Niclosamide, CCCP and BAM15 inhibited LPS plus ATP-induced increase of NFkappaB (P65) phosphorylation, and inhibited NFkappaB (P65) nuclear translocation in RAW264.7 macrophages.	Niclosamide	0-11	nuclear factor kappa B subunit 1	Homo sapiens	117-125
33524445-4	2021	Niclosamide and BAM15 inhibited LPS-induced increase of IkappaBalpha phosphorylation in RAW264.7 macrophages, and the inhibitory effect was dependent on increased intracellular [Ca2+]i; however, CCCP showed no significant effect on IkappaBalpha phosphorylation in RAW264.7 macrophages stimulated with LPS.	Niclosamide	0-11	NFKB inhibitor alpha	Homo sapiens	56-68
33524445-4	2021	Niclosamide and BAM15 inhibited LPS-induced increase of IkappaBalpha phosphorylation in RAW264.7 macrophages, and the inhibitory effect was dependent on increased intracellular [Ca2+]i; however, CCCP showed no significant effect on IkappaBalpha phosphorylation in RAW264.7 macrophages stimulated with LPS.	Niclosamide	0-11	NFKB inhibitor alpha	Homo sapiens	232-244
33524445-5	2021	In conclusion, chemical mitochondrial uncouplers niclosamide, CCCP and BAM15 share common inhibitory effect on NLRP3 inflammasome activation through inhibiting NFkappaB nuclear translocation.	Niclosamide	49-60	NLR family pyrin domain containing 3	Homo sapiens	111-116
33524445-5	2021	In conclusion, chemical mitochondrial uncouplers niclosamide, CCCP and BAM15 share common inhibitory effect on NLRP3 inflammasome activation through inhibiting NFkappaB nuclear translocation.	Niclosamide	49-60	nuclear factor kappa B subunit 1	Homo sapiens	160-168
33671112-0	2021	An Integrated Bioinformatics Study of a Novel Niclosamide Derivative, NSC765689, a Potential GSK3beta/beta-Catenin/STAT3/CD44 Suppressor with Anti-Glioblastoma Properties.	Niclosamide	46-57	glycogen synthase kinase 3 alpha	Homo sapiens	93-101
33671112-0	2021	An Integrated Bioinformatics Study of a Novel Niclosamide Derivative, NSC765689, a Potential GSK3beta/beta-Catenin/STAT3/CD44 Suppressor with Anti-Glioblastoma Properties.	Niclosamide	46-57	catenin beta 1	Homo sapiens	102-114
33671112-0	2021	An Integrated Bioinformatics Study of a Novel Niclosamide Derivative, NSC765689, a Potential GSK3beta/beta-Catenin/STAT3/CD44 Suppressor with Anti-Glioblastoma Properties.	Niclosamide	46-57	signal transducer and activator of transcription 3	Homo sapiens	115-120
33383327-7	2021	Mechanism study unfolded that, similar to niclosamide, 2 inhibited growth of cancer cells via p 53 activation and subsequent underwent cytochrome c dependent apoptosis.	Niclosamide	42-53	tumor protein p53	Homo sapiens	94-98
33383327-7	2021	Mechanism study unfolded that, similar to niclosamide, 2 inhibited growth of cancer cells via p 53 activation and subsequent underwent cytochrome c dependent apoptosis.	Niclosamide	42-53	cytochrome c, somatic	Homo sapiens	135-147
32579788-0	2021	Targeting Wnt/beta-catenin by anthelmintic drug niclosamide overcomes paclitaxel resistance in esophageal cancer.	Niclosamide	48-59	catenin (cadherin associated protein), beta 1	Mus musculus	14-26
32579788-7	2021	Mechanistically, we show that niclosamide decreases beta-catenin level and activity, and inhibits phosphorylation of STAT3 and mTORC1 substrate 70S6K.	Niclosamide	30-41	catenin (cadherin associated protein), beta 1	Mus musculus	52-64
32579788-7	2021	Mechanistically, we show that niclosamide decreases beta-catenin level and activity, and inhibits phosphorylation of STAT3 and mTORC1 substrate 70S6K.	Niclosamide	30-41	signal transducer and activator of transcription 3	Mus musculus	117-122
32579788-7	2021	Mechanistically, we show that niclosamide decreases beta-catenin level and activity, and inhibits phosphorylation of STAT3 and mTORC1 substrate 70S6K.	Niclosamide	30-41	CREB regulated transcription coactivator 1	Mus musculus	127-133
32579788-8	2021	Stabilization of beta-catenin level by Wnt activator lithium chloride (LiCl) significantly abolishes the inhibitory effects of niclosamide in inhibiting proliferation and survival but not suppressing phosphorylation of STAT3 and 70S6K in paclitaxel-resistant esophageal cancer cells, suggesting that niclosamide sensitizes esophageal cancer cell to paclitaxel mainly through inhibiting Wnt/beta-catenin.	Niclosamide	127-138	catenin (cadherin associated protein), beta 1	Mus musculus	17-29
32579788-8	2021	Stabilization of beta-catenin level by Wnt activator lithium chloride (LiCl) significantly abolishes the inhibitory effects of niclosamide in inhibiting proliferation and survival but not suppressing phosphorylation of STAT3 and 70S6K in paclitaxel-resistant esophageal cancer cells, suggesting that niclosamide sensitizes esophageal cancer cell to paclitaxel mainly through inhibiting Wnt/beta-catenin.	Niclosamide	127-138	catenin (cadherin associated protein), beta 1	Mus musculus	390-402
32579788-8	2021	Stabilization of beta-catenin level by Wnt activator lithium chloride (LiCl) significantly abolishes the inhibitory effects of niclosamide in inhibiting proliferation and survival but not suppressing phosphorylation of STAT3 and 70S6K in paclitaxel-resistant esophageal cancer cells, suggesting that niclosamide sensitizes esophageal cancer cell to paclitaxel mainly through inhibiting Wnt/beta-catenin.	Niclosamide	300-311	catenin (cadherin associated protein), beta 1	Mus musculus	17-29
33011217-0	2020	Repurposing of niclosamide as a STAT3 inhibitor to enhance the anticancer effect of chemotherapeutic drugs in treating colorectal cancer.	Niclosamide	15-26	signal transducer and activator of transcription 3	Homo sapiens	32-37
32993962-0	2020	Niclosamide activates the AMP-activated protein kinase complex containing the beta2 subunit independently of AMP.	Niclosamide	0-11	G protein-coupled receptor 162	Mus musculus	78-83
32993962-6	2020	Further, niclosamide shows greater AMPK activation for the AMPK complex containing beta2 subunit, but not the beta1 subunit.	Niclosamide	9-20	G protein-coupled receptor 162	Mus musculus	83-88
32882667-13	2020	RESULTS: The group of niclosamide-and-CCl4-treated rats showed a significant decrease in total bilirubin, ALT and AST, beta-catenin, l-hydroxyproline, l-glutaminase activity, and gene expression of TGF-beta1 and Dvl2.	Niclosamide	22-33	C-C motif chemokine ligand 4	Rattus norvegicus	38-42
32882667-13	2020	RESULTS: The group of niclosamide-and-CCl4-treated rats showed a significant decrease in total bilirubin, ALT and AST, beta-catenin, l-hydroxyproline, l-glutaminase activity, and gene expression of TGF-beta1 and Dvl2.	Niclosamide	22-33	catenin beta 1	Rattus norvegicus	119-131
32882667-13	2020	RESULTS: The group of niclosamide-and-CCl4-treated rats showed a significant decrease in total bilirubin, ALT and AST, beta-catenin, l-hydroxyproline, l-glutaminase activity, and gene expression of TGF-beta1 and Dvl2.	Niclosamide	22-33	glutaminase 2	Rattus norvegicus	151-164
32882667-13	2020	RESULTS: The group of niclosamide-and-CCl4-treated rats showed a significant decrease in total bilirubin, ALT and AST, beta-catenin, l-hydroxyproline, l-glutaminase activity, and gene expression of TGF-beta1 and Dvl2.	Niclosamide	22-33	transforming growth factor, beta 1	Rattus norvegicus	198-207
32882667-13	2020	RESULTS: The group of niclosamide-and-CCl4-treated rats showed a significant decrease in total bilirubin, ALT and AST, beta-catenin, l-hydroxyproline, l-glutaminase activity, and gene expression of TGF-beta1 and Dvl2.	Niclosamide	22-33	segment polarity protein dishevelled homolog DVL-2	Rattus norvegicus	212-216
32882667-16	2020	CONCLUSIONS: Niclosamide protected rats against liver fibrosis by inhibiting the Wnt/beta-catenin pathway and glutaminolysis.	Niclosamide	13-24	catenin beta 1	Rattus norvegicus	85-97
33011217-10	2020	KEY FINDINGS: Niclosamide was found to inhibit expression and activation of STAT3 in a concentration- and time-dependent manner, thereby downregulating STAT3 downstream targets including survivin and cyclin-D1 to induce apoptosis and cell cycle arrest.	Niclosamide	14-25	signal transducer and activator of transcription 3	Homo sapiens	76-81
33011217-10	2020	KEY FINDINGS: Niclosamide was found to inhibit expression and activation of STAT3 in a concentration- and time-dependent manner, thereby downregulating STAT3 downstream targets including survivin and cyclin-D1 to induce apoptosis and cell cycle arrest.	Niclosamide	14-25	signal transducer and activator of transcription 3	Homo sapiens	152-157
33011217-10	2020	KEY FINDINGS: Niclosamide was found to inhibit expression and activation of STAT3 in a concentration- and time-dependent manner, thereby downregulating STAT3 downstream targets including survivin and cyclin-D1 to induce apoptosis and cell cycle arrest.	Niclosamide	14-25	cyclin D1	Homo sapiens	200-209
33002501-10	2020	This study for the first time demonstrates that an anti-helminth drug compound, Niclosamide, is capable of inactivating both phospho-PTM sites on STAT3 and exhibits excellent anticancer efficacy in preclinical TNBC tumour model.	Niclosamide	80-91	signal transducer and activator of transcription 3	Homo sapiens	146-151
32961231-0	2020	Niclosamide-loaded polymeric micelles ameliorate hepatocellular carcinoma in vivo through targeting Wnt and Notch pathways.	Niclosamide	0-11	Wnt family member 3A	Rattus norvegicus	100-103
32961231-0	2020	Niclosamide-loaded polymeric micelles ameliorate hepatocellular carcinoma in vivo through targeting Wnt and Notch pathways.	Niclosamide	0-11	notch receptor 1	Rattus norvegicus	108-113
31846070-5	2020	Extensive in vitro and preclinical research has demonstrated that niclosamide was found to exert potent anticancer and anti-inflammatory properties by targeting STAT3, p65 NF-kappaB, and NFATc-1 signaling paradigm with minimal host toxicity.	Niclosamide	66-77	signal transducer and activator of transcription 3	Mus musculus	161-166
32866370-3	2020	Previously we identified niclosamide as a broad-spectrum inhibitor for flaviviruses by targeting the interface between viral protease NS3 and its cofactor NS2B.	Niclosamide	25-36	KRAS proto-oncogene, GTPase	Homo sapiens	134-137
33042403-0	2020	Niclosamide ethanolamine attenuates systemic lupus erythematosus and lupus nephritis in MRL/lpr mice.	Niclosamide	0-11	Fas (TNF receptor superfamily member 6)	Mus musculus	92-95
33042403-8	2020	NEN treatment also decreased urinary excretion of tubular injury biomarkers NGAL and Kim-1, restored renal tubule phenotypic alterations, inhibited tubular proliferation, and suppressed renal interstitial inflammation and fibrosis.	Niclosamide	0-3	hepatitis A virus cellular receptor 1	Mus musculus	85-90
32859916-6	2020	Knockout of Tmem16a or inhibition of TMEM16A in vivo by the FDA-approved drugs niclosamide and benzbromarone, as well as the TMEM16A-specific inhibitor Ani9 largely reduced cyst enlargement and abnormal cyst cell proliferation.	Niclosamide	79-90	anoctamin 1, calcium activated chloride channel	Mus musculus	12-19
32859916-6	2020	Knockout of Tmem16a or inhibition of TMEM16A in vivo by the FDA-approved drugs niclosamide and benzbromarone, as well as the TMEM16A-specific inhibitor Ani9 largely reduced cyst enlargement and abnormal cyst cell proliferation.	Niclosamide	79-90	anoctamin 1, calcium activated chloride channel	Mus musculus	37-44
32602250-0	2020	Niclosamide and its derivative DK-520 inhibit RANKL-induced osteoclastogenesis.	Niclosamide	0-11	TNF superfamily member 11	Homo sapiens	46-51
32602250-5	2020	Treatment with either Niclosamide or DK-520 did not affect the viability of osteoclast precursors (OCPs), but significantly inhibited RANKL-induced trans-differentiation of macrophages into OCPs, particularly in the early stage of osteoclastogenesis.	Niclosamide	22-33	TNF superfamily member 11	Homo sapiens	134-139
32602250-6	2020	Both Niclosamide and DK-520 significantly decreased the relative levels of transcription factor PU.1 mRNA transcripts and dendritic cell specific transmembrane protein (DC-STAMP), but not v-ATPasev0 d2 protein expression in OCPs.	Niclosamide	5-16	Spi-1 proto-oncogene	Homo sapiens	96-100
32602250-6	2020	Both Niclosamide and DK-520 significantly decreased the relative levels of transcription factor PU.1 mRNA transcripts and dendritic cell specific transmembrane protein (DC-STAMP), but not v-ATPasev0 d2 protein expression in OCPs.	Niclosamide	5-16	dendrocyte expressed seven transmembrane protein	Homo sapiens	122-167
32602250-6	2020	Both Niclosamide and DK-520 significantly decreased the relative levels of transcription factor PU.1 mRNA transcripts and dendritic cell specific transmembrane protein (DC-STAMP), but not v-ATPasev0 d2 protein expression in OCPs.	Niclosamide	5-16	dendrocyte expressed seven transmembrane protein	Homo sapiens	169-177
32774727-0	2020	Niclosamide: drug repurposing for human chondrosarcoma treatment via the caspase-dependent mitochondrial apoptotic pathway.	Niclosamide	0-11	caspase 9	Homo sapiens	73-80
32774727-11	2020	Niclosamide is as a potent chondrosarcoma tumor inhibitor that activates the caspase-dependent mitochondrial apoptotic pathway and could be a novel therapeutic approach to treat chondrosarcoma.	Niclosamide	0-11	caspase 9	Homo sapiens	77-84
32529067-0	2020	Inhibition of human immunodeficiency virus type 1 by niclosamide through mTORC1 inhibition.	Niclosamide	53-64	CREB regulated transcription coactivator 1	Mus musculus	73-79
32529067-8	2020	In addition, niclosamide was found to downregulate mTORC1 via AMPK activation, resulting in a decreased phosphorylation of the downstream substrates of S6K and 4EBP1.	Niclosamide	13-24	CREB regulated transcription coactivator 1	Mus musculus	51-57
32529067-8	2020	In addition, niclosamide was found to downregulate mTORC1 via AMPK activation, resulting in a decreased phosphorylation of the downstream substrates of S6K and 4EBP1.	Niclosamide	13-24	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	62-66
32529067-9	2020	Niclosamide could also reduce the synthesis of HIV-1 p24 protein.	Niclosamide	0-11	transmembrane p24 trafficking protein 2	Homo sapiens	53-56
32529067-10	2020	Likewise, MHY-1485 could partially reverse the inhibitory effect of niclosamide by increasing the phosphorylation in the mTORC1 pathway and HIV-1 viral protein synthesis.	Niclosamide	68-79	CREB regulated transcription coactivator 1	Mus musculus	121-127
32529067-11	2020	Our findings, therefore, demonstrated the antiviral mechanism of niclosamide is via the AMPK-mTORC1 pathway, which could be a common therapeutic target for various viruses.	Niclosamide	65-76	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	88-92
32529067-11	2020	Our findings, therefore, demonstrated the antiviral mechanism of niclosamide is via the AMPK-mTORC1 pathway, which could be a common therapeutic target for various viruses.	Niclosamide	65-76	CREB regulated transcription coactivator 1	Mus musculus	93-99
31846070-5	2020	Extensive in vitro and preclinical research has demonstrated that niclosamide was found to exert potent anticancer and anti-inflammatory properties by targeting STAT3, p65 NF-kappaB, and NFATc-1 signaling paradigm with minimal host toxicity.	Niclosamide	66-77	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	168-171
31846070-5	2020	Extensive in vitro and preclinical research has demonstrated that niclosamide was found to exert potent anticancer and anti-inflammatory properties by targeting STAT3, p65 NF-kappaB, and NFATc-1 signaling paradigm with minimal host toxicity.	Niclosamide	66-77	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	187-194
31846070-10	2020	Additionally, our results provided a preclinical rationale in imiquimod (IMQ)-induced BALB/c mouse model, where niclosamide diligently mitigated the IMQ-induced epidermal hyperplasia and inflammation by downregulating STAT3, p65 NF-kappaB, and NFATc-1 transcription factors along with Akt, Ki-67, and ICAM-1 protein expression.	Niclosamide	112-123	signal transducer and activator of transcription 3	Mus musculus	218-223
31846070-10	2020	Additionally, our results provided a preclinical rationale in imiquimod (IMQ)-induced BALB/c mouse model, where niclosamide diligently mitigated the IMQ-induced epidermal hyperplasia and inflammation by downregulating STAT3, p65 NF-kappaB, and NFATc-1 transcription factors along with Akt, Ki-67, and ICAM-1 protein expression.	Niclosamide	112-123	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	225-228
31846070-10	2020	Additionally, our results provided a preclinical rationale in imiquimod (IMQ)-induced BALB/c mouse model, where niclosamide diligently mitigated the IMQ-induced epidermal hyperplasia and inflammation by downregulating STAT3, p65 NF-kappaB, and NFATc-1 transcription factors along with Akt, Ki-67, and ICAM-1 protein expression.	Niclosamide	112-123	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	244-251
31846070-10	2020	Additionally, our results provided a preclinical rationale in imiquimod (IMQ)-induced BALB/c mouse model, where niclosamide diligently mitigated the IMQ-induced epidermal hyperplasia and inflammation by downregulating STAT3, p65 NF-kappaB, and NFATc-1 transcription factors along with Akt, Ki-67, and ICAM-1 protein expression.	Niclosamide	112-123	thymoma viral proto-oncogene 1	Mus musculus	285-288
31846070-10	2020	Additionally, our results provided a preclinical rationale in imiquimod (IMQ)-induced BALB/c mouse model, where niclosamide diligently mitigated the IMQ-induced epidermal hyperplasia and inflammation by downregulating STAT3, p65 NF-kappaB, and NFATc-1 transcription factors along with Akt, Ki-67, and ICAM-1 protein expression.	Niclosamide	112-123	antigen identified by monoclonal antibody Ki 67	Mus musculus	290-295
31846070-10	2020	Additionally, our results provided a preclinical rationale in imiquimod (IMQ)-induced BALB/c mouse model, where niclosamide diligently mitigated the IMQ-induced epidermal hyperplasia and inflammation by downregulating STAT3, p65 NF-kappaB, and NFATc-1 transcription factors along with Akt, Ki-67, and ICAM-1 protein expression.	Niclosamide	112-123	intercellular adhesion molecule 1	Mus musculus	301-307
32380794-8	2020	siRNA-knockout of CK2 and its pharmacological inhibition, as well as knockdown or inhibition of TMEM16A by either niclosamide or Ani9, attenuated cell proliferation.	Niclosamide	114-125	anoctamin 1	Homo sapiens	96-103
32380794-11	2020	Simultaneous inhibition of TMEM16A by niclosamide and inhibition of CK2 by silmitasertib was additive with respect to blocking cell proliferation, while cytotoxicity was reduced when compared to solely blockade of CK2.	Niclosamide	38-49	anoctamin 1	Homo sapiens	27-34
32380794-12	2020	Therefore, parallel blockade TMEM16A by niclosamide may assist with anticancer therapy by silmitasertib.	Niclosamide	40-51	anoctamin 1	Homo sapiens	29-36
32132037-7	2020	AMPK/AKT/mTOR pathway were involved in niclosamide-induced cell death and autophagy in response to ATP depletion.	Niclosamide	39-50	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	0-4
31950153-4	2020	We have reported that niclosamide reduces growth and progression of endometriosis-like lesions via targeting STAT3 and NFkB signaling in a mouse model of endometriosis.	Niclosamide	22-33	signal transducer and activator of transcription 3	Mus musculus	109-114
31950153-8	2020	Niclosamide dose-dependently reduced cell viability and the activity of STAT3 and NFkappaB signaling in hESCs.	Niclosamide	0-11	signal transducer and activator of transcription 3	Homo sapiens	72-77
31950153-8	2020	Niclosamide dose-dependently reduced cell viability and the activity of STAT3 and NFkappaB signaling in hESCs.	Niclosamide	0-11	nuclear factor kappa B subunit 1	Homo sapiens	82-90
31950153-12	2020	These results indicate that niclosamide is able to reduce macrophage-induced cell viability and cytokine/chemokine secretion in hESCs by inhibiting inflammatory mechanisms via STAT3 and/or NFkappaB signaling.	Niclosamide	28-39	signal transducer and activator of transcription 3	Homo sapiens	176-181
31950153-12	2020	These results indicate that niclosamide is able to reduce macrophage-induced cell viability and cytokine/chemokine secretion in hESCs by inhibiting inflammatory mechanisms via STAT3 and/or NFkappaB signaling.	Niclosamide	28-39	nuclear factor kappa B subunit 1	Homo sapiens	189-197
32272686-7	2020	The three well-known blockers benzbromarone, niclosamide, and Ani9 inhibited both TMEM16A and ATP-induced Ca2+ increase by variable degrees, depending on the cell type.	Niclosamide	45-56	anoctamin 1	Homo sapiens	82-89
32272686-8	2020	Niclosamide, while blocking Ca2+ activated TMEM16A, also induced a subtle but significant Ca2+ store release and inhibited store-operated Ca2+ influx.	Niclosamide	0-11	anoctamin 1	Homo sapiens	43-50
32272686-9	2020	Niclosamide, benzbromarone and Ani9 also affected TMEM16F whole cell currents, indicating limited specificity for these inhibitors.	Niclosamide	0-11	anoctamin 6	Homo sapiens	50-57
32132037-7	2020	AMPK/AKT/mTOR pathway were involved in niclosamide-induced cell death and autophagy in response to ATP depletion.	Niclosamide	39-50	AKT serine/threonine kinase 1	Homo sapiens	5-8
32132037-7	2020	AMPK/AKT/mTOR pathway were involved in niclosamide-induced cell death and autophagy in response to ATP depletion.	Niclosamide	39-50	mechanistic target of rapamycin kinase	Homo sapiens	9-13
33464864-13	2020	The potentiation of cell death due to dual effects of hyperthermia and niclosamide was further confirmed by Annexin-V/propidium iodide assay using flow cytometry.	Niclosamide	71-82	annexin A5	Homo sapiens	108-117
31894334-1	2020	Niclosamide is an FDA-approved anthelmintic drug, and may elicit antineoplastic effects through direct STAT3 inhibition, which has been revealed in numerous human cancer cells.	Niclosamide	0-11	signal transducer and activator of transcription 3	Homo sapiens	103-108
31894334-4	2020	Through western blot assay, it was demonstrated that niclosamide suppressed the STAT3 signaling pathway in esophageal adenocarcinoma cells (BE3) and esophageal squamous cell carcinoma cells (CE48T and CE81T).	Niclosamide	53-64	signal transducer and activator of transcription 3	Homo sapiens	80-85
31894334-5	2020	In addition, niclosamide inhibited cell proliferation as determined by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)- 2-(4-sulfophenyl)--2H-tetrazolium)-5-(3-carboxymethoxyphenyl)- 2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay and soft agar colony forming assay, and induced cell apoptosis as determined by Annexin V and PI staining.	Niclosamide	13-24	annexin A5	Homo sapiens	316-325
31894334-6	2020	The induction of p21 and G1 arrest of the cell cycle also was revealed in niclosamide-treated CE81T cells by qPCR and flow cytometric assays, respectively.	Niclosamide	74-85	H3 histone pseudogene 16	Homo sapiens	17-20
31433913-2	2020	Recent studies show that niclosamide exerts antitumor activity through inhibiting multiple signals including Wnt/beta-catenin, mTORC1, signal transducer and activator of transcription 3, NF-kappaB, notch signals; however, the insolubility and poor bioavailability limits its potential clinic use, the aim of the present work is to synthesize an injectable pegylated niclosamide (polyethylene glycol-modified niclosamide) and investigate its antitumor activity in vitro and in vivo.	Niclosamide	25-36	catenin (cadherin associated protein), beta 1	Mus musculus	113-125
31433913-2	2020	Recent studies show that niclosamide exerts antitumor activity through inhibiting multiple signals including Wnt/beta-catenin, mTORC1, signal transducer and activator of transcription 3, NF-kappaB, notch signals; however, the insolubility and poor bioavailability limits its potential clinic use, the aim of the present work is to synthesize an injectable pegylated niclosamide (polyethylene glycol-modified niclosamide) and investigate its antitumor activity in vitro and in vivo.	Niclosamide	25-36	CREB regulated transcription coactivator 1	Mus musculus	127-133
31433913-2	2020	Recent studies show that niclosamide exerts antitumor activity through inhibiting multiple signals including Wnt/beta-catenin, mTORC1, signal transducer and activator of transcription 3, NF-kappaB, notch signals; however, the insolubility and poor bioavailability limits its potential clinic use, the aim of the present work is to synthesize an injectable pegylated niclosamide (polyethylene glycol-modified niclosamide) and investigate its antitumor activity in vitro and in vivo.	Niclosamide	25-36	signal transducer and activator of transcription 3	Mus musculus	135-185
31465777-0	2019	Repurposing of the anti-helminthic drug niclosamide to treat melanoma and pulmonary metastasis via the STAT3 signaling pathway.	Niclosamide	40-51	signal transducer and activator of transcription 3	Homo sapiens	103-108
31208945-8	2019	These effects could be suppressed by niclosamide and inhibitors of beta-catenin and PI3 kinase.	Niclosamide	37-48	catenin beta 1	Homo sapiens	67-79
31465777-4	2019	Niclosamide, an FDA-approved anti-helminthic drug, has been identified as a potent STAT3 inhibitor that suppresses STAT3 phosphorylation at Tyr705 and its transcript activity.	Niclosamide	0-11	signal transducer and activator of transcription 3	Homo sapiens	83-88
31465777-4	2019	Niclosamide, an FDA-approved anti-helminthic drug, has been identified as a potent STAT3 inhibitor that suppresses STAT3 phosphorylation at Tyr705 and its transcript activity.	Niclosamide	0-11	signal transducer and activator of transcription 3	Homo sapiens	115-120
31465777-8	2019	Moreover, niclosamide markedly impaired melanoma cell migration and invasion, reduced phosphorylated STAT3Tyr705 levels, and inhibited matrix metalloproteinase-2 and -9 expression.	Niclosamide	10-21	signal transducer and activator of transcription 3	Homo sapiens	101-109
31465777-8	2019	Moreover, niclosamide markedly impaired melanoma cell migration and invasion, reduced phosphorylated STAT3Tyr705 levels, and inhibited matrix metalloproteinase-2 and -9 expression.	Niclosamide	10-21	matrix metallopeptidase 2	Homo sapiens	135-168
31611940-6	2019	In addition, PDGF-BB increased cell viability and migration in SDF-1alpha-treated pericytes, which were inhibited by AMD3100 and niclosamide, inhibitors for CXCR4 and STAT3 respectively.	Niclosamide	129-140	C-X-C motif chemokine receptor 4	Homo sapiens	157-162
31611940-6	2019	In addition, PDGF-BB increased cell viability and migration in SDF-1alpha-treated pericytes, which were inhibited by AMD3100 and niclosamide, inhibitors for CXCR4 and STAT3 respectively.	Niclosamide	129-140	signal transducer and activator of transcription 3	Homo sapiens	167-172
31511071-6	2019	RESULTS: In vitro, niclosamide, an antihelmintic drug, enhanced the cancer cell lysis mediated by T cells in the presence of PD-L1 blockade.	Niclosamide	19-30	CD274 molecule	Homo sapiens	125-130
31451218-6	2019	The regulation by STAT3 over NEDD4 can be abolished as long as the p-STAT3 was inactivated in the presence of Niclosamide, a kind of inhibitors that work specifically on STAT3 signaling pathway.	Niclosamide	110-121	signal transducer and activator of transcription 3	Homo sapiens	18-23
31451218-6	2019	The regulation by STAT3 over NEDD4 can be abolished as long as the p-STAT3 was inactivated in the presence of Niclosamide, a kind of inhibitors that work specifically on STAT3 signaling pathway.	Niclosamide	110-121	NEDD4 E3 ubiquitin protein ligase	Homo sapiens	29-34
31451218-6	2019	The regulation by STAT3 over NEDD4 can be abolished as long as the p-STAT3 was inactivated in the presence of Niclosamide, a kind of inhibitors that work specifically on STAT3 signaling pathway.	Niclosamide	110-121	signal transducer and activator of transcription 3	Homo sapiens	69-74
31451218-6	2019	The regulation by STAT3 over NEDD4 can be abolished as long as the p-STAT3 was inactivated in the presence of Niclosamide, a kind of inhibitors that work specifically on STAT3 signaling pathway.	Niclosamide	110-121	signal transducer and activator of transcription 3	Homo sapiens	69-74
31623154-0	2019	The S100A4 Transcriptional Inhibitor Niclosamide Reduces Pro-Inflammatory and Migratory Phenotypes of Microglia: Implications for Amyotrophic Lateral Sclerosis.	Niclosamide	37-48	S100 calcium binding protein A4	Homo sapiens	4-10
31623154-3	2019	In this study, we analyzed the expression of S100A4 and the effect of the S100A4 transcriptional inhibitor niclosamide in murine activated primary microglia.	Niclosamide	107-118	S100 calcium binding protein A4	Mus musculus	74-80
31623154-4	2019	We found that S100A4 was strongly up-regulated in reactive microglia and that niclosamide prevented NADPH oxidase 2, mTOR (mammalian target of rapamycin), and NF-kappaB (nuclear factor-kappa B) increase, cytoskeletal rearrangements, migration, and phagocytosis.	Niclosamide	78-89	S100 calcium binding protein A4	Homo sapiens	14-20
31623154-4	2019	We found that S100A4 was strongly up-regulated in reactive microglia and that niclosamide prevented NADPH oxidase 2, mTOR (mammalian target of rapamycin), and NF-kappaB (nuclear factor-kappa B) increase, cytoskeletal rearrangements, migration, and phagocytosis.	Niclosamide	78-89	cytochrome b-245 beta chain	Homo sapiens	100-115
31623154-4	2019	We found that S100A4 was strongly up-regulated in reactive microglia and that niclosamide prevented NADPH oxidase 2, mTOR (mammalian target of rapamycin), and NF-kappaB (nuclear factor-kappa B) increase, cytoskeletal rearrangements, migration, and phagocytosis.	Niclosamide	78-89	mechanistic target of rapamycin kinase	Homo sapiens	117-121
31623154-4	2019	We found that S100A4 was strongly up-regulated in reactive microglia and that niclosamide prevented NADPH oxidase 2, mTOR (mammalian target of rapamycin), and NF-kappaB (nuclear factor-kappa B) increase, cytoskeletal rearrangements, migration, and phagocytosis.	Niclosamide	78-89	mechanistic target of rapamycin kinase	Homo sapiens	123-152
31623154-4	2019	We found that S100A4 was strongly up-regulated in reactive microglia and that niclosamide prevented NADPH oxidase 2, mTOR (mammalian target of rapamycin), and NF-kappaB (nuclear factor-kappa B) increase, cytoskeletal rearrangements, migration, and phagocytosis.	Niclosamide	78-89	nuclear factor kappa B subunit 1	Homo sapiens	159-168
31623154-4	2019	We found that S100A4 was strongly up-regulated in reactive microglia and that niclosamide prevented NADPH oxidase 2, mTOR (mammalian target of rapamycin), and NF-kappaB (nuclear factor-kappa B) increase, cytoskeletal rearrangements, migration, and phagocytosis.	Niclosamide	78-89	nuclear factor kappa B subunit 1	Homo sapiens	170-192
31581665-0	2019	An Integrated Bioinformatics Analysis Repurposes an Antihelminthic Drug Niclosamide for Treating HMGA2-Overexpressing Human Colorectal Cancer.	Niclosamide	72-83	high mobility group AT-hook 2	Homo sapiens	97-102
31581665-6	2019	A repurposing S100A4 inhibitor, niclosamide, was found to reverse the HMGA2-driven gene signature both in colorectal cancer cell lines and patients" tissues.	Niclosamide	32-43	S100 calcium binding protein A4	Homo sapiens	14-20
31581665-6	2019	A repurposing S100A4 inhibitor, niclosamide, was found to reverse the HMGA2-driven gene signature both in colorectal cancer cell lines and patients" tissues.	Niclosamide	32-43	high mobility group AT-hook 2	Homo sapiens	70-75
31581665-7	2019	In vitro and in vivo experiments validated that HMGA2-overexpressing colorectal cancer cells were more sensitive to niclosamide.	Niclosamide	116-127	high mobility group AT-hook 2	Homo sapiens	48-53
31581665-9	2019	Further RNA sequencing analysis identified that niclosamide inhibited more cell-cycle-related gene expression in HMGA2-overexpressing colorectal cancer cells, which may explain its selective anticancer effect.	Niclosamide	48-59	high mobility group AT-hook 2	Homo sapiens	113-118
31581665-10	2019	Together, our study repurposes an anthelminthic drug niclosamide for treating HMGA2-overexpression colorectal cancer.	Niclosamide	53-64	high mobility group AT-hook 2	Homo sapiens	78-83
31511071-7	2019	Accordingly, mice treated with niclosamide and PD-L1 antibody showed significant delay in tumor growth and increased survival which were associated with the increase of tumor infiltrating T cells and granzyme B release.	Niclosamide	31-42	granzyme B	Mus musculus	200-210
31511071-8	2019	Importantly, we found niclosamide could decrease the expression of PD-L1 in both a concentration- and time-dependent manner in NSCLC cells, which was linked to the blockage of p-STAT3 binding to the promoter of PD-L1.	Niclosamide	22-33	CD274 antigen	Mus musculus	67-72
31511071-8	2019	Importantly, we found niclosamide could decrease the expression of PD-L1 in both a concentration- and time-dependent manner in NSCLC cells, which was linked to the blockage of p-STAT3 binding to the promoter of PD-L1.	Niclosamide	22-33	signal transducer and activator of transcription 3	Mus musculus	178-183
31511071-8	2019	Importantly, we found niclosamide could decrease the expression of PD-L1 in both a concentration- and time-dependent manner in NSCLC cells, which was linked to the blockage of p-STAT3 binding to the promoter of PD-L1.	Niclosamide	22-33	CD274 antigen	Mus musculus	211-216
31511071-9	2019	CONCLUSIONS: An enhancement of PD-L1 antibody by niclosamide was observed in inhibition of NSCLC growth in vitro and in vivo, which was involved in blockage of p-STAT3 binding to promoter of PD-L1 and finally downregulation of PD-L1 expression.	Niclosamide	49-60	CD274 antigen	Mus musculus	31-36
31511071-9	2019	CONCLUSIONS: An enhancement of PD-L1 antibody by niclosamide was observed in inhibition of NSCLC growth in vitro and in vivo, which was involved in blockage of p-STAT3 binding to promoter of PD-L1 and finally downregulation of PD-L1 expression.	Niclosamide	49-60	signal transducer and activator of transcription 3	Mus musculus	162-167
31511071-9	2019	CONCLUSIONS: An enhancement of PD-L1 antibody by niclosamide was observed in inhibition of NSCLC growth in vitro and in vivo, which was involved in blockage of p-STAT3 binding to promoter of PD-L1 and finally downregulation of PD-L1 expression.	Niclosamide	49-60	CD274 antigen	Mus musculus	191-196
31511071-9	2019	CONCLUSIONS: An enhancement of PD-L1 antibody by niclosamide was observed in inhibition of NSCLC growth in vitro and in vivo, which was involved in blockage of p-STAT3 binding to promoter of PD-L1 and finally downregulation of PD-L1 expression.	Niclosamide	49-60	CD274 antigen	Mus musculus	191-196
31391337-4	2019	Here we demonstrate that the FDA-approved drug niclosamide, a potent inhibitor of TMEM16A identified by high-throughput screening, is an inhibitor of both TMEM16A and TMEM16F.	Niclosamide	47-58	anoctamin 1, calcium activated chloride channel	Mus musculus	82-89
31271840-6	2019	In addition, we also found that the enhancing effect of IL-10 on phagocytosis and intracellular ROS levels of mIgM+ B lymphocytes were suppressed by the administration of niclosamide.	Niclosamide	171-182	interleukin 10	Rattus norvegicus	56-61
31271840-6	2019	In addition, we also found that the enhancing effect of IL-10 on phagocytosis and intracellular ROS levels of mIgM+ B lymphocytes were suppressed by the administration of niclosamide.	Niclosamide	171-182	immunoglobulin heavy constant mu	Mus musculus	110-114
31243136-3	2019	Inhibition of STAT3 by niclosamide, small interfering RNA, or exogenous expression of SOCS3 all significantly suppressed the replication of RABV.	Niclosamide	23-34	signal transducer and activator of transcription 3	Homo sapiens	14-19
31391337-4	2019	Here we demonstrate that the FDA-approved drug niclosamide, a potent inhibitor of TMEM16A identified by high-throughput screening, is an inhibitor of both TMEM16A and TMEM16F.	Niclosamide	47-58	anoctamin 1, calcium activated chloride channel	Mus musculus	155-162
31391337-4	2019	Here we demonstrate that the FDA-approved drug niclosamide, a potent inhibitor of TMEM16A identified by high-throughput screening, is an inhibitor of both TMEM16A and TMEM16F.	Niclosamide	47-58	anoctamin 6	Mus musculus	167-174
31391337-7	2019	TMEM16A and TMEM16F support exocytic release of mucus and inflammatory mediators, both of which are blocked by niclosamide.	Niclosamide	111-122	anoctamin 1, calcium activated chloride channel	Mus musculus	0-7
31391337-7	2019	TMEM16A and TMEM16F support exocytic release of mucus and inflammatory mediators, both of which are blocked by niclosamide.	Niclosamide	111-122	anoctamin 6	Mus musculus	12-19
31383893-0	2019	Niclosamide reverses adipocyte induced epithelial-mesenchymal transition in breast cancer cells via suppression of the interleukin-6/STAT3 signalling axis.	Niclosamide	0-11	interleukin 6	Homo sapiens	119-132
31371076-5	2019	In the present study we hypothesise the selective targeting of CSC"s using CD 133 mediated delivery of STAT 3 inhibitor, Niclosamide to specifically target CSC"s and Non CSC"s.	Niclosamide	121-132	prominin 1	Homo sapiens	75-81
31371076-5	2019	In the present study we hypothesise the selective targeting of CSC"s using CD 133 mediated delivery of STAT 3 inhibitor, Niclosamide to specifically target CSC"s and Non CSC"s.	Niclosamide	121-132	signal transducer and activator of transcription 3	Homo sapiens	103-109
31383893-0	2019	Niclosamide reverses adipocyte induced epithelial-mesenchymal transition in breast cancer cells via suppression of the interleukin-6/STAT3 signalling axis.	Niclosamide	0-11	signal transducer and activator of transcription 3	Homo sapiens	133-138
31383893-8	2019	Additionally, niclosamide reversed adipocyte-induced EMT with a correlated inhibition of IL-6/Stat3 activation and downregulation of EMT-TFs TWIST and SNAIL.	Niclosamide	14-25	interleukin 6	Homo sapiens	89-93
31383893-8	2019	Additionally, niclosamide reversed adipocyte-induced EMT with a correlated inhibition of IL-6/Stat3 activation and downregulation of EMT-TFs TWIST and SNAIL.	Niclosamide	14-25	signal transducer and activator of transcription 3	Homo sapiens	94-99
31383893-8	2019	Additionally, niclosamide reversed adipocyte-induced EMT with a correlated inhibition of IL-6/Stat3 activation and downregulation of EMT-TFs TWIST and SNAIL.	Niclosamide	14-25	twist family bHLH transcription factor 1	Homo sapiens	141-146
31383893-8	2019	Additionally, niclosamide reversed adipocyte-induced EMT with a correlated inhibition of IL-6/Stat3 activation and downregulation of EMT-TFs TWIST and SNAIL.	Niclosamide	14-25	snail family transcriptional repressor 1	Homo sapiens	151-156
30952635-7	2019	We also quantified the proteomic changes during niclosamide treatment to pinpoint nucleoside diphosphate kinase 3 (NME3) downregulation as a potential mechanism for its antitumor activity.	Niclosamide	48-59	NME/NM23 nucleoside diphosphate kinase 3	Homo sapiens	115-119
30952315-0	2019	Quantification of niclosamide polymorphic forms - A comparative study by Raman, NIR and MIR using chemometric techniques.	Niclosamide	18-29	membrane associated ring-CH-type finger 8	Homo sapiens	88-91
30893776-9	2019	The reported anticancer effects of the anthelminthic drug niclosamide are probably related to the potent inhibitory effect on ANO1, apart from inducing cell cycle arrest through the Let-7d/CDC34 axis.	Niclosamide	58-69	anoctamin 1	Homo sapiens	126-130
30599391-7	2019	Niclosamide displayed low host toxicity and its 50% inhibitory concentration was 8.3 mug/mL.	Niclosamide	0-11	thrombopoietin	Mus musculus	89-91
30599391-9	2019	Niclosamide also inhibited T. gondii tachyzoite proliferation, with a 50% effective concentration of 45.3 ng/mL, and reduced the invasion of cells by tachyzoites (17.8% for the parasite control versus 1.9% for the niclosamide group treated with 100 ng/mL).	Niclosamide	0-11	thrombopoietin	Mus musculus	109-111
30599391-9	2019	Niclosamide also inhibited T. gondii tachyzoite proliferation, with a 50% effective concentration of 45.3 ng/mL, and reduced the invasion of cells by tachyzoites (17.8% for the parasite control versus 1.9% for the niclosamide group treated with 100 ng/mL).	Niclosamide	0-11	thrombopoietin	Mus musculus	252-254
30893776-9	2019	The reported anticancer effects of the anthelminthic drug niclosamide are probably related to the potent inhibitory effect on ANO1, apart from inducing cell cycle arrest through the Let-7d/CDC34 axis.	Niclosamide	58-69	microRNA let-7d	Homo sapiens	182-188
30893776-9	2019	The reported anticancer effects of the anthelminthic drug niclosamide are probably related to the potent inhibitory effect on ANO1, apart from inducing cell cycle arrest through the Let-7d/CDC34 axis.	Niclosamide	58-69	cell division cycle 34, ubiqiutin conjugating enzyme	Homo sapiens	189-194
30875964-0	2019	Niclosamide Triggers Non-Canonical LC3 Lipidation.	Niclosamide	0-11	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	35-38
30875964-4	2019	We and others have reported that niclosamide (Nic), an anti-helminthic drug approved by the Food and Drug Administration, could induce canonical autophagy via a feedback downregulation of mTOR complex 1.	Niclosamide	33-44	mechanistic target of rapamycin kinase	Homo sapiens	188-192
30875964-4	2019	We and others have reported that niclosamide (Nic), an anti-helminthic drug approved by the Food and Drug Administration, could induce canonical autophagy via a feedback downregulation of mTOR complex 1.	Niclosamide	46-49	mechanistic target of rapamycin kinase	Homo sapiens	188-192
30875964-7	2019	In addition, the Golgi complex and vimentin were involved in Nic-induced NCLL, which might be a platform or membrane source for Nic-induced LC3-positive structures.	Niclosamide	61-64	vimentin	Homo sapiens	35-43
30875964-7	2019	In addition, the Golgi complex and vimentin were involved in Nic-induced NCLL, which might be a platform or membrane source for Nic-induced LC3-positive structures.	Niclosamide	61-64	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	140-143
30842311-4	2019	Niclosamide reduces the growth of colorectal cancer cells by targeting several intracellular signalling pathways, including the beta-catenin-dependent WNT signalling pathway.	Niclosamide	0-11	catenin beta 1	Homo sapiens	128-140
30842311-7	2019	(2019) 476, 535-546], Wang and colleagues revealed that niclosamide down-regulates beta-catenin-dependent WNT signalling in colorectal cancer cells by degrading components of the pathway via autophagy.	Niclosamide	56-67	catenin beta 1	Homo sapiens	83-95
30837866-0	2019	Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate Airways.	Niclosamide	36-47	anoctamin 1	Homo sapiens	76-83
30611787-0	2019	Niclosamide alleviates pulmonary fibrosis in vitro and in vivo by attenuation of epithelial-to-mesenchymal transition, matrix proteins &amp; Wnt/beta-catenin signaling: A drug repurposing study.	Niclosamide	0-11	catenin beta 1	Homo sapiens	145-157
30611787-7	2019	Our study is aimed at investigating the anti-fibrotic potential of Niclosamide in TGF-beta1 induced in vitro model of PF and 21-day model of Bleomycin induced PF in vivo respectively.	Niclosamide	67-78	transforming growth factor beta 1	Homo sapiens	82-91
30611787-8	2019	Our study results showed that Niclosamide holds the potential to exert anti-fibrotic effect by hampering fibroblast migration, attenuating EMT, inhibiting fibrotic signaling and by regulating WNT/beta-catenin signaling as evident from protein expression studies.	Niclosamide	30-41	IL2 inducible T cell kinase	Homo sapiens	139-142
30611787-8	2019	Our study results showed that Niclosamide holds the potential to exert anti-fibrotic effect by hampering fibroblast migration, attenuating EMT, inhibiting fibrotic signaling and by regulating WNT/beta-catenin signaling as evident from protein expression studies.	Niclosamide	30-41	catenin beta 1	Homo sapiens	196-208
30446587-0	2019	Inhibition of LEF1-Mediated DCLK1 by Niclosamide Attenuates Colorectal Cancer Stemness.	Niclosamide	37-48	lymphoid enhancer binding factor 1	Homo sapiens	14-18
30446587-0	2019	Inhibition of LEF1-Mediated DCLK1 by Niclosamide Attenuates Colorectal Cancer Stemness.	Niclosamide	37-48	doublecortin like kinase 1	Homo sapiens	28-33
30446587-6	2019	Mechanistically, niclosamide downregulates multiple signaling components of the Wnt pathway, specifically lymphoid enhancer-binding factor 1 (LEF1) expression, which is critical for regulating stemness.	Niclosamide	17-28	lymphoid enhancer binding factor 1	Homo sapiens	106-140
30446587-6	2019	Mechanistically, niclosamide downregulates multiple signaling components of the Wnt pathway, specifically lymphoid enhancer-binding factor 1 (LEF1) expression, which is critical for regulating stemness.	Niclosamide	17-28	lymphoid enhancer binding factor 1	Homo sapiens	142-146
30446587-8	2019	We first documented that niclosamide blocks the transcription of DCLK1-B by interrupting the binding of LEF1 to DCLK1-B promoter.	Niclosamide	25-36	doublecortin like kinase 1	Homo sapiens	65-70
30446587-8	2019	We first documented that niclosamide blocks the transcription of DCLK1-B by interrupting the binding of LEF1 to DCLK1-B promoter.	Niclosamide	25-36	lymphoid enhancer binding factor 1	Homo sapiens	104-108
30446587-8	2019	We first documented that niclosamide blocks the transcription of DCLK1-B by interrupting the binding of LEF1 to DCLK1-B promoter.	Niclosamide	25-36	doublecortin like kinase 1	Homo sapiens	112-117
30446587-10	2019	CONCLUSIONS: Disruption of the LEF1/DCLK1-B axis by niclosamide eradicates cancer stemness and elicits therapeutic effects on colorectal cancer initiation, progression, and resistance.	Niclosamide	52-63	lymphoid enhancer binding factor 1	Homo sapiens	31-35
30446587-10	2019	CONCLUSIONS: Disruption of the LEF1/DCLK1-B axis by niclosamide eradicates cancer stemness and elicits therapeutic effects on colorectal cancer initiation, progression, and resistance.	Niclosamide	52-63	doublecortin like kinase 1	Homo sapiens	36-41
30837866-4	2019	The anthelmintics niclosamide, nitazoxanide, and related compounds were identified as potent TMEM16A antagonists that blocked airway smooth muscle depolarization and contraction.	Niclosamide	18-29	anoctamin 1	Homo sapiens	93-100
30329025-2	2019	We have recently reported that niclosamide treatment reduces growth and progression of endometriosis-like lesions and inflammatory signaling (NF${\rm \small K}$B and STAT3) in a mouse model.	Niclosamide	31-42	signal transducer and activator of transcription 3	Mus musculus	166-171
30635359-2	2019	Previously, we identified that the anthelmintic drug niclosamide inhibited Wnt signaling by promoting internalization of Wnt receptor Frizzled 1 and degradation of Wnt signaling pathway proteins, Dishevelled 2 and beta-catenin, contributing to suppression of colorectal cancer growth in vitro and in vivo Here, we provide evidence that niclosamide-mediated inhibition of Wnt signaling is mediated through autophagosomes induced by niclosamide.	Niclosamide	53-64	catenin beta 1	Homo sapiens	214-226
30635359-3	2019	Specifically, niclosamide promotes the co-localization of Frizzled 1 or beta-catenin with LC3, an autophagosome marker.	Niclosamide	14-25	frizzled class receptor 1	Homo sapiens	58-68
30635359-3	2019	Specifically, niclosamide promotes the co-localization of Frizzled 1 or beta-catenin with LC3, an autophagosome marker.	Niclosamide	14-25	catenin beta 1	Homo sapiens	72-84
30635359-3	2019	Specifically, niclosamide promotes the co-localization of Frizzled 1 or beta-catenin with LC3, an autophagosome marker.	Niclosamide	14-25	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	90-93
30635359-4	2019	Niclosamide inhibition of Wnt signaling is attenuated in autophagosome-deficient ATG5-/- MEF cells or cells expressing shRNA targeting Beclin1, a critical constituent of autophagosome.	Niclosamide	0-11	beclin 1, autophagy related	Mus musculus	135-142
30635359-5	2019	Treatment with the autophagosome inhibitor 3MA blocks niclosamide-mediated Frizzled 1 degradation.	Niclosamide	54-65	frizzled class receptor 1	Homo sapiens	75-85
30635359-7	2019	Niclosamide inhibits mTORC1 and ULK1 activities and induces LC3B expression in niclosamide-sensitive cell lines, but not in the niclosamide-resistant cell lines tested.	Niclosamide	0-11	CREB regulated transcription coactivator 1	Mus musculus	21-27
30635359-7	2019	Niclosamide inhibits mTORC1 and ULK1 activities and induces LC3B expression in niclosamide-sensitive cell lines, but not in the niclosamide-resistant cell lines tested.	Niclosamide	0-11	unc-51 like autophagy activating kinase 1	Homo sapiens	32-36
30635359-7	2019	Niclosamide inhibits mTORC1 and ULK1 activities and induces LC3B expression in niclosamide-sensitive cell lines, but not in the niclosamide-resistant cell lines tested.	Niclosamide	0-11	microtubule associated protein 1 light chain 3 beta	Homo sapiens	60-64
30635359-7	2019	Niclosamide inhibits mTORC1 and ULK1 activities and induces LC3B expression in niclosamide-sensitive cell lines, but not in the niclosamide-resistant cell lines tested.	Niclosamide	79-90	microtubule associated protein 1 light chain 3 beta	Homo sapiens	60-64
30635359-8	2019	Interestingly, niclosamide is a less effective inhibitor of Wnt-responsive genes (beta-catenin, c-Myc, and Survivin) in the niclosamide-resistant cells than in the niclosamide-sensitive cells, suggesting that deficient autophagy induction by niclosamide compromises the effect of niclosamide on Wnt signaling.	Niclosamide	15-26	catenin beta 1	Homo sapiens	82-94
30635359-8	2019	Interestingly, niclosamide is a less effective inhibitor of Wnt-responsive genes (beta-catenin, c-Myc, and Survivin) in the niclosamide-resistant cells than in the niclosamide-sensitive cells, suggesting that deficient autophagy induction by niclosamide compromises the effect of niclosamide on Wnt signaling.	Niclosamide	15-26	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	96-101
30635359-8	2019	Interestingly, niclosamide is a less effective inhibitor of Wnt-responsive genes (beta-catenin, c-Myc, and Survivin) in the niclosamide-resistant cells than in the niclosamide-sensitive cells, suggesting that deficient autophagy induction by niclosamide compromises the effect of niclosamide on Wnt signaling.	Niclosamide	124-135	catenin beta 1	Homo sapiens	82-94
30635359-8	2019	Interestingly, niclosamide is a less effective inhibitor of Wnt-responsive genes (beta-catenin, c-Myc, and Survivin) in the niclosamide-resistant cells than in the niclosamide-sensitive cells, suggesting that deficient autophagy induction by niclosamide compromises the effect of niclosamide on Wnt signaling.	Niclosamide	124-135	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	96-101
30635359-8	2019	Interestingly, niclosamide is a less effective inhibitor of Wnt-responsive genes (beta-catenin, c-Myc, and Survivin) in the niclosamide-resistant cells than in the niclosamide-sensitive cells, suggesting that deficient autophagy induction by niclosamide compromises the effect of niclosamide on Wnt signaling.	Niclosamide	124-135	catenin beta 1	Homo sapiens	82-94
30635359-8	2019	Interestingly, niclosamide is a less effective inhibitor of Wnt-responsive genes (beta-catenin, c-Myc, and Survivin) in the niclosamide-resistant cells than in the niclosamide-sensitive cells, suggesting that deficient autophagy induction by niclosamide compromises the effect of niclosamide on Wnt signaling.	Niclosamide	124-135	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	96-101
30635359-8	2019	Interestingly, niclosamide is a less effective inhibitor of Wnt-responsive genes (beta-catenin, c-Myc, and Survivin) in the niclosamide-resistant cells than in the niclosamide-sensitive cells, suggesting that deficient autophagy induction by niclosamide compromises the effect of niclosamide on Wnt signaling.	Niclosamide	124-135	catenin beta 1	Homo sapiens	82-94
30635359-8	2019	Interestingly, niclosamide is a less effective inhibitor of Wnt-responsive genes (beta-catenin, c-Myc, and Survivin) in the niclosamide-resistant cells than in the niclosamide-sensitive cells, suggesting that deficient autophagy induction by niclosamide compromises the effect of niclosamide on Wnt signaling.	Niclosamide	124-135	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	96-101
30635359-8	2019	Interestingly, niclosamide is a less effective inhibitor of Wnt-responsive genes (beta-catenin, c-Myc, and Survivin) in the niclosamide-resistant cells than in the niclosamide-sensitive cells, suggesting that deficient autophagy induction by niclosamide compromises the effect of niclosamide on Wnt signaling.	Niclosamide	124-135	catenin beta 1	Homo sapiens	82-94
30635359-8	2019	Interestingly, niclosamide is a less effective inhibitor of Wnt-responsive genes (beta-catenin, c-Myc, and Survivin) in the niclosamide-resistant cells than in the niclosamide-sensitive cells, suggesting that deficient autophagy induction by niclosamide compromises the effect of niclosamide on Wnt signaling.	Niclosamide	124-135	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	96-101
30329025-4	2019	Niclosamide dose dependently reduced 12Z viability, reduced STAT3 and NF${\rm \small K}$B activity, and increased both cleaved caspase-3 and cleaved PARP.	Niclosamide	0-11	signal transducer and activator of transcription 3	Homo sapiens	60-65
30329025-4	2019	Niclosamide dose dependently reduced 12Z viability, reduced STAT3 and NF${\rm \small K}$B activity, and increased both cleaved caspase-3 and cleaved PARP.	Niclosamide	0-11	caspase 3	Homo sapiens	127-136
30329025-4	2019	Niclosamide dose dependently reduced 12Z viability, reduced STAT3 and NF${\rm \small K}$B activity, and increased both cleaved caspase-3 and cleaved PARP.	Niclosamide	0-11	poly(ADP-ribose) polymerase 1	Homo sapiens	149-153
30329025-13	2019	These results indicate that niclosamide can inhibit the inflammatory factors in endometriotic epithelial cells stimulated by macrophages by targeting STAT3 and/or NF${\rm \small K}$B signaling.	Niclosamide	28-39	signal transducer and activator of transcription 3	Homo sapiens	150-155
30348020-1	2019	In the present study, solid lipid nanoparticles (SLNs) have been formulated as a carrier system for effective intracellular delivery of STAT3 inhibitor, niclosamide (Niclo) to triple negative breast cancer (TNBC) cells.	Niclosamide	166-171	signal transducer and activator of transcription 3	Homo sapiens	136-141
30779072-7	2019	SW480 cells were transfected with STAT3 siRNA or treated with STAT3 inhibitor Niclosamide, and then stimulated with EGF to change the expressions of STAT3 and p-STAT3.	Niclosamide	78-89	signal transducer and activator of transcription 3	Homo sapiens	62-67
30779072-7	2019	SW480 cells were transfected with STAT3 siRNA or treated with STAT3 inhibitor Niclosamide, and then stimulated with EGF to change the expressions of STAT3 and p-STAT3.	Niclosamide	78-89	signal transducer and activator of transcription 3	Homo sapiens	62-67
30779072-7	2019	SW480 cells were transfected with STAT3 siRNA or treated with STAT3 inhibitor Niclosamide, and then stimulated with EGF to change the expressions of STAT3 and p-STAT3.	Niclosamide	78-89	signal transducer and activator of transcription 3	Homo sapiens	62-67
32010892-6	2019	Significantly decreased serum levels of inflammatory biomarkers including TNF-alpha, IL-1beta, and IL-6 were observed in rats treated with high-dose oral NCL or intramuscular injection of diclofenac sodium, compared with groups B and C. Histopathological examination revealed that a high dose of NCL significantly reduced the infiltration of inflammatory cells, synovial hyperplasia, and bone and cartilage destruction.	Niclosamide	154-157	tumor necrosis factor	Rattus norvegicus	74-83
32010892-6	2019	Significantly decreased serum levels of inflammatory biomarkers including TNF-alpha, IL-1beta, and IL-6 were observed in rats treated with high-dose oral NCL or intramuscular injection of diclofenac sodium, compared with groups B and C. Histopathological examination revealed that a high dose of NCL significantly reduced the infiltration of inflammatory cells, synovial hyperplasia, and bone and cartilage destruction.	Niclosamide	154-157	interleukin 1 alpha	Rattus norvegicus	85-93
32010892-6	2019	Significantly decreased serum levels of inflammatory biomarkers including TNF-alpha, IL-1beta, and IL-6 were observed in rats treated with high-dose oral NCL or intramuscular injection of diclofenac sodium, compared with groups B and C. Histopathological examination revealed that a high dose of NCL significantly reduced the infiltration of inflammatory cells, synovial hyperplasia, and bone and cartilage destruction.	Niclosamide	154-157	interleukin 6	Rattus norvegicus	99-103
30551901-0	2019	Identification of novel triazole inhibitors of Wnt/beta-catenin signaling based on the Niclosamide chemotype.	Niclosamide	87-98	catenin beta 1	Homo sapiens	51-63
30551901-3	2019	We reported previously that the anthelmintic drug Niclosamide inhibits the Wnt/beta-catenin signaling pathway and suppresses colorectal cancer cell growth in vitro and in vivo.	Niclosamide	50-61	catenin beta 1	Homo sapiens	79-91
30551901-5	2019	Here, we asked a specific SAR question unresolved in previous SAR studies of Niclosamide"s inhibition of Wnt/beta-catenin signaling to identify a new structural class of Wnt/beta-catenin signaling inhibitors based on a triazole motif.	Niclosamide	77-88	sarcosine dehydrogenase	Homo sapiens	26-29
30551901-5	2019	Here, we asked a specific SAR question unresolved in previous SAR studies of Niclosamide"s inhibition of Wnt/beta-catenin signaling to identify a new structural class of Wnt/beta-catenin signaling inhibitors based on a triazole motif.	Niclosamide	77-88	sarcosine dehydrogenase	Homo sapiens	62-65
30551901-5	2019	Here, we asked a specific SAR question unresolved in previous SAR studies of Niclosamide"s inhibition of Wnt/beta-catenin signaling to identify a new structural class of Wnt/beta-catenin signaling inhibitors based on a triazole motif.	Niclosamide	77-88	catenin beta 1	Homo sapiens	109-121
30551901-5	2019	Here, we asked a specific SAR question unresolved in previous SAR studies of Niclosamide"s inhibition of Wnt/beta-catenin signaling to identify a new structural class of Wnt/beta-catenin signaling inhibitors based on a triazole motif.	Niclosamide	77-88	catenin beta 1	Homo sapiens	174-186
30687101-0	2018	Niclosamide Induces Cell Cycle Arrest in G1 Phase in Head and Neck Squamous Cell Carcinoma Through Let-7d/CDC34 Axis.	Niclosamide	0-11	microRNA let-7d	Homo sapiens	99-105
30687101-0	2018	Niclosamide Induces Cell Cycle Arrest in G1 Phase in Head and Neck Squamous Cell Carcinoma Through Let-7d/CDC34 Axis.	Niclosamide	0-11	cell division cycle 34, ubiqiutin conjugating enzyme	Homo sapiens	106-111
30687101-8	2018	Briefly, an exposure to niclosamide treatment led to an increased let-7d expression and a decreased expression of cell cycle regulator CDC34, finally leading to G1 phase arrest.	Niclosamide	24-35	microRNA let-7d	Homo sapiens	66-72
30687101-8	2018	Briefly, an exposure to niclosamide treatment led to an increased let-7d expression and a decreased expression of cell cycle regulator CDC34, finally leading to G1 phase arrest.	Niclosamide	24-35	cell division cycle 34, ubiqiutin conjugating enzyme	Homo sapiens	135-140
30687101-9	2018	Moreover, an overexpression of let-7d induced G1 phase arrest and downregulated CDC34, while the knockdown of let-7d partially rescued the niclosamide-induced G1 phase arrest.	Niclosamide	139-150	microRNA let-7d	Homo sapiens	110-116
30687101-11	2018	Furthermore, niclosamide markedly inhibited the xenografts growth through up-regulation of let-7d and down-regulation of CDC34.	Niclosamide	13-24	microRNA let-7d	Homo sapiens	91-97
30687101-11	2018	Furthermore, niclosamide markedly inhibited the xenografts growth through up-regulation of let-7d and down-regulation of CDC34.	Niclosamide	13-24	cell division cycle 34, ubiqiutin conjugating enzyme	Homo sapiens	121-126
30687101-12	2018	To sum up, our findings suggest that niclosamide induces cell cycle arrest in G1 phase in HNSCC through let-7d/CDC34 axis, which enriches the anti-cancer mechanism of niclosamide.	Niclosamide	37-48	microRNA let-7d	Homo sapiens	104-110
30687101-12	2018	To sum up, our findings suggest that niclosamide induces cell cycle arrest in G1 phase in HNSCC through let-7d/CDC34 axis, which enriches the anti-cancer mechanism of niclosamide.	Niclosamide	37-48	cell division cycle 34, ubiqiutin conjugating enzyme	Homo sapiens	111-116
30687101-12	2018	To sum up, our findings suggest that niclosamide induces cell cycle arrest in G1 phase in HNSCC through let-7d/CDC34 axis, which enriches the anti-cancer mechanism of niclosamide.	Niclosamide	167-178	microRNA let-7d	Homo sapiens	104-110
30687101-12	2018	To sum up, our findings suggest that niclosamide induces cell cycle arrest in G1 phase in HNSCC through let-7d/CDC34 axis, which enriches the anti-cancer mechanism of niclosamide.	Niclosamide	167-178	cell division cycle 34, ubiqiutin conjugating enzyme	Homo sapiens	111-116
30740538-0	2019	Niclosamide activates the NLRP3 inflammasome by intracellular acidification and mitochondrial inhibition.	Niclosamide	0-11	NLR family pyrin domain containing 3	Homo sapiens	26-31
30740538-3	2019	Here we identified niclosamide, a mitochondrial uncoupler, as an activator of NLRP3 inflammasome.	Niclosamide	19-30	NLR family pyrin domain containing 3	Homo sapiens	78-83
30775247-7	2019	Among these are the anti-helminthic drug, niclosamide, which selectively promotes degradation of AR variants over full length AR and re-sensitizes anti-androgen resistant prostate cancer cells to treatment with enzalutamide and abiraterone.	Niclosamide	42-53	androgen receptor	Homo sapiens	97-99
30775247-7	2019	Among these are the anti-helminthic drug, niclosamide, which selectively promotes degradation of AR variants over full length AR and re-sensitizes anti-androgen resistant prostate cancer cells to treatment with enzalutamide and abiraterone.	Niclosamide	42-53	androgen receptor	Homo sapiens	126-128
30775253-12	2019	In this review, two examples of such MAD-PSA detonated molecular grenades are presented-one based upon thapsigagin and the other on niclosamide.	Niclosamide	132-143	kallikrein related peptidase 3	Homo sapiens	41-44
30651927-11	2018	These results suggest that uncouplers such as SR4 and niclosamide may be useful as first line treatment against melanoma regardless of BRAF/NRAS status, and as an adjuvant therapy for patients failing MAPK inhibitors.	Niclosamide	54-65	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	135-139
30551901-8	2019	Overall, these studies demonstrate the ability to use the SAR of the Niclosamide salicylanilide chemical class to expand the structural diversity of Wnt/beta-catenin inhibitors.	Niclosamide	69-80	sarcosine dehydrogenase	Homo sapiens	58-61
30551901-8	2019	Overall, these studies demonstrate the ability to use the SAR of the Niclosamide salicylanilide chemical class to expand the structural diversity of Wnt/beta-catenin inhibitors.	Niclosamide	69-80	catenin beta 1	Homo sapiens	153-165
30651927-11	2018	These results suggest that uncouplers such as SR4 and niclosamide may be useful as first line treatment against melanoma regardless of BRAF/NRAS status, and as an adjuvant therapy for patients failing MAPK inhibitors.	Niclosamide	54-65	NRAS proto-oncogene, GTPase	Homo sapiens	140-144
30651927-11	2018	These results suggest that uncouplers such as SR4 and niclosamide may be useful as first line treatment against melanoma regardless of BRAF/NRAS status, and as an adjuvant therapy for patients failing MAPK inhibitors.	Niclosamide	54-65	mitogen-activated protein kinase 1	Homo sapiens	201-205
30083960-0	2018	Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer.	Niclosamide	63-74	androgen receptor	Homo sapiens	18-35
30272302-7	2018	The STAT3 pathway was inhibited using niclosamide.	Niclosamide	38-49	signal transducer and activator of transcription 3	Homo sapiens	4-9
30519314-0	2018	Niclosamide Inhibits Cell Growth and Enhances Drug Sensitivity of Hepatocellular Carcinoma Cells via STAT3 Signaling Pathway.	Niclosamide	0-11	signal transducer and activator of transcription 3	Homo sapiens	101-106
30274939-2	2018	Previously, we reported that the drug Niclosamide inhibits Wnt/beta-catenin signaling by decreasing the cytosolic levels of Dishevelled and beta-catenin, and inhibits the growth of colon cancers both in vitro and in vivo.	Niclosamide	38-49	catenin beta 1	Homo sapiens	63-75
30274939-2	2018	Previously, we reported that the drug Niclosamide inhibits Wnt/beta-catenin signaling by decreasing the cytosolic levels of Dishevelled and beta-catenin, and inhibits the growth of colon cancers both in vitro and in vivo.	Niclosamide	38-49	catenin beta 1	Homo sapiens	140-152
30519314-9	2018	With niclosamide treatment, phospho-STAT3 (Y705) was inactivated and the downstream antiapoptotic proteins Mcl-1 and survivin were downregulated at both mRNA and protein levels in HCC cells.	Niclosamide	5-16	signal transducer and activator of transcription 3	Homo sapiens	36-41
30519314-9	2018	With niclosamide treatment, phospho-STAT3 (Y705) was inactivated and the downstream antiapoptotic proteins Mcl-1 and survivin were downregulated at both mRNA and protein levels in HCC cells.	Niclosamide	5-16	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	107-112
30519314-10	2018	Conclusion: Niclosamide has effective function in anti-HCC and may be a single or combined drug treatment for HCC and acts via the STAT3 signaling pathway.	Niclosamide	12-23	signal transducer and activator of transcription 3	Homo sapiens	131-136
30081104-3	2018	This study was performed to determine the renal protection of niclosamide ethanolamine salt (NEN) which was identified as mTOR inhibitor.	Niclosamide	62-91	mechanistic target of rapamycin kinase	Mus musculus	122-126
30053001-13	2018	When treated with niclosamide and PNU-74654, the H295R cell line showed a decrease in beta-catenin expression, cell proliferation, and steroid secretion.	Niclosamide	18-29	catenin beta 1	Homo sapiens	86-98
30081104-3	2018	This study was performed to determine the renal protection of niclosamide ethanolamine salt (NEN) which was identified as mTOR inhibitor.	Niclosamide	93-96	mechanistic target of rapamycin kinase	Mus musculus	122-126
30258081-3	2018	Here we identify niclosamide through a HTS screen for compounds selectively killing p53-deficient cells.	Niclosamide	17-28	tumor protein p53	Homo sapiens	84-87
30258081-4	2018	Niclosamide impairs the growth of p53-deficient cells and of p53 mutant patient-derived ovarian xenografts.	Niclosamide	0-11	tumor protein p53	Homo sapiens	34-37
30258081-4	2018	Niclosamide impairs the growth of p53-deficient cells and of p53 mutant patient-derived ovarian xenografts.	Niclosamide	0-11	tumor protein p53	Homo sapiens	61-64
30258081-5	2018	Metabolome profiling reveals that niclosamide induces mitochondrial uncoupling, which renders mutant p53 cells susceptible to mitochondrial-dependent apoptosis through preferential accumulation of arachidonic acid (AA), and represents a first-in-class inhibitor of p53 mutant tumors.	Niclosamide	34-45	tumor protein p53	Homo sapiens	101-104
30258081-5	2018	Metabolome profiling reveals that niclosamide induces mitochondrial uncoupling, which renders mutant p53 cells susceptible to mitochondrial-dependent apoptosis through preferential accumulation of arachidonic acid (AA), and represents a first-in-class inhibitor of p53 mutant tumors.	Niclosamide	34-45	tumor protein p53	Homo sapiens	265-268
30258081-7	2018	Therefore, we propose a new paradigm for targeting cancers defective in the p53 pathway, by exploiting their vulnerability to niclosamide-induced mitochondrial uncoupling.	Niclosamide	126-137	tumor protein p53	Homo sapiens	76-79
30189637-0	2018	Involvement of Up-Regulation of DR5 Expression and Down-Regulation of c-FLIP in Niclosamide-Mediated TRAIL Sensitization in Human Renal Carcinoma Caki Cells.	Niclosamide	80-91	CASP8 and FADD like apoptosis regulator	Homo sapiens	70-76
30189637-0	2018	Involvement of Up-Regulation of DR5 Expression and Down-Regulation of c-FLIP in Niclosamide-Mediated TRAIL Sensitization in Human Renal Carcinoma Caki Cells.	Niclosamide	80-91	TNF superfamily member 10	Homo sapiens	101-106
30189637-3	2018	Here, niclosamide was evaluated for identifying strategies to overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resistance.	Niclosamide	6-17	TNF superfamily member 10	Homo sapiens	71-126
30189637-3	2018	Here, niclosamide was evaluated for identifying strategies to overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resistance.	Niclosamide	6-17	TNF superfamily member 10	Homo sapiens	128-133
30189637-5	2018	Niclosamide markedly increased DR5 protein levels, including cell-surface DR5, and decreased c-FLIP protein levels.	Niclosamide	0-11	TNF receptor superfamily member 10b	Homo sapiens	31-34
30189637-5	2018	Niclosamide markedly increased DR5 protein levels, including cell-surface DR5, and decreased c-FLIP protein levels.	Niclosamide	0-11	TNF receptor superfamily member 10b	Homo sapiens	74-77
30189637-5	2018	Niclosamide markedly increased DR5 protein levels, including cell-surface DR5, and decreased c-FLIP protein levels.	Niclosamide	0-11	CASP8 and FADD like apoptosis regulator	Homo sapiens	93-99
30189637-6	2018	Down-regulation of DR5 by specific small interfering RNA (siRNA) and ectopic expression of c-FLIP markedly blocked niclosamide plus TRAIL-induced apoptosis.	Niclosamide	115-126	TNF receptor superfamily member 10b	Homo sapiens	19-22
30189637-6	2018	Down-regulation of DR5 by specific small interfering RNA (siRNA) and ectopic expression of c-FLIP markedly blocked niclosamide plus TRAIL-induced apoptosis.	Niclosamide	115-126	CASP8 and FADD like apoptosis regulator	Homo sapiens	91-97
30189637-7	2018	Our findings provide that niclosamide could overcome resistance to TRAIL through up-regulating DR5 on the cell surface and down-regulating c-FLIP in cancer cells.	Niclosamide	26-37	TNF superfamily member 10	Homo sapiens	67-72
30189637-7	2018	Our findings provide that niclosamide could overcome resistance to TRAIL through up-regulating DR5 on the cell surface and down-regulating c-FLIP in cancer cells.	Niclosamide	26-37	TNF receptor superfamily member 10b	Homo sapiens	95-98
30189637-7	2018	Our findings provide that niclosamide could overcome resistance to TRAIL through up-regulating DR5 on the cell surface and down-regulating c-FLIP in cancer cells.	Niclosamide	26-37	CASP8 and FADD like apoptosis regulator	Homo sapiens	139-145
30189637-8	2018	Taken together, niclosamide may be an attractive candidate to overcome TRAIL resistance.	Niclosamide	16-27	TNF superfamily member 10	Homo sapiens	71-76
29855616-0	2018	Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide.	Niclosamide	155-166	signal transducer and activator of transcription 3	Homo sapiens	14-19
29855616-0	2018	Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide.	Niclosamide	155-166	BCL2 apoptosis regulator	Homo sapiens	24-29
29855616-6	2018	Niclosamide, a potent inhibitor of STAT3, overcame the radioresistance in TNBC cells via inhibition of STAT3 and Bcl-2 and induction of ROS.	Niclosamide	0-11	signal transducer and activator of transcription 3	Homo sapiens	35-40
29855616-6	2018	Niclosamide, a potent inhibitor of STAT3, overcame the radioresistance in TNBC cells via inhibition of STAT3 and Bcl-2 and induction of ROS.	Niclosamide	0-11	signal transducer and activator of transcription 3	Homo sapiens	103-108
29855616-6	2018	Niclosamide, a potent inhibitor of STAT3, overcame the radioresistance in TNBC cells via inhibition of STAT3 and Bcl-2 and induction of ROS.	Niclosamide	0-11	BCL2 apoptosis regulator	Homo sapiens	113-118
29855616-8	2018	These findings demonstrate that activation of STAT3 and Bcl-2 and reduction of ROS contribute to the development of radioresistance in TNBC, and niclosamide acts as a potent radiosensitizer via inhibiting STAT3 and Bcl-2 and increasing ROS generation in TNBC cells and xenograft tumors.	Niclosamide	145-156	signal transducer and activator of transcription 3	Homo sapiens	205-210
29855616-8	2018	These findings demonstrate that activation of STAT3 and Bcl-2 and reduction of ROS contribute to the development of radioresistance in TNBC, and niclosamide acts as a potent radiosensitizer via inhibiting STAT3 and Bcl-2 and increasing ROS generation in TNBC cells and xenograft tumors.	Niclosamide	145-156	BCL2 apoptosis regulator	Homo sapiens	215-220
29480568-0	2018	Niclosamide, an oral antihelmintic drug, exhibits antimetastatic activity in hepatocellular carcinoma cells through downregulating twist-mediated CD10 expression.	Niclosamide	0-11	membrane metalloendopeptidase	Homo sapiens	146-150
30143678-0	2018	The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear beta-catenin/c-Myc axis in OSCC.	Niclosamide	19-30	catenin beta 1	Homo sapiens	142-154
30143678-0	2018	The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear beta-catenin/c-Myc axis in OSCC.	Niclosamide	19-30	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	155-160
30143678-3	2018	We also showed that niclosamide effectively inhibits activation of the Wnt/beta-catenin signaling pathway by targeting multiple components of this pathway, including downregulating the expression beta-catenin, Dishevelled 2 (DVL2), phosphorylated glycogen synthase kinase-3beta (p-GSK3beta) and Cyclin D1, in human OSCC SCC4 and SCC25 cell lines, as well as reduced the formation of primary and secondary tumorspheres.	Niclosamide	20-31	catenin beta 1	Homo sapiens	75-87
30143678-3	2018	We also showed that niclosamide effectively inhibits activation of the Wnt/beta-catenin signaling pathway by targeting multiple components of this pathway, including downregulating the expression beta-catenin, Dishevelled 2 (DVL2), phosphorylated glycogen synthase kinase-3beta (p-GSK3beta) and Cyclin D1, in human OSCC SCC4 and SCC25 cell lines, as well as reduced the formation of primary and secondary tumorspheres.	Niclosamide	20-31	catenin beta 1	Homo sapiens	196-208
30143678-3	2018	We also showed that niclosamide effectively inhibits activation of the Wnt/beta-catenin signaling pathway by targeting multiple components of this pathway, including downregulating the expression beta-catenin, Dishevelled 2 (DVL2), phosphorylated glycogen synthase kinase-3beta (p-GSK3beta) and Cyclin D1, in human OSCC SCC4 and SCC25 cell lines, as well as reduced the formation of primary and secondary tumorspheres.	Niclosamide	20-31	dishevelled segment polarity protein 2	Homo sapiens	210-223
30143678-3	2018	We also showed that niclosamide effectively inhibits activation of the Wnt/beta-catenin signaling pathway by targeting multiple components of this pathway, including downregulating the expression beta-catenin, Dishevelled 2 (DVL2), phosphorylated glycogen synthase kinase-3beta (p-GSK3beta) and Cyclin D1, in human OSCC SCC4 and SCC25 cell lines, as well as reduced the formation of primary and secondary tumorspheres.	Niclosamide	20-31	dishevelled segment polarity protein 2	Homo sapiens	225-229
30143678-3	2018	We also showed that niclosamide effectively inhibits activation of the Wnt/beta-catenin signaling pathway by targeting multiple components of this pathway, including downregulating the expression beta-catenin, Dishevelled 2 (DVL2), phosphorylated glycogen synthase kinase-3beta (p-GSK3beta) and Cyclin D1, in human OSCC SCC4 and SCC25 cell lines, as well as reduced the formation of primary and secondary tumorspheres.	Niclosamide	20-31	glycogen synthase kinase 3 alpha	Homo sapiens	281-289
30143678-3	2018	We also showed that niclosamide effectively inhibits activation of the Wnt/beta-catenin signaling pathway by targeting multiple components of this pathway, including downregulating the expression beta-catenin, Dishevelled 2 (DVL2), phosphorylated glycogen synthase kinase-3beta (p-GSK3beta) and Cyclin D1, in human OSCC SCC4 and SCC25 cell lines, as well as reduced the formation of primary and secondary tumorspheres.	Niclosamide	20-31	cyclin D1	Homo sapiens	295-304
30143678-4	2018	In addition, we showed that niclosamide inhibits the epithelial-to-mesenchymal transition (EMT), migration and colony formation of the OSCC cells, by dose-dependently upregulating E-cadherin and the tissue inhibitor of metalloproteinases 2 (TIMP2) mRNA levels, while reducing the expression levels of vimentin, snail, MMP2 and MMP9 mRNA.	Niclosamide	28-39	cadherin 1	Homo sapiens	180-190
30143678-4	2018	In addition, we showed that niclosamide inhibits the epithelial-to-mesenchymal transition (EMT), migration and colony formation of the OSCC cells, by dose-dependently upregulating E-cadherin and the tissue inhibitor of metalloproteinases 2 (TIMP2) mRNA levels, while reducing the expression levels of vimentin, snail, MMP2 and MMP9 mRNA.	Niclosamide	28-39	TIMP metallopeptidase inhibitor 2	Homo sapiens	199-239
30143678-4	2018	In addition, we showed that niclosamide inhibits the epithelial-to-mesenchymal transition (EMT), migration and colony formation of the OSCC cells, by dose-dependently upregulating E-cadherin and the tissue inhibitor of metalloproteinases 2 (TIMP2) mRNA levels, while reducing the expression levels of vimentin, snail, MMP2 and MMP9 mRNA.	Niclosamide	28-39	TIMP metallopeptidase inhibitor 2	Homo sapiens	241-246
30143678-4	2018	In addition, we showed that niclosamide inhibits the epithelial-to-mesenchymal transition (EMT), migration and colony formation of the OSCC cells, by dose-dependently upregulating E-cadherin and the tissue inhibitor of metalloproteinases 2 (TIMP2) mRNA levels, while reducing the expression levels of vimentin, snail, MMP2 and MMP9 mRNA.	Niclosamide	28-39	vimentin	Homo sapiens	301-309
30143678-4	2018	In addition, we showed that niclosamide inhibits the epithelial-to-mesenchymal transition (EMT), migration and colony formation of the OSCC cells, by dose-dependently upregulating E-cadherin and the tissue inhibitor of metalloproteinases 2 (TIMP2) mRNA levels, while reducing the expression levels of vimentin, snail, MMP2 and MMP9 mRNA.	Niclosamide	28-39	snail family transcriptional repressor 1	Homo sapiens	311-316
30143678-4	2018	In addition, we showed that niclosamide inhibits the epithelial-to-mesenchymal transition (EMT), migration and colony formation of the OSCC cells, by dose-dependently upregulating E-cadherin and the tissue inhibitor of metalloproteinases 2 (TIMP2) mRNA levels, while reducing the expression levels of vimentin, snail, MMP2 and MMP9 mRNA.	Niclosamide	28-39	matrix metallopeptidase 2	Homo sapiens	318-322
30143678-4	2018	In addition, we showed that niclosamide inhibits the epithelial-to-mesenchymal transition (EMT), migration and colony formation of the OSCC cells, by dose-dependently upregulating E-cadherin and the tissue inhibitor of metalloproteinases 2 (TIMP2) mRNA levels, while reducing the expression levels of vimentin, snail, MMP2 and MMP9 mRNA.	Niclosamide	28-39	matrix metallopeptidase 9	Homo sapiens	327-331
30143678-5	2018	These anticancer activities of niclosamide were similar to those caused by interference with nuclear beta-catenin/c-Myc expression using the siRNA transfection.	Niclosamide	31-42	catenin beta 1	Homo sapiens	101-113
30143678-5	2018	These anticancer activities of niclosamide were similar to those caused by interference with nuclear beta-catenin/c-Myc expression using the siRNA transfection.	Niclosamide	31-42	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	114-119
29935261-6	2018	The typical types of chemical mitochondrial uncouplers, carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP), niclosamide, and BAM15, induced biphasic change of STAT3 activity in cardiomyocytes, activating STAT3 at low dose and inhibiting STAT3 at high dose, though the dose range of these drugs was distinct.	Niclosamide	117-128	signal transducer and activator of transcription 3	Rattus norvegicus	168-173
29935261-6	2018	The typical types of chemical mitochondrial uncouplers, carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP), niclosamide, and BAM15, induced biphasic change of STAT3 activity in cardiomyocytes, activating STAT3 at low dose and inhibiting STAT3 at high dose, though the dose range of these drugs was distinct.	Niclosamide	117-128	signal transducer and activator of transcription 3	Rattus norvegicus	213-218
29935261-6	2018	The typical types of chemical mitochondrial uncouplers, carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP), niclosamide, and BAM15, induced biphasic change of STAT3 activity in cardiomyocytes, activating STAT3 at low dose and inhibiting STAT3 at high dose, though the dose range of these drugs was distinct.	Niclosamide	117-128	signal transducer and activator of transcription 3	Rattus norvegicus	213-218
30125275-0	2018	The antiparasitic drug niclosamide inhibits dengue virus infection by interfering with endosomal acidification independent of mTOR.	Niclosamide	23-34	mechanistic target of rapamycin kinase	Homo sapiens	126-130
30125275-6	2018	Niclosamide has been reported to competitively inhibit the mTOR (mammalian target of rapamycin), STAT3 (signal transducer and activator of transcription 3), and NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling pathways; however, selective inhibitors of those pathways did not reduce DENV infection.	Niclosamide	0-11	mechanistic target of rapamycin kinase	Homo sapiens	59-63
30125275-6	2018	Niclosamide has been reported to competitively inhibit the mTOR (mammalian target of rapamycin), STAT3 (signal transducer and activator of transcription 3), and NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling pathways; however, selective inhibitors of those pathways did not reduce DENV infection.	Niclosamide	0-11	mechanistic target of rapamycin kinase	Homo sapiens	65-94
30125275-6	2018	Niclosamide has been reported to competitively inhibit the mTOR (mammalian target of rapamycin), STAT3 (signal transducer and activator of transcription 3), and NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling pathways; however, selective inhibitors of those pathways did not reduce DENV infection.	Niclosamide	0-11	signal transducer and activator of transcription 3	Homo sapiens	97-102
30125275-6	2018	Niclosamide has been reported to competitively inhibit the mTOR (mammalian target of rapamycin), STAT3 (signal transducer and activator of transcription 3), and NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling pathways; however, selective inhibitors of those pathways did not reduce DENV infection.	Niclosamide	0-11	signal transducer and activator of transcription 3	Homo sapiens	104-154
29869315-6	2018	Niclosamide-DLB1 dispersion had the lowest flux due to a significant reduction in Papp.	Niclosamide	0-11	deleted in lymphocytic leukemia 1	Homo sapiens	12-16
29528187-10	2018	Also, niclosamide, a Food and Drug Administration approved antihelminth compound, could effectively inhibit HB cell growth in vitro and in vivo via downregulation of Dvl-2 and beta-catenin expression.	Niclosamide	6-17	catenin beta 1	Homo sapiens	176-188
29603892-4	2018	Such diverse pharmacological activities are a result of niclosamide"s ability to uncouple mitochondrial phosphorylation and modulate a selection of signaling pathways, such as Wnt/beta-catenin, mTOR and JAK/STAT3, which are implicated in many diseases.	Niclosamide	56-67	catenin beta 1	Homo sapiens	180-192
29603892-4	2018	Such diverse pharmacological activities are a result of niclosamide"s ability to uncouple mitochondrial phosphorylation and modulate a selection of signaling pathways, such as Wnt/beta-catenin, mTOR and JAK/STAT3, which are implicated in many diseases.	Niclosamide	56-67	mechanistic target of rapamycin kinase	Homo sapiens	194-198
29603892-4	2018	Such diverse pharmacological activities are a result of niclosamide"s ability to uncouple mitochondrial phosphorylation and modulate a selection of signaling pathways, such as Wnt/beta-catenin, mTOR and JAK/STAT3, which are implicated in many diseases.	Niclosamide	56-67	signal transducer and activator of transcription 3	Homo sapiens	207-212
29480568-3	2018	The present study demonstrated that niclosamide, at 0-40 nM, concentration-dependently inhibited wound closure and the migratory/invasive capacities of human Huh7 and SK-Hep-1 HCC cells without exhibiting cytotoxicity.	Niclosamide	36-47	MIR7-3 host gene	Homo sapiens	158-162
29480568-4	2018	A protease array analysis showed that CD10 was dramatically downregulated in Huh7 cells after niclosamide treatment.	Niclosamide	94-105	membrane metalloendopeptidase	Homo sapiens	38-42
29480568-4	2018	A protease array analysis showed that CD10 was dramatically downregulated in Huh7 cells after niclosamide treatment.	Niclosamide	94-105	MIR7-3 host gene	Homo sapiens	77-81
29480568-5	2018	Western blot and flow cytometric assays further demonstrated that CD10 expression was concentration-dependently downregulated in Huh7 and SK-Hep-1 cells after niclosamide treatment.	Niclosamide	159-170	membrane metalloendopeptidase	Homo sapiens	66-70
29480568-5	2018	Western blot and flow cytometric assays further demonstrated that CD10 expression was concentration-dependently downregulated in Huh7 and SK-Hep-1 cells after niclosamide treatment.	Niclosamide	159-170	MIR7-3 host gene	Homo sapiens	129-133
29480568-6	2018	Mechanistic investigations found that niclosamide suppressed Twist-mediated CD10 transactivation.	Niclosamide	38-49	membrane metalloendopeptidase	Homo sapiens	76-80
29480568-7	2018	Moreover, knockdown of CD10 expression by CD10 small interfering RNA in HCC cells suppressed cell migratory/invasive abilities and overexpression of CD10 relieved the migration inhibition induced by niclosamide.	Niclosamide	199-210	membrane metalloendopeptidase	Homo sapiens	23-27
29480568-8	2018	Taken together, our results indicated that niclosamide could be a potential agent for inhibiting metastasis of HCC, and CD10 is an important target of niclosamide for suppressing the motility of HCC cells.	Niclosamide	151-162	membrane metalloendopeptidase	Homo sapiens	120-124
29910813-6	2018	Finally, we inhibit S100a4 in vivo in the bleomycin-induced lung fibrosis model by treatment with niclosamide.	Niclosamide	98-109	S100 calcium binding protein A4	Mus musculus	20-26
29802333-8	2018	We showed that the upregulated fission induced by niclosamide is accompanied by an increase in the number of large Drp1 oligomers.	Niclosamide	50-61	dynamin 1 like	Homo sapiens	115-119
29721216-0	2018	Correction: Niclosamide and its analogs are potent inhibitors of Wnt/beta-catenin, mTOR and STAT3 signaling in ovarian cancer.	Niclosamide	12-23	catenin beta 1	Homo sapiens	69-81
29783777-2	2018	Current Wnt/beta-catenin inhibitors, such as niclosamide, target the pathway nonspecifically and exhibit poor pharmacokinetics/pharmacodynamics in vivo.	Niclosamide	45-56	catenin beta 1	Homo sapiens	12-24
29783777-3	2018	Niclosamide targets other pathways, including mTOR, STAT3 and Notch.	Niclosamide	0-11	mechanistic target of rapamycin kinase	Homo sapiens	46-50
29783777-3	2018	Niclosamide targets other pathways, including mTOR, STAT3 and Notch.	Niclosamide	0-11	signal transducer and activator of transcription 3	Homo sapiens	52-57
29486057-1	2018	BACKGROUND AND PURPOSE: The anti-helminthic drug niclosamide regulates multiple cellular signals including STAT3, AMP-activated protein kinase (AMPK), Akt, Wnt/beta-catenin and mitochondrial uncoupling which are involved in neointimal hyperplasia.	Niclosamide	49-60	signal transducer and activator of transcription 3	Rattus norvegicus	107-112
29486057-1	2018	BACKGROUND AND PURPOSE: The anti-helminthic drug niclosamide regulates multiple cellular signals including STAT3, AMP-activated protein kinase (AMPK), Akt, Wnt/beta-catenin and mitochondrial uncoupling which are involved in neointimal hyperplasia.	Niclosamide	49-60	AKT serine/threonine kinase 1	Rattus norvegicus	151-154
29486057-1	2018	BACKGROUND AND PURPOSE: The anti-helminthic drug niclosamide regulates multiple cellular signals including STAT3, AMP-activated protein kinase (AMPK), Akt, Wnt/beta-catenin and mitochondrial uncoupling which are involved in neointimal hyperplasia.	Niclosamide	49-60	Wnt family member 2	Rattus norvegicus	156-159
29486057-1	2018	BACKGROUND AND PURPOSE: The anti-helminthic drug niclosamide regulates multiple cellular signals including STAT3, AMP-activated protein kinase (AMPK), Akt, Wnt/beta-catenin and mitochondrial uncoupling which are involved in neointimal hyperplasia.	Niclosamide	49-60	catenin beta 1	Rattus norvegicus	160-172
29486057-8	2018	Niclosamide treatment inhibited serum-induced (15% FBS) and PDGF-BB-induced STAT3 activation (increased protein levels of p-STAT3 at Tyr705 ) but activated AMPK, in A10 cells.	Niclosamide	0-11	signal transducer and activator of transcription 3	Rattus norvegicus	76-81
29486057-8	2018	Niclosamide treatment inhibited serum-induced (15% FBS) and PDGF-BB-induced STAT3 activation (increased protein levels of p-STAT3 at Tyr705 ) but activated AMPK, in A10 cells.	Niclosamide	0-11	signal transducer and activator of transcription 3	Rattus norvegicus	124-129
29721216-0	2018	Correction: Niclosamide and its analogs are potent inhibitors of Wnt/beta-catenin, mTOR and STAT3 signaling in ovarian cancer.	Niclosamide	12-23	mechanistic target of rapamycin kinase	Homo sapiens	83-87
29721216-0	2018	Correction: Niclosamide and its analogs are potent inhibitors of Wnt/beta-catenin, mTOR and STAT3 signaling in ovarian cancer.	Niclosamide	12-23	signal transducer and activator of transcription 3	Homo sapiens	92-97
29545902-8	2018	The effect of an inhibitor of STAT3, niclosamide, was evaluated in ovarian clear-cell cancer cells, and niclosamide treatment decreased expression of p-STAT3, leading to increased apoptosis in a dose-dependent manner in vitro.	Niclosamide	37-48	signal transducer and activator of transcription 3	Homo sapiens	30-35
29486057-12	2018	CONCLUSIONS AND IMPLICATIONS: Niclosamide inhibited vascular smooth muscle cell proliferation and migration and attenuated neointimal hyperplasia in balloon-injured rat carotid arteries through a mechanism involving inhibition of STAT3.	Niclosamide	30-41	signal transducer and activator of transcription 3	Rattus norvegicus	230-235
29545902-8	2018	The effect of an inhibitor of STAT3, niclosamide, was evaluated in ovarian clear-cell cancer cells, and niclosamide treatment decreased expression of p-STAT3, leading to increased apoptosis in a dose-dependent manner in vitro.	Niclosamide	104-115	signal transducer and activator of transcription 3	Homo sapiens	30-35
29545902-8	2018	The effect of an inhibitor of STAT3, niclosamide, was evaluated in ovarian clear-cell cancer cells, and niclosamide treatment decreased expression of p-STAT3, leading to increased apoptosis in a dose-dependent manner in vitro.	Niclosamide	104-115	signal transducer and activator of transcription 3	Homo sapiens	152-157
29544454-4	2018	The Food and Drug Administration (FDA)-approved anti-helminthic drug niclosamide is known to intervene in the Wnt/beta-catenin pathway signaling, leading to reduced expression of S100A4 linked to restricted in vivo metastasis formation.	Niclosamide	69-80	catenin beta 1	Homo sapiens	114-126
29544454-4	2018	The Food and Drug Administration (FDA)-approved anti-helminthic drug niclosamide is known to intervene in the Wnt/beta-catenin pathway signaling, leading to reduced expression of S100A4 linked to restricted in vivo metastasis formation.	Niclosamide	69-80	S100 calcium binding protein A4	Homo sapiens	179-185
29278854-7	2018	STAT3 inhibitor (Niclosamide) obviously enhanced ALK4-inhibted glioma cell proliferation and invasion.	Niclosamide	17-28	signal transducer and activator of transcription 3	Homo sapiens	0-5
29226533-0	2018	The Anthelmintic Drug Niclosamide and Its Analogues Activate the Parkinson"s Disease Associated Protein Kinase PINK1.	Niclosamide	22-33	PTEN induced kinase 1	Homo sapiens	111-116
29226533-3	2018	Herein, it is shown that the anthelmintic drug niclosamide and its analogues are capable of activating PINK1 in cells through the reversible impairment of the mitochondrial membrane potential.	Niclosamide	47-58	PTEN induced kinase 1	Homo sapiens	103-108
29226533-5	2018	These findings suggest that niclosamide and its analogues are robust compounds for the study of the PINK1 pathway and may hold promise as a therapeutic strategy in PD and related disorders.	Niclosamide	28-39	PTEN induced kinase 1	Homo sapiens	100-105
29257330-0	2018	Niclosamide enhances the cytotoxic effect of cisplatin in cisplatin-resistant human lung cancer cells via suppression of lung resistance-related protein and c-myc.	Niclosamide	0-11	major vault protein	Homo sapiens	121-152
29257330-0	2018	Niclosamide enhances the cytotoxic effect of cisplatin in cisplatin-resistant human lung cancer cells via suppression of lung resistance-related protein and c-myc.	Niclosamide	0-11	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	157-162
29257330-6	2018	The impact of niclosamide on the apoptosis of A549/DDP cells was detected by Annexin V-fluorescein isothiocyanate/propidium iodide assay.	Niclosamide	14-25	annexin A5	Homo sapiens	77-86
29257330-7	2018	The expression levels of cisplatin-resistant-associated molecules (lung resistance-related protein and c-myc) following niclosamide treatment in A549/DDP cells were evaluated by western blot analysis.	Niclosamide	120-131	major vault protein	Homo sapiens	67-98
29257330-7	2018	The expression levels of cisplatin-resistant-associated molecules (lung resistance-related protein and c-myc) following niclosamide treatment in A549/DDP cells were evaluated by western blot analysis.	Niclosamide	120-131	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	103-108
29257330-8	2018	The results indicated that niclosamide in combination with DDP demonstrated a synergistic effect in A549/DDP cells and directly induced apoptosis, which may be associated with caspase-3 activation.	Niclosamide	27-38	caspase 3	Homo sapiens	176-185
29257330-9	2018	Furthermore, niclosamide decreased the expression level of c-myc protein, which may influence DDP sensitivity of A549/DDP cells.	Niclosamide	13-24	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	59-64
29278854-7	2018	STAT3 inhibitor (Niclosamide) obviously enhanced ALK4-inhibted glioma cell proliferation and invasion.	Niclosamide	17-28	ALX homeobox 4	Homo sapiens	49-53
29251334-0	2018	Niclosamide acts as a new inhibitor of vasculogenic mimicry in oral cancer through upregulation of miR-124 and downregulation of STAT3.	Niclosamide	0-11	signal transducer and activator of transcription 3	Homo sapiens	129-134
29251334-7	2018	In this study, we found that niclosamide could not only inhibit proliferation and promote apoptosis of oral cancer cells, but also inhibited VM formation in vitro and in vivo through downregulation of the expression of VM-related genes VEGFA, MMP2, ROCK1 and Cdc42.	Niclosamide	29-40	vascular endothelial growth factor A	Homo sapiens	236-241
29251334-7	2018	In this study, we found that niclosamide could not only inhibit proliferation and promote apoptosis of oral cancer cells, but also inhibited VM formation in vitro and in vivo through downregulation of the expression of VM-related genes VEGFA, MMP2, ROCK1 and Cdc42.	Niclosamide	29-40	matrix metallopeptidase 2	Homo sapiens	243-247
29251334-7	2018	In this study, we found that niclosamide could not only inhibit proliferation and promote apoptosis of oral cancer cells, but also inhibited VM formation in vitro and in vivo through downregulation of the expression of VM-related genes VEGFA, MMP2, ROCK1 and Cdc42.	Niclosamide	29-40	Rho associated coiled-coil containing protein kinase 1	Homo sapiens	249-254
29251334-7	2018	In this study, we found that niclosamide could not only inhibit proliferation and promote apoptosis of oral cancer cells, but also inhibited VM formation in vitro and in vivo through downregulation of the expression of VM-related genes VEGFA, MMP2, ROCK1 and Cdc42.	Niclosamide	29-40	cell division cycle 42	Homo sapiens	259-264
29251334-8	2018	In addition, niclosamide upregulated miR-124 and downregulate phosphorylated (p)-STAT3 expression.	Niclosamide	13-24	signal transducer and activator of transcription 3	Homo sapiens	81-86
29251334-9	2018	Further studies showed that, the stable highly expressing miR-124 cell line HN6-miR-124, such as niclosamide, could downregulate p-STAT3 expression.	Niclosamide	97-108	signal transducer and activator of transcription 3	Homo sapiens	131-136
29251334-11	2018	Taken together, our study suggests that niclosamide functions as a new inhibitor of VM in oral cancer through upregulation of miR-124 and downregulation of STAT3, providing a new and safe potential drug candidate for anti-VM therapy.	Niclosamide	40-51	signal transducer and activator of transcription 3	Homo sapiens	156-161
29358661-0	2018	Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.	Niclosamide	13-24	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	53-60
29843133-8	2018	Mechanistically, Niclosamide inhibits the expression of C-MYC and E2F1 while inducing the expression of PTEN in RCC cells.	Niclosamide	17-28	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	56-61
29358661-7	2018	Treatment of WT- and T315I-BCR-ABL-expressing CML cells by niclosamide diminished such an enrichment of Sp1, and decreased WT- and T315I-BCR-ABL transcription and its downstream signaling molecules such as STAT5 and Akt.	Niclosamide	59-70	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	27-34
29358661-7	2018	Treatment of WT- and T315I-BCR-ABL-expressing CML cells by niclosamide diminished such an enrichment of Sp1, and decreased WT- and T315I-BCR-ABL transcription and its downstream signaling molecules such as STAT5 and Akt.	Niclosamide	59-70	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	137-144
29358661-7	2018	Treatment of WT- and T315I-BCR-ABL-expressing CML cells by niclosamide diminished such an enrichment of Sp1, and decreased WT- and T315I-BCR-ABL transcription and its downstream signaling molecules such as STAT5 and Akt.	Niclosamide	59-70	signal transducer and activator of transcription 5A	Homo sapiens	206-211
29358661-7	2018	Treatment of WT- and T315I-BCR-ABL-expressing CML cells by niclosamide diminished such an enrichment of Sp1, and decreased WT- and T315I-BCR-ABL transcription and its downstream signaling molecules such as STAT5 and Akt.	Niclosamide	59-70	AKT serine/threonine kinase 1	Homo sapiens	216-219
29358661-9	2018	The in vivo efficacy validation of p-niclosamide, a water soluble derivative of niclosamide, showed that p-niclosamide significantly inhibited the tumor burden of nude mice subcutaneously bearing T315I-BCR-ABL-expressing CML cells, and prolonged the survival of allografted leukemic mice harboring BaF3-T315I-BCR-ABL.	Niclosamide	37-48	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	202-209
29358661-9	2018	The in vivo efficacy validation of p-niclosamide, a water soluble derivative of niclosamide, showed that p-niclosamide significantly inhibited the tumor burden of nude mice subcutaneously bearing T315I-BCR-ABL-expressing CML cells, and prolonged the survival of allografted leukemic mice harboring BaF3-T315I-BCR-ABL.	Niclosamide	37-48	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	309-316
29358661-10	2018	We conclude that niclosamide is active against T315I-BCR-ABL-expressing cells, and may be a promising agent for CML patients regardless of T315I mutation status.	Niclosamide	17-28	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	53-60
28389414-4	2018	Among the underlying mechanisms associated with the drug actions of niclosamide are uncoupling of oxidative phosphorylation, and modulation of Wnt/beta-catenin, mTORC1, STAT3, NF-kappaB and Notch signaling pathways.	Niclosamide	68-79	catenin beta 1	Homo sapiens	147-159
28389414-4	2018	Among the underlying mechanisms associated with the drug actions of niclosamide are uncoupling of oxidative phosphorylation, and modulation of Wnt/beta-catenin, mTORC1, STAT3, NF-kappaB and Notch signaling pathways.	Niclosamide	68-79	CREB regulated transcription coactivator 1	Mus musculus	161-167
28389414-4	2018	Among the underlying mechanisms associated with the drug actions of niclosamide are uncoupling of oxidative phosphorylation, and modulation of Wnt/beta-catenin, mTORC1, STAT3, NF-kappaB and Notch signaling pathways.	Niclosamide	68-79	signal transducer and activator of transcription 3	Homo sapiens	169-174
28389414-4	2018	Among the underlying mechanisms associated with the drug actions of niclosamide are uncoupling of oxidative phosphorylation, and modulation of Wnt/beta-catenin, mTORC1, STAT3, NF-kappaB and Notch signaling pathways.	Niclosamide	68-79	nuclear factor kappa B subunit 1	Homo sapiens	176-185
29843133-8	2018	Mechanistically, Niclosamide inhibits the expression of C-MYC and E2F1 while inducing the expression of PTEN in RCC cells.	Niclosamide	17-28	E2F transcription factor 1	Homo sapiens	66-70
29843133-8	2018	Mechanistically, Niclosamide inhibits the expression of C-MYC and E2F1 while inducing the expression of PTEN in RCC cells.	Niclosamide	17-28	phosphatase and tensin homolog	Homo sapiens	104-108
29435104-0	2018	Niclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways.	Niclosamide	0-11	cAMP responsive element binding protein 1	Mus musculus	87-91
29435104-4	2018	Niclosamide significantly inhibited CREB function and CREB-mediated gene expression in cells, leading to apoptosis and G1/S cell cycle arrest with reduced phosphorylated CREB levels.	Niclosamide	0-11	cAMP responsive element binding protein 1	Mus musculus	36-40
29435104-4	2018	Niclosamide significantly inhibited CREB function and CREB-mediated gene expression in cells, leading to apoptosis and G1/S cell cycle arrest with reduced phosphorylated CREB levels.	Niclosamide	0-11	cAMP responsive element binding protein 1	Mus musculus	54-58
29435104-4	2018	Niclosamide significantly inhibited CREB function and CREB-mediated gene expression in cells, leading to apoptosis and G1/S cell cycle arrest with reduced phosphorylated CREB levels.	Niclosamide	0-11	cAMP responsive element binding protein 1	Mus musculus	54-58
29435104-5	2018	CREB knockdown protected cells from niclosamide treatment-mediated cytotoxic effects.	Niclosamide	36-47	cAMP responsive element binding protein 1	Mus musculus	0-4
29435104-6	2018	Furthermore, treatment with a combination of niclosamide and CREB inhibitor XX-650-23 showed an additive anti-proliferative effect, consistent with the hypothesis that niclosamide and XX-650-23 regulate the same targets or pathways to inhibit proliferation and survival of AML cells.	Niclosamide	168-179	cAMP responsive element binding protein 1	Mus musculus	61-65
29435104-10	2018	Therefore, our results demonstrate niclosamide as a potential drug to treat AML by inducing apoptosis and cell cycle arrest through inhibition of CREB-dependent pathways in AML cells.	Niclosamide	35-46	cAMP responsive element binding protein 1	Mus musculus	146-150
28376661-3	2017	RESULTS: Protein succination and the ER stress marker C/EBP homologous protein (CHOP) were diminished after pharmaceutical targeting of mitochondrial stress with the chemical uncoupler niclosamide in adipocytes matured in high-glucose concentrations.	Niclosamide	185-196	DNA-damage inducible transcript 3	Mus musculus	80-84
29031202-0	2017	Targeting of cell cycle and let-7a/STAT3 pathway by niclosamide inhibits proliferation, migration and invasion in oral squamous cell carcinoma cells.	Niclosamide	52-63	signal transducer and activator of transcription 3	Homo sapiens	35-40
29031202-5	2017	We showed that niclosamide could inhibit OSCC cells proliferation through causing cell cycle arrest in G1 phase and promoting apoptosis, while the cell cycle-related proteins MCM2, MCM7, CDK2 and CDK4 were downregulated and the apoptosis-related proteins p53 and cleaved caspase-3 were upregulated.	Niclosamide	15-26	minichromosome maintenance complex component 7	Homo sapiens	181-185
29031202-5	2017	We showed that niclosamide could inhibit OSCC cells proliferation through causing cell cycle arrest in G1 phase and promoting apoptosis, while the cell cycle-related proteins MCM2, MCM7, CDK2 and CDK4 were downregulated and the apoptosis-related proteins p53 and cleaved caspase-3 were upregulated.	Niclosamide	15-26	cyclin dependent kinase 2	Homo sapiens	187-191
29031202-5	2017	We showed that niclosamide could inhibit OSCC cells proliferation through causing cell cycle arrest in G1 phase and promoting apoptosis, while the cell cycle-related proteins MCM2, MCM7, CDK2 and CDK4 were downregulated and the apoptosis-related proteins p53 and cleaved caspase-3 were upregulated.	Niclosamide	15-26	cyclin dependent kinase 4	Homo sapiens	196-200
29031202-5	2017	We showed that niclosamide could inhibit OSCC cells proliferation through causing cell cycle arrest in G1 phase and promoting apoptosis, while the cell cycle-related proteins MCM2, MCM7, CDK2 and CDK4 were downregulated and the apoptosis-related proteins p53 and cleaved caspase-3 were upregulated.	Niclosamide	15-26	tumor protein p53	Homo sapiens	255-258
29031202-6	2017	Furthermore, niclosamide could inhibit migration and invasion of OSCC through upregulation of let-7a expression and downregulation of p-STAT3 expression.	Niclosamide	13-24	signal transducer and activator of transcription 3	Homo sapiens	136-141
29031202-8	2017	Like niclosamide, HN6-let-7a could decrease the ability of the cell migration, invasion as well as the expression of p-STAT3.	Niclosamide	5-16	MT-RNR2 like 6 (pseudogene)	Homo sapiens	18-21
29031202-8	2017	Like niclosamide, HN6-let-7a could decrease the ability of the cell migration, invasion as well as the expression of p-STAT3.	Niclosamide	5-16	signal transducer and activator of transcription 3	Homo sapiens	119-124
29031202-9	2017	Collectively, our study finds the new mechanisms that niclosamide inhibits OSCC proliferation through causing cell cycle arrest in G1 phase via downregulation of the above cell cycle-related genes; promotes OSCC apoptosis through upregulation of pro-apoptotic genes; decreases migration and invasion of OSCC by let-7a/STAT3 axis, thus providing a preferred therapeutic candidate for OSCC in future.	Niclosamide	54-65	signal transducer and activator of transcription 3	Homo sapiens	318-323
28813646-0	2017	Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells.	Niclosamide	20-31	cellular inhibitor of PP2A	Homo sapiens	41-46
28813646-0	2017	Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells.	Niclosamide	20-31	protein phosphatase 2 phosphatase activator	Homo sapiens	88-102
28813646-4	2017	We demonstrated that the antihelminthic drug niclosamide inhibited the expression of CIP2A and reactivated the tumor suppressor PP2A in NSCLC cells.	Niclosamide	45-56	cellular inhibitor of PP2A	Homo sapiens	85-90
28813646-4	2017	We demonstrated that the antihelminthic drug niclosamide inhibited the expression of CIP2A and reactivated the tumor suppressor PP2A in NSCLC cells.	Niclosamide	45-56	protein phosphatase 2 phosphatase activator	Homo sapiens	128-132
28813646-5	2017	We performed a drug-repurposing screen and identified niclosamide asa CIP2A suppressor in NSCLC cells.	Niclosamide	54-65	cellular inhibitor of PP2A	Homo sapiens	70-75
28813646-6	2017	Niclosamide inhibited cell proliferation, colony formation, and tumor sphere formation, and induced mitochondrial dysfunction through increased mitochondrial ROS production in NSCLC cells; however, these effects were rescued by CIP2A overexpression, which indicated that the antitumor activity of niclosamide was dependent on CIP2A.	Niclosamide	0-11	cellular inhibitor of PP2A	Homo sapiens	228-233
28813646-6	2017	Niclosamide inhibited cell proliferation, colony formation, and tumor sphere formation, and induced mitochondrial dysfunction through increased mitochondrial ROS production in NSCLC cells; however, these effects were rescued by CIP2A overexpression, which indicated that the antitumor activity of niclosamide was dependent on CIP2A.	Niclosamide	0-11	cellular inhibitor of PP2A	Homo sapiens	326-331
28813646-6	2017	Niclosamide inhibited cell proliferation, colony formation, and tumor sphere formation, and induced mitochondrial dysfunction through increased mitochondrial ROS production in NSCLC cells; however, these effects were rescued by CIP2A overexpression, which indicated that the antitumor activity of niclosamide was dependent on CIP2A.	Niclosamide	297-308	cellular inhibitor of PP2A	Homo sapiens	228-233
28813646-7	2017	We found that niclosamide increased PP2A activity through CIP2A inhibition, which reduced the phosphorylation of several oncogenic proteins.	Niclosamide	14-25	protein phosphatase 2 phosphatase activator	Homo sapiens	36-40
28813646-7	2017	We found that niclosamide increased PP2A activity through CIP2A inhibition, which reduced the phosphorylation of several oncogenic proteins.	Niclosamide	14-25	cellular inhibitor of PP2A	Homo sapiens	58-63
28813646-8	2017	Moreover, we found that a niclosamide analog inhibited CIP2A expression and increased PP2A activity in several types of NSCLC cells.	Niclosamide	26-37	cellular inhibitor of PP2A	Homo sapiens	55-60
28813646-8	2017	Moreover, we found that a niclosamide analog inhibited CIP2A expression and increased PP2A activity in several types of NSCLC cells.	Niclosamide	26-37	protein phosphatase 2 phosphatase activator	Homo sapiens	86-90
28813646-10	2017	Collectively, our data suggested that niclosamide effectively suppressed CIP2A expression and subsequently activated PP2A in NSCLC cells.	Niclosamide	38-49	cellular inhibitor of PP2A	Homo sapiens	73-78
28813646-10	2017	Collectively, our data suggested that niclosamide effectively suppressed CIP2A expression and subsequently activated PP2A in NSCLC cells.	Niclosamide	38-49	protein phosphatase 2 phosphatase activator	Homo sapiens	117-121
28813646-11	2017	This provided strong evidence for the potential use of niclosamide asa PP2A-activating drug in the clinical treatment of NSCLC.	Niclosamide	55-66	protein phosphatase 2 phosphatase activator	Homo sapiens	71-75
28877265-5	2017	In addition, niclosamide treatment led to down-regulation of Wnt/beta-catenin, PI3K/AKT, MAPK/ERK, and STAT3 pro-survival signal transduction pathways to further reduce U-87 MG cell viability.	Niclosamide	13-24	catenin beta 1	Homo sapiens	65-77
28376661-3	2017	RESULTS: Protein succination and the ER stress marker C/EBP homologous protein (CHOP) were diminished after pharmaceutical targeting of mitochondrial stress with the chemical uncoupler niclosamide in adipocytes matured in high-glucose concentrations.	Niclosamide	185-196	DNA-damage inducible transcript 3	Mus musculus	54-78
28877265-5	2017	In addition, niclosamide treatment led to down-regulation of Wnt/beta-catenin, PI3K/AKT, MAPK/ERK, and STAT3 pro-survival signal transduction pathways to further reduce U-87 MG cell viability.	Niclosamide	13-24	AKT serine/threonine kinase 1	Homo sapiens	84-87
28877265-5	2017	In addition, niclosamide treatment led to down-regulation of Wnt/beta-catenin, PI3K/AKT, MAPK/ERK, and STAT3 pro-survival signal transduction pathways to further reduce U-87 MG cell viability.	Niclosamide	13-24	signal transducer and activator of transcription 3	Homo sapiens	103-108
28318631-0	2017	The antihelmenthic phosphate niclosamide impedes renal fibrosis by inhibiting homeodomain-interacting protein kinase 2 expression.	Niclosamide	29-40	homeodomain interacting protein kinase 2	Mus musculus	78-118
28828438-2	2017	Previously, we reported that the anthelmintic drug Niclosamide (NIC) inhibits Wnt/beta-catenin signaling and suppresses colon cancer cell growth.	Niclosamide	51-62	catenin beta 1	Homo sapiens	82-94
28828438-2	2017	Previously, we reported that the anthelmintic drug Niclosamide (NIC) inhibits Wnt/beta-catenin signaling and suppresses colon cancer cell growth.	Niclosamide	64-67	catenin beta 1	Homo sapiens	82-94
28861168-0	2017	Inhibition of Wnt/beta-catenin by anthelmintic drug niclosamide effectively targets growth, survival, and angiogenesis of retinoblastoma.	Niclosamide	52-63	catenin beta 1	Homo sapiens	18-30
28861168-6	2017	We also demonstrated that niclosamide specifically suppresses the levels of p-LRP6, Dvl2, and beta-catenin, but not p-STAT3, in Y79 cells.	Niclosamide	26-37	LDL receptor related protein 6	Homo sapiens	78-82
28861168-6	2017	We also demonstrated that niclosamide specifically suppresses the levels of p-LRP6, Dvl2, and beta-catenin, but not p-STAT3, in Y79 cells.	Niclosamide	26-37	dishevelled segment polarity protein 2	Homo sapiens	84-88
28861168-6	2017	We also demonstrated that niclosamide specifically suppresses the levels of p-LRP6, Dvl2, and beta-catenin, but not p-STAT3, in Y79 cells.	Niclosamide	26-37	catenin beta 1	Homo sapiens	94-106
28861168-8	2017	Stabilization of beta-catenin with the Wnt activator lithium or overexpression of beta-catenin reversed the inhibitory effects of niclosamide in Y79 cells, confirming Wnt/beta-catenin as the molecular target of niclosamide in retinoblastoma cells.	Niclosamide	130-141	catenin beta 1	Homo sapiens	17-29
28861168-8	2017	Stabilization of beta-catenin with the Wnt activator lithium or overexpression of beta-catenin reversed the inhibitory effects of niclosamide in Y79 cells, confirming Wnt/beta-catenin as the molecular target of niclosamide in retinoblastoma cells.	Niclosamide	130-141	catenin beta 1	Homo sapiens	82-94
28861168-8	2017	Stabilization of beta-catenin with the Wnt activator lithium or overexpression of beta-catenin reversed the inhibitory effects of niclosamide in Y79 cells, confirming Wnt/beta-catenin as the molecular target of niclosamide in retinoblastoma cells.	Niclosamide	130-141	catenin beta 1	Homo sapiens	82-94
28861168-8	2017	Stabilization of beta-catenin with the Wnt activator lithium or overexpression of beta-catenin reversed the inhibitory effects of niclosamide in Y79 cells, confirming Wnt/beta-catenin as the molecular target of niclosamide in retinoblastoma cells.	Niclosamide	211-222	catenin beta 1	Homo sapiens	17-29
28861168-8	2017	Stabilization of beta-catenin with the Wnt activator lithium or overexpression of beta-catenin reversed the inhibitory effects of niclosamide in Y79 cells, confirming Wnt/beta-catenin as the molecular target of niclosamide in retinoblastoma cells.	Niclosamide	211-222	catenin beta 1	Homo sapiens	82-94
28861168-8	2017	Stabilization of beta-catenin with the Wnt activator lithium or overexpression of beta-catenin reversed the inhibitory effects of niclosamide in Y79 cells, confirming Wnt/beta-catenin as the molecular target of niclosamide in retinoblastoma cells.	Niclosamide	211-222	catenin beta 1	Homo sapiens	82-94
28861168-9	2017	Importantly, niclosamide significantly enhanced the in vitro and in vivo efficacy of carboplatin and inhibited Wnt/beta-catenin signaling in a retinoblastoma xenograft mouse model.	Niclosamide	13-24	catenin (cadherin associated protein), beta 1	Mus musculus	115-127
28575805-6	2017	Niclosamide potently inhibited cell proliferation and induced apoptosis in human papillary thyroid cancer cell lines TPC-1 and BCPAP, as well as anaplastic thyroid cancer cell line ACT-1.	Niclosamide	0-11	two pore segment channel 1	Homo sapiens	117-122
28575805-6	2017	Niclosamide potently inhibited cell proliferation and induced apoptosis in human papillary thyroid cancer cell lines TPC-1 and BCPAP, as well as anaplastic thyroid cancer cell line ACT-1.	Niclosamide	0-11	TRAF3 interacting protein 2	Homo sapiens	181-186
28575805-7	2017	In addition, the occurrence of TPC-1 apoptosis was correlated with activation of Bax and cleaved caspases-3, and inhibition of Bcl-2 and the mitochondrial membrane potential (DeltaYm), indicating that niclosamide may induce apoptosis through a mitochondria-mediated intrinsic apoptotic pathway.	Niclosamide	201-212	two pore segment channel 1	Homo sapiens	31-36
28575805-7	2017	In addition, the occurrence of TPC-1 apoptosis was correlated with activation of Bax and cleaved caspases-3, and inhibition of Bcl-2 and the mitochondrial membrane potential (DeltaYm), indicating that niclosamide may induce apoptosis through a mitochondria-mediated intrinsic apoptotic pathway.	Niclosamide	201-212	BCL2 apoptosis regulator	Homo sapiens	127-132
28575805-8	2017	Moreover, niclosamide markedly impaired TPC-1 cells and ACT-1 cells invasion.	Niclosamide	10-21	two pore segment channel 1	Homo sapiens	40-45
28575805-8	2017	Moreover, niclosamide markedly impaired TPC-1 cells and ACT-1 cells invasion.	Niclosamide	10-21	TRAF3 interacting protein 2	Homo sapiens	56-61
28685770-4	2017	By screening a total of 2 816 approved and investigational drugs, we identified three potent candidates, temoporfin, niclosamide, and nitazoxanide, as flavivirus NS2B-NS3 interaction inhibitors with nanomolar potencies.	Niclosamide	117-128	KRAS proto-oncogene, GTPase	Homo sapiens	167-170
28500234-6	2017	Niclosamide, a potent inhibitor of AR variants, significantly enhanced bicalutamide treatment.	Niclosamide	0-11	androgen receptor	Homo sapiens	35-37
28781637-0	2017	Niclosamide enhances the antitumor effects of radiation by inhibiting the hypoxia-inducible factor-1alpha/vascular endothelial growth factor signaling pathway in human lung cancer cells.	Niclosamide	0-11	hypoxia inducible factor 1 subunit alpha	Homo sapiens	74-105
28781637-0	2017	Niclosamide enhances the antitumor effects of radiation by inhibiting the hypoxia-inducible factor-1alpha/vascular endothelial growth factor signaling pathway in human lung cancer cells.	Niclosamide	0-11	vascular endothelial growth factor A	Homo sapiens	106-140
28781637-5	2017	The present study demonstrated that niclosamide enhanced the effect of irradiation by inhibiting the hypoxia-inducible factor-1alpha/vascular endothelial growth factor signaling pathway.	Niclosamide	36-47	hypoxia inducible factor 1 subunit alpha	Homo sapiens	101-132
28781637-5	2017	The present study demonstrated that niclosamide enhanced the effect of irradiation by inhibiting the hypoxia-inducible factor-1alpha/vascular endothelial growth factor signaling pathway.	Niclosamide	36-47	vascular endothelial growth factor A	Homo sapiens	133-167
28824321-0	2017	The Simultaneous Inhibitory Effect of Niclosamide on RANKL-Induced Osteoclast Formation and Osteoblast Differentiation.	Niclosamide	38-49	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	53-58
28824321-7	2017	However, the cytotoxic effects of niclosamide obviously appeared at the effective concentrations for inhibiting osteoclastogenesis (0.5-1uM) with increase of apoptosis through caspase-3 activation in osteoblast precursor cell line, MC3T3-E1.	Niclosamide	34-45	caspase 3	Mus musculus	176-185
28500234-7	2017	Niclosamide and bicalutamide combination treatment not only suppressed AR and AR variants expression and inhibited their recruitment to the PSA promoter, but also significantly induced apoptosis in bicalutamide- and enzalutamide-resistant CWR22Rv1 and C4-2B MDVR cells.	Niclosamide	0-11	androgen receptor	Homo sapiens	71-73
28500234-7	2017	Niclosamide and bicalutamide combination treatment not only suppressed AR and AR variants expression and inhibited their recruitment to the PSA promoter, but also significantly induced apoptosis in bicalutamide- and enzalutamide-resistant CWR22Rv1 and C4-2B MDVR cells.	Niclosamide	0-11	androgen receptor	Homo sapiens	78-80
28551619-3	2017	MATERIALS AND METHODS: Niclosamide derivatives were synthesized and tested against a panel of human cancer cells: MDA and MCF7 breast cancer cells, PC3 and DU-145 prostate cancer cells, Hela cervical cancer cells, and HL-60 acute promyelocytic leukemia cells.	Niclosamide	23-34	BTG anti-proliferation factor 2	Homo sapiens	148-151
28437447-5	2017	We observed lower protein levels of Car3 in high-fat diet fed mice treated with niclosamide, a drug published to improve fatty liver symptoms in mice.	Niclosamide	80-91	carbonic anhydrase 3	Mus musculus	36-40
28418862-0	2017	Niclosamide is a potential therapeutic for familial adenomatosis polyposis by disrupting Axin-GSK3 interaction.	Niclosamide	0-11	axin 1	Homo sapiens	89-93
28418862-4	2017	In this study, we show that niclosamide directly targets Axin-GSK3 interaction, at least in part, resulting in suppression of Wnt/Snail-mediated EMT.	Niclosamide	28-39	axin 1	Homo sapiens	57-61
28418862-4	2017	In this study, we show that niclosamide directly targets Axin-GSK3 interaction, at least in part, resulting in suppression of Wnt/Snail-mediated EMT.	Niclosamide	28-39	snail family transcriptional repressor 1	Homo sapiens	130-135
28418862-5	2017	In vitro and in vivo, disruption of Axin-GSK3 complex by niclosamide induces mesenchymal to epithelial reversion at nM concentrations, accompanied with suppression of the tumorigenic potential of colon cancer.	Niclosamide	57-68	axin 1	Homo sapiens	36-40
28418862-6	2017	Niclosamide treatment successfully attenuates Snail abundance while increasing E-cadherin abundance in xenograft tumor.	Niclosamide	0-11	snail family transcriptional repressor 1	Homo sapiens	46-51
28418862-6	2017	Niclosamide treatment successfully attenuates Snail abundance while increasing E-cadherin abundance in xenograft tumor.	Niclosamide	0-11	cadherin 1	Homo sapiens	79-89
28418865-3	2017	In the accompanying report, we show that the anti-helminthic niclosamide directly binds to GSK-3 and inhibits Axin functions in colon cancer cells, with reversion of Snail-mediated epithelial-mesenchymal transition.	Niclosamide	61-72	axin 1	Homo sapiens	110-114
28418865-3	2017	In the accompanying report, we show that the anti-helminthic niclosamide directly binds to GSK-3 and inhibits Axin functions in colon cancer cells, with reversion of Snail-mediated epithelial-mesenchymal transition.	Niclosamide	61-72	snail family transcriptional repressor 1	Homo sapiens	166-171
28418865-6	2017	Further, niclosamide activates Raf-1 kinase inhibitory protein, a downstream target of Snail repressor.	Niclosamide	9-20	snail family transcriptional repressor 1	Homo sapiens	87-92
28903339-5	2017	PI3K inhibitor ZSTK474 or STAT3 inhibitor Niclosamide not only abolished ING5 knockdown-promoted proliferation, colony formation, migration and invasion of lung cancer A549 cells, but also impaired ING5 knockdown-stimulated metastasis of cancer cells in mouse xenograft models with tail vein injection of A549 cells.	Niclosamide	42-53	signal transducer and activator of transcription 3	Mus musculus	26-31
28903339-5	2017	PI3K inhibitor ZSTK474 or STAT3 inhibitor Niclosamide not only abolished ING5 knockdown-promoted proliferation, colony formation, migration and invasion of lung cancer A549 cells, but also impaired ING5 knockdown-stimulated metastasis of cancer cells in mouse xenograft models with tail vein injection of A549 cells.	Niclosamide	42-53	inhibitor of growth family, member 5	Mus musculus	73-77
28903339-5	2017	PI3K inhibitor ZSTK474 or STAT3 inhibitor Niclosamide not only abolished ING5 knockdown-promoted proliferation, colony formation, migration and invasion of lung cancer A549 cells, but also impaired ING5 knockdown-stimulated metastasis of cancer cells in mouse xenograft models with tail vein injection of A549 cells.	Niclosamide	42-53	inhibitor of growth family, member 5	Mus musculus	198-202
28903339-6	2017	Furthermore, treatment with ZSTK474 or Niclosamide decreased protein level of EGFR, p-Akt, IL-6 and p-STAT3, and reversed ING5 knockdown-promoted EMT, as indicated by downregulated expression of EMT marker E-cadherin, an epithelial marker, increased expression of N-cadherin, a mesenchymal marker, and EMT-related transcription factors including Snail, Slug, Smad3 and Twist.	Niclosamide	39-50	epidermal growth factor receptor	Mus musculus	78-82
28903339-6	2017	Furthermore, treatment with ZSTK474 or Niclosamide decreased protein level of EGFR, p-Akt, IL-6 and p-STAT3, and reversed ING5 knockdown-promoted EMT, as indicated by downregulated expression of EMT marker E-cadherin, an epithelial marker, increased expression of N-cadherin, a mesenchymal marker, and EMT-related transcription factors including Snail, Slug, Smad3 and Twist.	Niclosamide	39-50	thymoma viral proto-oncogene 1	Mus musculus	86-89
28903339-6	2017	Furthermore, treatment with ZSTK474 or Niclosamide decreased protein level of EGFR, p-Akt, IL-6 and p-STAT3, and reversed ING5 knockdown-promoted EMT, as indicated by downregulated expression of EMT marker E-cadherin, an epithelial marker, increased expression of N-cadherin, a mesenchymal marker, and EMT-related transcription factors including Snail, Slug, Smad3 and Twist.	Niclosamide	39-50	interleukin 6	Mus musculus	91-95
28903339-6	2017	Furthermore, treatment with ZSTK474 or Niclosamide decreased protein level of EGFR, p-Akt, IL-6 and p-STAT3, and reversed ING5 knockdown-promoted EMT, as indicated by downregulated expression of EMT marker E-cadherin, an epithelial marker, increased expression of N-cadherin, a mesenchymal marker, and EMT-related transcription factors including Snail, Slug, Smad3 and Twist.	Niclosamide	39-50	signal transducer and activator of transcription 3	Mus musculus	102-107
28903339-6	2017	Furthermore, treatment with ZSTK474 or Niclosamide decreased protein level of EGFR, p-Akt, IL-6 and p-STAT3, and reversed ING5 knockdown-promoted EMT, as indicated by downregulated expression of EMT marker E-cadherin, an epithelial marker, increased expression of N-cadherin, a mesenchymal marker, and EMT-related transcription factors including Snail, Slug, Smad3 and Twist.	Niclosamide	39-50	inhibitor of growth family, member 5	Mus musculus	122-126
28903339-6	2017	Furthermore, treatment with ZSTK474 or Niclosamide decreased protein level of EGFR, p-Akt, IL-6 and p-STAT3, and reversed ING5 knockdown-promoted EMT, as indicated by downregulated expression of EMT marker E-cadherin, an epithelial marker, increased expression of N-cadherin, a mesenchymal marker, and EMT-related transcription factors including Snail, Slug, Smad3 and Twist.	Niclosamide	39-50	cadherin 1	Mus musculus	206-216
28903339-6	2017	Furthermore, treatment with ZSTK474 or Niclosamide decreased protein level of EGFR, p-Akt, IL-6 and p-STAT3, and reversed ING5 knockdown-promoted EMT, as indicated by downregulated expression of EMT marker E-cadherin, an epithelial marker, increased expression of N-cadherin, a mesenchymal marker, and EMT-related transcription factors including Snail, Slug, Smad3 and Twist.	Niclosamide	39-50	cadherin 2	Mus musculus	264-274
28903339-6	2017	Furthermore, treatment with ZSTK474 or Niclosamide decreased protein level of EGFR, p-Akt, IL-6 and p-STAT3, and reversed ING5 knockdown-promoted EMT, as indicated by downregulated expression of EMT marker E-cadherin, an epithelial marker, increased expression of N-cadherin, a mesenchymal marker, and EMT-related transcription factors including Snail, Slug, Smad3 and Twist.	Niclosamide	39-50	snail family zinc finger 1	Mus musculus	346-351
28903339-6	2017	Furthermore, treatment with ZSTK474 or Niclosamide decreased protein level of EGFR, p-Akt, IL-6 and p-STAT3, and reversed ING5 knockdown-promoted EMT, as indicated by downregulated expression of EMT marker E-cadherin, an epithelial marker, increased expression of N-cadherin, a mesenchymal marker, and EMT-related transcription factors including Snail, Slug, Smad3 and Twist.	Niclosamide	39-50	snail family zinc finger 2	Mus musculus	353-357
28903339-6	2017	Furthermore, treatment with ZSTK474 or Niclosamide decreased protein level of EGFR, p-Akt, IL-6 and p-STAT3, and reversed ING5 knockdown-promoted EMT, as indicated by downregulated expression of EMT marker E-cadherin, an epithelial marker, increased expression of N-cadherin, a mesenchymal marker, and EMT-related transcription factors including Snail, Slug, Smad3 and Twist.	Niclosamide	39-50	SMAD family member 3	Mus musculus	359-364
28529629-6	2017	Mechanistically, niclosamide abrogated the activation of the NF-kappaB pathway induced by tumor necrosis factor alpha (TNFalpha) in UM cells, while niclosamide elevated the levels of intracellullar and mitochondrial reactive oxygen species (ROS) in UM cells.	Niclosamide	17-28	tumor necrosis factor	Homo sapiens	90-117
28529629-6	2017	Mechanistically, niclosamide abrogated the activation of the NF-kappaB pathway induced by tumor necrosis factor alpha (TNFalpha) in UM cells, while niclosamide elevated the levels of intracellullar and mitochondrial reactive oxygen species (ROS) in UM cells.	Niclosamide	17-28	tumor necrosis factor	Homo sapiens	119-127
28529629-8	2017	Matrix metalloproteinase 9 (MMP-9) knockdown by shRNA potentiated, while ectopic expression of MMP-9 rescued, the niclosamide-attenuated invasion, implying that MMP-9 is pivotal for invasion blockage by niclosamide in UM cells.	Niclosamide	114-125	matrix metallopeptidase 9	Homo sapiens	0-26
28529629-8	2017	Matrix metalloproteinase 9 (MMP-9) knockdown by shRNA potentiated, while ectopic expression of MMP-9 rescued, the niclosamide-attenuated invasion, implying that MMP-9 is pivotal for invasion blockage by niclosamide in UM cells.	Niclosamide	114-125	matrix metallopeptidase 9	Homo sapiens	28-33
28529629-8	2017	Matrix metalloproteinase 9 (MMP-9) knockdown by shRNA potentiated, while ectopic expression of MMP-9 rescued, the niclosamide-attenuated invasion, implying that MMP-9 is pivotal for invasion blockage by niclosamide in UM cells.	Niclosamide	114-125	matrix metallopeptidase 9	Homo sapiens	95-100
28529629-8	2017	Matrix metalloproteinase 9 (MMP-9) knockdown by shRNA potentiated, while ectopic expression of MMP-9 rescued, the niclosamide-attenuated invasion, implying that MMP-9 is pivotal for invasion blockage by niclosamide in UM cells.	Niclosamide	114-125	matrix metallopeptidase 9	Homo sapiens	95-100
28529629-8	2017	Matrix metalloproteinase 9 (MMP-9) knockdown by shRNA potentiated, while ectopic expression of MMP-9 rescued, the niclosamide-attenuated invasion, implying that MMP-9 is pivotal for invasion blockage by niclosamide in UM cells.	Niclosamide	203-214	matrix metallopeptidase 9	Homo sapiens	0-26
28529629-8	2017	Matrix metalloproteinase 9 (MMP-9) knockdown by shRNA potentiated, while ectopic expression of MMP-9 rescued, the niclosamide-attenuated invasion, implying that MMP-9 is pivotal for invasion blockage by niclosamide in UM cells.	Niclosamide	203-214	matrix metallopeptidase 9	Homo sapiens	28-33
28529629-8	2017	Matrix metalloproteinase 9 (MMP-9) knockdown by shRNA potentiated, while ectopic expression of MMP-9 rescued, the niclosamide-attenuated invasion, implying that MMP-9 is pivotal for invasion blockage by niclosamide in UM cells.	Niclosamide	203-214	matrix metallopeptidase 9	Homo sapiens	95-100
28529629-8	2017	Matrix metalloproteinase 9 (MMP-9) knockdown by shRNA potentiated, while ectopic expression of MMP-9 rescued, the niclosamide-attenuated invasion, implying that MMP-9 is pivotal for invasion blockage by niclosamide in UM cells.	Niclosamide	203-214	matrix metallopeptidase 9	Homo sapiens	95-100
28529629-9	2017	Furthermore, our results showed that niclosamide eliminated cancer stem-like cells (CSCs) as reflected by a decrease in the Aldefluor+ percentage and serial re-plating melanosphere formation, and these phenotypes were associated with the suppressed Wnt/beta-catenin pathway by niclosamide in UM.	Niclosamide	37-48	catenin beta 1	Homo sapiens	253-265
28529629-10	2017	Niclosamide caused a dose- and time-dependent reduction of beta-catenin and the key components [e.g., DVLs, phospho-GSK3beta (S9), c-Myc and Cyclin D1] in the canonical Wnt/beta-catenin pathway.	Niclosamide	0-11	catenin beta 1	Homo sapiens	59-71
28529629-10	2017	Niclosamide caused a dose- and time-dependent reduction of beta-catenin and the key components [e.g., DVLs, phospho-GSK3beta (S9), c-Myc and Cyclin D1] in the canonical Wnt/beta-catenin pathway.	Niclosamide	0-11	glycogen synthase kinase 3 beta	Homo sapiens	116-124
28529629-10	2017	Niclosamide caused a dose- and time-dependent reduction of beta-catenin and the key components [e.g., DVLs, phospho-GSK3beta (S9), c-Myc and Cyclin D1] in the canonical Wnt/beta-catenin pathway.	Niclosamide	0-11	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	131-136
28529629-10	2017	Niclosamide caused a dose- and time-dependent reduction of beta-catenin and the key components [e.g., DVLs, phospho-GSK3beta (S9), c-Myc and Cyclin D1] in the canonical Wnt/beta-catenin pathway.	Niclosamide	0-11	cyclin D1	Homo sapiens	141-150
28529629-10	2017	Niclosamide caused a dose- and time-dependent reduction of beta-catenin and the key components [e.g., DVLs, phospho-GSK3beta (S9), c-Myc and Cyclin D1] in the canonical Wnt/beta-catenin pathway.	Niclosamide	0-11	catenin beta 1	Homo sapiens	173-185
28529629-11	2017	Additionally, niclosamide treatment in UM cells reduced ATP and cAMP contents, and decreased PKA-dependent phosphorylation of beta-catenin at S552 and S675 which determine the stability of beta-catenin protein, suggesting that niclosamide may work as a mitochondrial un-coupler.	Niclosamide	14-25	catenin beta 1	Homo sapiens	126-138
28529629-11	2017	Additionally, niclosamide treatment in UM cells reduced ATP and cAMP contents, and decreased PKA-dependent phosphorylation of beta-catenin at S552 and S675 which determine the stability of beta-catenin protein, suggesting that niclosamide may work as a mitochondrial un-coupler.	Niclosamide	14-25	catenin beta 1	Homo sapiens	189-201
28529629-11	2017	Additionally, niclosamide treatment in UM cells reduced ATP and cAMP contents, and decreased PKA-dependent phosphorylation of beta-catenin at S552 and S675 which determine the stability of beta-catenin protein, suggesting that niclosamide may work as a mitochondrial un-coupler.	Niclosamide	227-238	catenin beta 1	Homo sapiens	126-138
28529629-11	2017	Additionally, niclosamide treatment in UM cells reduced ATP and cAMP contents, and decreased PKA-dependent phosphorylation of beta-catenin at S552 and S675 which determine the stability of beta-catenin protein, suggesting that niclosamide may work as a mitochondrial un-coupler.	Niclosamide	227-238	catenin beta 1	Homo sapiens	189-201
27492973-0	2017	Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/beta-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.	Niclosamide	13-24	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	51-54
28367059-0	2017	Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer.	Niclosamide	0-11	signal transducer and activator of transcription 3	Homo sapiens	26-31
28367059-2	2017	In this study, we show that niclosamide can potentially inhibit signal transducer and activator of transcription 3 (STAT3) in colon cancer cell lines.	Niclosamide	28-39	signal transducer and activator of transcription 3	Homo sapiens	64-114
28367059-2	2017	In this study, we show that niclosamide can potentially inhibit signal transducer and activator of transcription 3 (STAT3) in colon cancer cell lines.	Niclosamide	28-39	signal transducer and activator of transcription 3	Homo sapiens	116-121
28367059-3	2017	Combined inhibition of epidermal growth factor receptor and STAT3 by erlotinib and niclosamide synergistically induces apoptosis and antiproliferation in colon cancer cell lines.	Niclosamide	83-94	epidermal growth factor receptor	Homo sapiens	23-55
28367059-3	2017	Combined inhibition of epidermal growth factor receptor and STAT3 by erlotinib and niclosamide synergistically induces apoptosis and antiproliferation in colon cancer cell lines.	Niclosamide	83-94	signal transducer and activator of transcription 3	Homo sapiens	60-65
28233680-0	2017	Benzimidazole inhibitors from the Niclosamide chemotype inhibit Wnt/beta-catenin signaling with selectivity over effects on ATP homeostasis.	Niclosamide	34-45	catenin beta 1	Homo sapiens	68-80
28233680-2	2017	We reported previously that the anthelmintic drug Niclosamide inhibits Wnt/beta-catenin signaling and suppresses colon cancer cell growth in vitro and in vivo.	Niclosamide	50-61	catenin beta 1	Homo sapiens	75-87
28233680-3	2017	To define Niclosamide"s mechanism of Wnt/beta-catenin inhibition, and to improve its selectivity and pharmacokinetic properties as an anticancer treatment, we designed a novel class of benzimidazole inhibitors of Wnt/beta-catenin signaling based on SAR studies of the Niclosamide salicylanilide chemotype.	Niclosamide	10-21	catenin beta 1	Homo sapiens	41-53
28233680-3	2017	To define Niclosamide"s mechanism of Wnt/beta-catenin inhibition, and to improve its selectivity and pharmacokinetic properties as an anticancer treatment, we designed a novel class of benzimidazole inhibitors of Wnt/beta-catenin signaling based on SAR studies of the Niclosamide salicylanilide chemotype.	Niclosamide	10-21	catenin beta 1	Homo sapiens	217-229
28344555-8	2017	GSH synthetase (GS) was predicted as a target of niclosamide.	Niclosamide	49-60	glutathione synthetase	Homo sapiens	0-14
28344555-8	2017	GSH synthetase (GS) was predicted as a target of niclosamide.	Niclosamide	49-60	glutathione synthetase	Homo sapiens	0-2
28344555-9	2017	Molecular docking showed that niclosamide probably binds to the ATP-binding site of GS with a binding energy of -9.40 kcal/mol.	Niclosamide	30-41	glutathione synthetase	Homo sapiens	84-86
28344555-10	2017	Using microscale thermophoresis, the binding affinity between niclosamide and recombinant human GS was measured (binding constant: 5.64 muM).	Niclosamide	62-73	glutathione synthetase	Homo sapiens	96-98
28137584-0	2017	Anthelminthic drug niclosamide sensitizes the responsiveness of cervical cancer cells to paclitaxel via oxidative stress-mediated mTOR inhibition.	Niclosamide	19-30	mechanistic target of rapamycin kinase	Homo sapiens	130-134
28137584-9	2017	ROS scavenge agent N-acetyl-l-cysteine (NAC) completely reversed the effects of niclosamide in increasing cellular ROS, inhibiting proliferation and inducing apoptosis, suggesting that oxidative stress induction is the mechanism of action of niclosamide in cervical cancer cells.	Niclosamide	80-91	X-linked Kx blood group	Homo sapiens	40-43
28137584-9	2017	ROS scavenge agent N-acetyl-l-cysteine (NAC) completely reversed the effects of niclosamide in increasing cellular ROS, inhibiting proliferation and inducing apoptosis, suggesting that oxidative stress induction is the mechanism of action of niclosamide in cervical cancer cells.	Niclosamide	242-253	X-linked Kx blood group	Homo sapiens	40-43
28137584-10	2017	In addition, niclosamide significantly inhibited mammalian target of rapamycin (mTOR) signaling pathway in cervical cancer cells and its inhibitory effect on mTOR is modulated by oxidative stress.	Niclosamide	13-24	mechanistic target of rapamycin kinase	Homo sapiens	49-78
28137584-10	2017	In addition, niclosamide significantly inhibited mammalian target of rapamycin (mTOR) signaling pathway in cervical cancer cells and its inhibitory effect on mTOR is modulated by oxidative stress.	Niclosamide	13-24	mechanistic target of rapamycin kinase	Homo sapiens	80-84
28137584-10	2017	In addition, niclosamide significantly inhibited mammalian target of rapamycin (mTOR) signaling pathway in cervical cancer cells and its inhibitory effect on mTOR is modulated by oxidative stress.	Niclosamide	13-24	mechanistic target of rapamycin kinase	Homo sapiens	158-162
27492973-0	2017	Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/beta-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.	Niclosamide	13-24	forkhead box M1	Mus musculus	59-64
27492973-0	2017	Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/beta-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.	Niclosamide	13-24	catenin (cadherin associated protein), beta 1	Mus musculus	65-77
27492973-5	2017	The effect of disturbing NF-kappaB and FOXM1/beta-catenin by niclosamide on the self-renewal capacity and survival of LSCs was evaluated in vitro in human primary CML CD34+ cells and in vivo in CML mice.	Niclosamide	61-72	forkhead box M1	Homo sapiens	39-44
27492973-10	2017	Niclosamide disrupted the positive feedback loop between NF-kappaB and FOXM1/beta-catenin, thereby impairing the self-renewal capacity and survival of CML LSCs.	Niclosamide	0-11	forkhead box M1	Mus musculus	71-76
27492973-10	2017	Niclosamide disrupted the positive feedback loop between NF-kappaB and FOXM1/beta-catenin, thereby impairing the self-renewal capacity and survival of CML LSCs.	Niclosamide	0-11	catenin (cadherin associated protein), beta 1	Mus musculus	77-89
27492973-12	2017	CONCLUSIONS: Interaction of p65 with FOXM1/beta-catenin is critical in CML and its disruption by niclosamide eradicates LSCs.	Niclosamide	97-108	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	28-31
27492973-12	2017	CONCLUSIONS: Interaction of p65 with FOXM1/beta-catenin is critical in CML and its disruption by niclosamide eradicates LSCs.	Niclosamide	97-108	forkhead box M1	Mus musculus	37-42
27492973-12	2017	CONCLUSIONS: Interaction of p65 with FOXM1/beta-catenin is critical in CML and its disruption by niclosamide eradicates LSCs.	Niclosamide	97-108	catenin (cadherin associated protein), beta 1	Mus musculus	43-55
27449264-9	2016	Treatment with PI3K inhibitor ZSTK474 or STAT3 inhibitor niclosamide reversed the effects of WSTF overexpression by inhibiting cell proliferation, migration and invasion, with decreased level of p-Akt, p-STAT3 and IL-6.	Niclosamide	57-68	signal transducer and activator of transcription 3	Homo sapiens	41-46
27980107-13	2017	Niclosamide prevents oxaliplatin-induced increased levels of IL6, TNFalpha, and advanced oxidized protein products.	Niclosamide	0-11	interleukin 6	Mus musculus	61-64
27980107-13	2017	Niclosamide prevents oxaliplatin-induced increased levels of IL6, TNFalpha, and advanced oxidized protein products.	Niclosamide	0-11	tumor necrosis factor	Mus musculus	66-74
28049163-0	2017	Correction: Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer.	Niclosamide	12-23	androgen receptor	Homo sapiens	33-50
27888804-0	2016	Niclosamide and its analogs are potent inhibitors of Wnt/beta-catenin, mTOR and STAT3 signaling in ovarian cancer.	Niclosamide	0-11	catenin beta 1	Homo sapiens	57-69
27888804-0	2016	Niclosamide and its analogs are potent inhibitors of Wnt/beta-catenin, mTOR and STAT3 signaling in ovarian cancer.	Niclosamide	0-11	mechanistic target of rapamycin kinase	Homo sapiens	71-75
27888804-0	2016	Niclosamide and its analogs are potent inhibitors of Wnt/beta-catenin, mTOR and STAT3 signaling in ovarian cancer.	Niclosamide	0-11	signal transducer and activator of transcription 3	Homo sapiens	80-85
27888804-5	2016	Here we demonstrate that niclosamide, a salicylamide derivative, and two synthetically manufactured niclosamide analogs (analog 11 and 32) caused significant inhibition of proliferation of two chemoresistant ovarian cancer cell lines (A2780cp20 and SKOV3Trip2), tumorspheres isolated from the ascites of EOC patients, and cells from a chemoresistant patient-derived xenograft (PDX).	Niclosamide	25-36	mediator complex subunit 1	Homo sapiens	249-259
27888804-5	2016	Here we demonstrate that niclosamide, a salicylamide derivative, and two synthetically manufactured niclosamide analogs (analog 11 and 32) caused significant inhibition of proliferation of two chemoresistant ovarian cancer cell lines (A2780cp20 and SKOV3Trip2), tumorspheres isolated from the ascites of EOC patients, and cells from a chemoresistant patient-derived xenograft (PDX).	Niclosamide	100-111	mediator complex subunit 1	Homo sapiens	249-259
27631130-7	2016	The phenolic hydroxyl group of niclosamide forms a crucial hydrogen bond with mGluR1/5.	Niclosamide	31-42	glutamate metabotropic receptor 1	Rattus norvegicus	78-84
27793003-8	2016	Our data provide further support that niclosamide inhibits STAT3 through interaction with the DNA-binding domain.	Niclosamide	38-49	signal transducer and activator of transcription 3	Homo sapiens	59-64
27449264-9	2016	Treatment with PI3K inhibitor ZSTK474 or STAT3 inhibitor niclosamide reversed the effects of WSTF overexpression by inhibiting cell proliferation, migration and invasion, with decreased level of p-Akt, p-STAT3 and IL-6.	Niclosamide	57-68	bromodomain adjacent to zinc finger domain 1B	Homo sapiens	93-97
27449264-9	2016	Treatment with PI3K inhibitor ZSTK474 or STAT3 inhibitor niclosamide reversed the effects of WSTF overexpression by inhibiting cell proliferation, migration and invasion, with decreased level of p-Akt, p-STAT3 and IL-6.	Niclosamide	57-68	AKT serine/threonine kinase 1	Homo sapiens	197-200
27449264-9	2016	Treatment with PI3K inhibitor ZSTK474 or STAT3 inhibitor niclosamide reversed the effects of WSTF overexpression by inhibiting cell proliferation, migration and invasion, with decreased level of p-Akt, p-STAT3 and IL-6.	Niclosamide	57-68	signal transducer and activator of transcription 3	Homo sapiens	204-209
27449264-9	2016	Treatment with PI3K inhibitor ZSTK474 or STAT3 inhibitor niclosamide reversed the effects of WSTF overexpression by inhibiting cell proliferation, migration and invasion, with decreased level of p-Akt, p-STAT3 and IL-6.	Niclosamide	57-68	interleukin 6	Homo sapiens	214-218
27449264-10	2016	ZSTK474 and niclosamide also reversed EMT markers and EMT-inducing proteins including Snail, Slug, Twist and CEACAM6 in WSTF-overexpressing A549 cells.	Niclosamide	12-23	snail family transcriptional repressor 1	Homo sapiens	86-91
27449264-10	2016	ZSTK474 and niclosamide also reversed EMT markers and EMT-inducing proteins including Snail, Slug, Twist and CEACAM6 in WSTF-overexpressing A549 cells.	Niclosamide	12-23	snail family transcriptional repressor 2	Homo sapiens	93-97
27449264-10	2016	ZSTK474 and niclosamide also reversed EMT markers and EMT-inducing proteins including Snail, Slug, Twist and CEACAM6 in WSTF-overexpressing A549 cells.	Niclosamide	12-23	CEA cell adhesion molecule 6	Homo sapiens	109-116
27449264-10	2016	ZSTK474 and niclosamide also reversed EMT markers and EMT-inducing proteins including Snail, Slug, Twist and CEACAM6 in WSTF-overexpressing A549 cells.	Niclosamide	12-23	bromodomain adjacent to zinc finger domain 1B	Homo sapiens	120-124
27424318-7	2016	Beneficial immunological effects were also observed: niclosamide decreased the production of effector memory CD4 and CD8 T cells, T-cell infiltration of the skin and visceral organs, and decreased productions of IL-4 and IL-13, and autoimmune B-cell activation.	Niclosamide	53-64	CD4 antigen	Mus musculus	109-112
27424318-7	2016	Beneficial immunological effects were also observed: niclosamide decreased the production of effector memory CD4 and CD8 T cells, T-cell infiltration of the skin and visceral organs, and decreased productions of IL-4 and IL-13, and autoimmune B-cell activation.	Niclosamide	53-64	interleukin 4	Mus musculus	212-216
27424318-7	2016	Beneficial immunological effects were also observed: niclosamide decreased the production of effector memory CD4 and CD8 T cells, T-cell infiltration of the skin and visceral organs, and decreased productions of IL-4 and IL-13, and autoimmune B-cell activation.	Niclosamide	53-64	interleukin 13	Mus musculus	221-226
27545321-4	2016	A theranostics nanoplatform based on luminescent carbon particles decorated with cucurbit[6]uril is introduced for enhancing the solubility of niclosamide, a STAT-3 inhibitor.	Niclosamide	143-154	signal transducer and activator of transcription 3	Homo sapiens	158-164
27613696-9	2016	Beneficial immunological effects were also observed because niclosamide decreased the activation of CD4+ and CD8+ T cells, autoimmune B cell activation, as well as IL-4 and IL-13 production in the skin.	Niclosamide	60-71	interleukin 4	Mus musculus	164-168
27613696-9	2016	Beneficial immunological effects were also observed because niclosamide decreased the activation of CD4+ and CD8+ T cells, autoimmune B cell activation, as well as IL-4 and IL-13 production in the skin.	Niclosamide	60-71	interleukin 13	Mus musculus	173-178
27460529-0	2016	Niclosamide inhibits colon cancer progression through downregulation of the Notch pathway and upregulation of the tumor suppressor miR-200 family.	Niclosamide	0-11	notch receptor 1	Homo sapiens	76-81
28642838-7	2016	For instance, targeting AR-V7 with niclosamide or AKR1C3 with indomethacin can improve enzalutamide and abiraterone treatment.	Niclosamide	35-46	androgen receptor	Homo sapiens	24-26
27535961-5	2016	When the recipient mice were treated with niclosamide for 3 weeks, niclosamide reduced the size of endometriotic implants with inhibition of cell proliferation, and inflammatory signaling including RELA (NFKB) and STAT3 activation, but did not alter expression of steroid hormone receptors.	Niclosamide	42-53	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	198-202
27535961-5	2016	When the recipient mice were treated with niclosamide for 3 weeks, niclosamide reduced the size of endometriotic implants with inhibition of cell proliferation, and inflammatory signaling including RELA (NFKB) and STAT3 activation, but did not alter expression of steroid hormone receptors.	Niclosamide	42-53	signal transducer and activator of transcription 3	Mus musculus	214-219
27535961-5	2016	When the recipient mice were treated with niclosamide for 3 weeks, niclosamide reduced the size of endometriotic implants with inhibition of cell proliferation, and inflammatory signaling including RELA (NFKB) and STAT3 activation, but did not alter expression of steroid hormone receptors.	Niclosamide	67-78	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	198-202
27535961-5	2016	When the recipient mice were treated with niclosamide for 3 weeks, niclosamide reduced the size of endometriotic implants with inhibition of cell proliferation, and inflammatory signaling including RELA (NFKB) and STAT3 activation, but did not alter expression of steroid hormone receptors.	Niclosamide	67-78	signal transducer and activator of transcription 3	Mus musculus	214-219
27520370-0	2016	Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.	Niclosamide	18-29	EPH receptor B2	Homo sapiens	121-124
27520370-0	2016	Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.	Niclosamide	18-29	MAPK interacting serine/threonine kinase 1	Homo sapiens	125-129
27520370-0	2016	Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.	Niclosamide	18-29	eukaryotic translation initiation factor 4E	Homo sapiens	130-135
27520370-2	2016	Here we show that niclosamide, a FDA-approved anthelmintic drug, enhances the sensitivity of BP-CML cells to dasatinib (2nd generation of BCR-ABL TKI) through inhibiting Erk/Mnk1/eIF4E signaling pathway.	Niclosamide	18-29	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	138-145
27520370-2	2016	Here we show that niclosamide, a FDA-approved anthelmintic drug, enhances the sensitivity of BP-CML cells to dasatinib (2nd generation of BCR-ABL TKI) through inhibiting Erk/Mnk1/eIF4E signaling pathway.	Niclosamide	18-29	EPH receptor B2	Homo sapiens	170-173
27520370-2	2016	Here we show that niclosamide, a FDA-approved anthelmintic drug, enhances the sensitivity of BP-CML cells to dasatinib (2nd generation of BCR-ABL TKI) through inhibiting Erk/Mnk1/eIF4E signaling pathway.	Niclosamide	18-29	MAPK interacting serine/threonine kinase 1	Homo sapiens	174-178
27520370-2	2016	Here we show that niclosamide, a FDA-approved anthelmintic drug, enhances the sensitivity of BP-CML cells to dasatinib (2nd generation of BCR-ABL TKI) through inhibiting Erk/Mnk1/eIF4E signaling pathway.	Niclosamide	18-29	eukaryotic translation initiation factor 4E	Homo sapiens	179-184
27520370-5	2016	In addition, combination of niclosamide and dasatinib is synergistic in CML cell lines and BP-CML CD34 cells.	Niclosamide	28-39	CD34 molecule	Homo sapiens	98-102
27520370-6	2016	Importantly, niclosamide inhibits phosphorylation of Erk, Mnk1 and eIF4E in CML cells.	Niclosamide	13-24	EPH receptor B2	Homo sapiens	53-56
27520370-6	2016	Importantly, niclosamide inhibits phosphorylation of Erk, Mnk1 and eIF4E in CML cells.	Niclosamide	13-24	MAPK interacting serine/threonine kinase 1	Homo sapiens	58-62
27520370-6	2016	Importantly, niclosamide inhibits phosphorylation of Erk, Mnk1 and eIF4E in CML cells.	Niclosamide	13-24	eukaryotic translation initiation factor 4E	Homo sapiens	67-72
27520370-7	2016	Overexpression of phosphomimetic but not nonphosphorylatable form of eIF4E reverses the inhibitory effects of niclosamide, suggesting that eIF4E inhibition is required for the action of niclosamide in CML.	Niclosamide	110-121	eukaryotic translation initiation factor 4E	Homo sapiens	139-144
27520370-7	2016	Overexpression of phosphomimetic but not nonphosphorylatable form of eIF4E reverses the inhibitory effects of niclosamide, suggesting that eIF4E inhibition is required for the action of niclosamide in CML.	Niclosamide	186-197	eukaryotic translation initiation factor 4E	Homo sapiens	139-144
27520370-8	2016	Compared to NBM, the increased levels of eIF4E and its activity in CML CD34 cells might explain the selective toxicity of niclosamide in CML versus NBM.	Niclosamide	122-133	eukaryotic translation initiation factor 4E	Homo sapiens	41-46
27520370-8	2016	Compared to NBM, the increased levels of eIF4E and its activity in CML CD34 cells might explain the selective toxicity of niclosamide in CML versus NBM.	Niclosamide	122-133	CD34 molecule	Homo sapiens	71-75
27520370-10	2016	The combination of eIF4E depletion and dasatinib results in similar effects as the combination of niclosamide and dasatinib, suggesting that niclosamide enhances dasatinib through targeting eIF4E.	Niclosamide	141-152	eukaryotic translation initiation factor 4E	Homo sapiens	19-24
27520370-10	2016	The combination of eIF4E depletion and dasatinib results in similar effects as the combination of niclosamide and dasatinib, suggesting that niclosamide enhances dasatinib through targeting eIF4E.	Niclosamide	141-152	eukaryotic translation initiation factor 4E	Homo sapiens	190-195
27520370-11	2016	Our work is the first to demonstrate that niclosamide is a potential drug to overcome resistance to BCR-ABL TKI treatment in BP-CML.	Niclosamide	42-53	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	100-107
27542212-11	2016	We propose that PP and Niclo should be further investigated as potential therapeutics for the treatment of tumors or diseases carrying the constitutive activation of the PI3K/P70S6K signalling axis.	Niclosamide	23-28	ribosomal protein S6 kinase B1	Homo sapiens	175-181
27460529-0	2016	Niclosamide inhibits colon cancer progression through downregulation of the Notch pathway and upregulation of the tumor suppressor miR-200 family.	Niclosamide	0-11	membrane associated ring-CH-type finger 8	Homo sapiens	131-134
27460529-9	2016	Collectively, these findings demonstrate that niclosamide potentially inhibits the progression of colon cancer by downregulating Notch signaling and by upregulating the miR-200 family members.	Niclosamide	46-57	notch receptor 1	Homo sapiens	129-134
27460529-9	2016	Collectively, these findings demonstrate that niclosamide potentially inhibits the progression of colon cancer by downregulating Notch signaling and by upregulating the miR-200 family members.	Niclosamide	46-57	membrane associated ring-CH-type finger 8	Homo sapiens	169-172
27363012-7	2016	These findings indicate that Wnt/beta-catenin signaling pathway plays an important role in the development of radioresistance of TNBC cells, and that niclosamide had significant radiosensitizing effects by inhibiting Wnt/beta-catenin signaling in TNBC cells.	Niclosamide	150-161	catenin beta 1	Homo sapiens	221-233
27652012-0	2016	Niclosamide suppresses renal cell carcinoma by inhibiting Wnt/beta-catenin and inducing mitochondrial dysfunctions.	Niclosamide	0-11	catenin (cadherin associated protein), beta 1	Mus musculus	62-74
27652012-6	2016	Mechanistically, niclosamide decreases beta-catenin levels and therefore suppresses Wnt/beta-catenin activities.	Niclosamide	17-28	catenin (cadherin associated protein), beta 1	Mus musculus	39-51
27652012-6	2016	Mechanistically, niclosamide decreases beta-catenin levels and therefore suppresses Wnt/beta-catenin activities.	Niclosamide	17-28	catenin (cadherin associated protein), beta 1	Mus musculus	88-100
27652012-7	2016	Overexpression of beta-catenin partially reverses the inhibitory effects of niclosamide in RCC cells, demonstrating that besides beta-catenin, other mechanisms are involved in niclosamide"s anti-cancer activity.	Niclosamide	76-87	catenin (cadherin associated protein), beta 1	Mus musculus	18-30
27652012-7	2016	Overexpression of beta-catenin partially reverses the inhibitory effects of niclosamide in RCC cells, demonstrating that besides beta-catenin, other mechanisms are involved in niclosamide"s anti-cancer activity.	Niclosamide	176-187	catenin (cadherin associated protein), beta 1	Mus musculus	18-30
26873959-9	2016	Niclosamide also decreased cellular migration and reduced the level of mediators of epithelial-to-mesenchymal transition, such as N-cadherin and vimentin.	Niclosamide	0-11	cadherin 2	Mus musculus	130-140
26873959-9	2016	Niclosamide also decreased cellular migration and reduced the level of mediators of epithelial-to-mesenchymal transition, such as N-cadherin and vimentin.	Niclosamide	0-11	vimentin	Mus musculus	145-153
26873959-10	2016	Furthermore, niclosamide treatment resulted in decreased expression of beta-catenin.	Niclosamide	13-24	catenin (cadherin associated protein), beta 1	Mus musculus	71-83
27226553-5	2016	Furthermore, the mechanistic view that the proliferative function of Crlz-1 is caused by relaying Wnt/beta-catenin to pre-B cell receptor signaling pathways through the regulation of Runx/CBFbeta heterodimerization was also verified by employing niclosamide, XAV939, and LiCl as Wnt inhibitors and activator, respectively.	Niclosamide	246-257	UTP3 small subunit processome component	Homo sapiens	69-75
27363012-0	2016	Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/beta-catenin signaling.	Niclosamide	0-11	catenin beta 1	Homo sapiens	123-135
27363012-4	2016	Niclosamide, a potent inhibitor of Wnt/beta-catenin signaling, not only inhibited constitutive Wnt/beta-catenin signaling, but also blocked IR-induced Wnt/beta-catenin signaling in TNBC cells.	Niclosamide	0-11	catenin beta 1	Homo sapiens	39-51
27363012-4	2016	Niclosamide, a potent inhibitor of Wnt/beta-catenin signaling, not only inhibited constitutive Wnt/beta-catenin signaling, but also blocked IR-induced Wnt/beta-catenin signaling in TNBC cells.	Niclosamide	0-11	catenin beta 1	Homo sapiens	99-111
27363012-4	2016	Niclosamide, a potent inhibitor of Wnt/beta-catenin signaling, not only inhibited constitutive Wnt/beta-catenin signaling, but also blocked IR-induced Wnt/beta-catenin signaling in TNBC cells.	Niclosamide	0-11	catenin beta 1	Homo sapiens	99-111
27363012-5	2016	In addition, niclosamide sensitized TNBC cells to IR, prevented Wnt3a-induced radioresistance, and overcame beta-catenin-induced radioresistance in TNBC cells.	Niclosamide	13-24	Wnt family member 3A	Homo sapiens	64-69
27363012-5	2016	In addition, niclosamide sensitized TNBC cells to IR, prevented Wnt3a-induced radioresistance, and overcame beta-catenin-induced radioresistance in TNBC cells.	Niclosamide	13-24	catenin beta 1	Homo sapiens	108-120
26810188-8	2016	In addition, niclosamide reversed the EMT phenotype of 231-CR by downregulation of snail and vimentin.	Niclosamide	13-24	snail family transcriptional repressor 1	Homo sapiens	83-88
27160867-10	2016	Treatment of porcine jejunal epithelial (IPEC-J2) cells with the STAT inhibitors fludarabine, niclosamide and teriflunomide, which inhibit the phosphorylation of STAT-1, STAT-3 and STAT-6, respectively, weakened the defense capacity of these cells against bacterial infection.	Niclosamide	94-105	signal transducer and activator of transcription 1	Sus scrofa	162-168
27160867-10	2016	Treatment of porcine jejunal epithelial (IPEC-J2) cells with the STAT inhibitors fludarabine, niclosamide and teriflunomide, which inhibit the phosphorylation of STAT-1, STAT-3 and STAT-6, respectively, weakened the defense capacity of these cells against bacterial infection.	Niclosamide	94-105	signal transducer and activator of transcription 3	Sus scrofa	170-176
27160867-10	2016	Treatment of porcine jejunal epithelial (IPEC-J2) cells with the STAT inhibitors fludarabine, niclosamide and teriflunomide, which inhibit the phosphorylation of STAT-1, STAT-3 and STAT-6, respectively, weakened the defense capacity of these cells against bacterial infection.	Niclosamide	94-105	STAT6	Sus scrofa	181-187
26810188-8	2016	In addition, niclosamide reversed the EMT phenotype of 231-CR by downregulation of snail and vimentin.	Niclosamide	13-24	vimentin	Homo sapiens	93-101
26810188-9	2016	Mechanistically, niclosamide treatment in combination with or without cisplatin significantly inhibited Akt, ERK, and Src signaling pathways.	Niclosamide	17-28	AKT serine/threonine kinase 1	Homo sapiens	104-107
26810188-9	2016	Mechanistically, niclosamide treatment in combination with or without cisplatin significantly inhibited Akt, ERK, and Src signaling pathways.	Niclosamide	17-28	mitogen-activated protein kinase 1	Homo sapiens	109-112
26810188-9	2016	Mechanistically, niclosamide treatment in combination with or without cisplatin significantly inhibited Akt, ERK, and Src signaling pathways.	Niclosamide	17-28	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	118-121
27127879-0	2016	S100A4 drives non-small cell lung cancer invasion, associates with poor prognosis, and is effectively targeted by the FDA-approved anti-helminthic agent niclosamide.	Niclosamide	153-164	S100 calcium binding protein A4	Homo sapiens	0-6
27127879-8	2016	Niclosamide, a reported inhibitor of S100A4, blocks expression and function of S100A4 with a reduction in proliferation, invasion and NF-kappaB-mediated MMP9 expression.	Niclosamide	0-11	S100 calcium binding protein A4	Homo sapiens	37-43
27127879-8	2016	Niclosamide, a reported inhibitor of S100A4, blocks expression and function of S100A4 with a reduction in proliferation, invasion and NF-kappaB-mediated MMP9 expression.	Niclosamide	0-11	S100 calcium binding protein A4	Homo sapiens	79-85
27127879-8	2016	Niclosamide, a reported inhibitor of S100A4, blocks expression and function of S100A4 with a reduction in proliferation, invasion and NF-kappaB-mediated MMP9 expression.	Niclosamide	0-11	nuclear factor kappa B subunit 1	Homo sapiens	134-143
27127879-8	2016	Niclosamide, a reported inhibitor of S100A4, blocks expression and function of S100A4 with a reduction in proliferation, invasion and NF-kappaB-mediated MMP9 expression.	Niclosamide	0-11	matrix metallopeptidase 9	Homo sapiens	153-157
27338550-2	2016	Niclosamide, a salicylamide derivative used in the treatment of tapeworm infections, targets the Wnt/beta-catenin pathway.	Niclosamide	0-11	catenin beta 1	Homo sapiens	101-113
27413334-6	2016	Recovery of ailing sheep was observed after oral treatment of niclosamide @ of 100 mg/kg bwt along with supportive therapy.	Niclosamide	62-73	BWT	Ovis aries	89-92
27338550-10	2016	The Wnt promoter activity of LEF/TCF significantly decreased with niclosamide concentrations of 10 and 50 muM after 12 h of incubation.	Niclosamide	66-77	lymphoid enhancer binding factor 1	Homo sapiens	33-36
26964897-6	2016	Interestingly, both niclosamide and the PKA inhibitor H89 blocked the glucagon effect on beta-catenin signalling, leading to a reduction in target gene expression.	Niclosamide	20-31	catenin beta 1	Rattus norvegicus	89-101
27049719-0	2016	Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer.	Niclosamide	0-11	androgen receptor	Homo sapiens	61-78
26964897-0	2016	Niclosamide blocks glucagon phosphorylation of Ser552 on beta-catenin in primary rat hepatocytes via PKA signalling.	Niclosamide	0-11	catenin beta 1	Rattus norvegicus	57-69
26964897-0	2016	Niclosamide blocks glucagon phosphorylation of Ser552 on beta-catenin in primary rat hepatocytes via PKA signalling.	Niclosamide	0-11	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	101-104
26912210-7	2016	Blocking Wnt signaling using a Frizzled receptor inhibitor (Niclosamide) abolished TGF-beta/Smad3-induced beta-catenin stabilization.	Niclosamide	60-71	Wnt family member 2	Rattus norvegicus	9-12
26912210-7	2016	Blocking Wnt signaling using a Frizzled receptor inhibitor (Niclosamide) abolished TGF-beta/Smad3-induced beta-catenin stabilization.	Niclosamide	60-71	transforming growth factor, beta 1	Rattus norvegicus	83-91
26912210-7	2016	Blocking Wnt signaling using a Frizzled receptor inhibitor (Niclosamide) abolished TGF-beta/Smad3-induced beta-catenin stabilization.	Niclosamide	60-71	SMAD family member 3	Rattus norvegicus	92-97
26912210-7	2016	Blocking Wnt signaling using a Frizzled receptor inhibitor (Niclosamide) abolished TGF-beta/Smad3-induced beta-catenin stabilization.	Niclosamide	60-71	catenin beta 1	Rattus norvegicus	106-118
26964897-7	2016	Likewise, niclosamide inhibited cAMP levels and the direct addition of db-cAMP (dibutyryl-cAMP sodium salt) also resulted in Ser(552) phosphorylation of beta-catenin.	Niclosamide	10-21	catenin beta 1	Rattus norvegicus	153-165
26964897-8	2016	We have identified a new pathway via glucagon signalling that leads to increased beta-catenin activity that can be reversed with the antihelminthic drug niclosamide, which has recently shown promise as a potential treatment of T2D (Type 2 diabetes).	Niclosamide	153-164	catenin beta 1	Rattus norvegicus	81-93
26917416-0	2016	Niclosamide induced cell apoptosis via upregulation of ATF3 and activation of PERK in Hepatocellular carcinoma cells.	Niclosamide	0-11	activating transcription factor 3	Homo sapiens	55-59
26917416-0	2016	Niclosamide induced cell apoptosis via upregulation of ATF3 and activation of PERK in Hepatocellular carcinoma cells.	Niclosamide	0-11	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	78-82
26917416-6	2016	Furthermore, our study revealed that RNA-dependent protein kinase-like kinase (PERK) is activated and its expression is up-regulated in HCC cells which are exposed to niclosamide.	Niclosamide	167-178	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	79-83
26917416-7	2016	niclosamide also significantly increase activating transcription factor 3 (ATF3), activating transcription factor 4 (ATF4) and CCAAT/enhancer-binding protein-homologous protein (CHOP) expression in HCC cells.	Niclosamide	0-11	activating transcription factor 3	Homo sapiens	75-79
26917416-7	2016	niclosamide also significantly increase activating transcription factor 3 (ATF3), activating transcription factor 4 (ATF4) and CCAAT/enhancer-binding protein-homologous protein (CHOP) expression in HCC cells.	Niclosamide	0-11	activating transcription factor 4	Homo sapiens	82-115
26917416-7	2016	niclosamide also significantly increase activating transcription factor 3 (ATF3), activating transcription factor 4 (ATF4) and CCAAT/enhancer-binding protein-homologous protein (CHOP) expression in HCC cells.	Niclosamide	0-11	activating transcription factor 4	Homo sapiens	117-121
26917416-7	2016	niclosamide also significantly increase activating transcription factor 3 (ATF3), activating transcription factor 4 (ATF4) and CCAAT/enhancer-binding protein-homologous protein (CHOP) expression in HCC cells.	Niclosamide	0-11	DNA damage inducible transcript 3	Homo sapiens	127-176
26917416-7	2016	niclosamide also significantly increase activating transcription factor 3 (ATF3), activating transcription factor 4 (ATF4) and CCAAT/enhancer-binding protein-homologous protein (CHOP) expression in HCC cells.	Niclosamide	0-11	DNA damage inducible transcript 3	Homo sapiens	178-182
26917416-8	2016	It"s suggested that the function of niclosamide was abrogated by PERK inhibitor or absent ATF3.	Niclosamide	36-47	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	65-69
26917416-8	2016	It"s suggested that the function of niclosamide was abrogated by PERK inhibitor or absent ATF3.	Niclosamide	36-47	activating transcription factor 3	Homo sapiens	90-94
26917416-10	2016	CONCLUSION: Taken together, our results indicate that ATF3 plays an integral role in ER stress activated and cell apoptosis induced by niclosamide in HCC cells.	Niclosamide	135-146	activating transcription factor 3	Homo sapiens	54-58
26882567-8	2016	Moreover, the identified HIF-1 inhibitors, such as mycophenolate mofetil, niclosamide, and trametinib, were able to suppress cancer cell proliferation and angiogenesis.	Niclosamide	74-85	hypoxia inducible factor 1 subunit alpha	Homo sapiens	25-30
26792726-0	2016	Niclosamide suppresses RANKL-induced osteoclastogenesis and prevents LPS-induced bone loss.	Niclosamide	0-11	TNF superfamily member 11	Homo sapiens	23-28
26792726-5	2016	Our in vitro study showed that receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclast differentiation was inhibited by niclosamide, due to inhibition of serine-threonine protein kinase (Akt) phosphorylation, inhibitor of nuclear factor-kappaB (IkappaB), and STAT3 serine(727).	Niclosamide	142-153	TNF superfamily member 11	Homo sapiens	31-81
26792726-5	2016	Our in vitro study showed that receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclast differentiation was inhibited by niclosamide, due to inhibition of serine-threonine protein kinase (Akt) phosphorylation, inhibitor of nuclear factor-kappaB (IkappaB), and STAT3 serine(727).	Niclosamide	142-153	TNF superfamily member 11	Homo sapiens	83-88
26792726-5	2016	Our in vitro study showed that receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclast differentiation was inhibited by niclosamide, due to inhibition of serine-threonine protein kinase (Akt) phosphorylation, inhibitor of nuclear factor-kappaB (IkappaB), and STAT3 serine(727).	Niclosamide	142-153	AKT serine/threonine kinase 1	Homo sapiens	209-212
26792726-5	2016	Our in vitro study showed that receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclast differentiation was inhibited by niclosamide, due to inhibition of serine-threonine protein kinase (Akt) phosphorylation, inhibitor of nuclear factor-kappaB (IkappaB), and STAT3 serine(727).	Niclosamide	142-153	signal transducer and activator of transcription 3	Homo sapiens	281-286
26792726-6	2016	Niclosamide decreased the expression of the major transcription factors c-Fos and NFATc1, and thereafter abrogated the mRNA expression of osteoclast-specific genes, including TRAP, OSCAR, alphav/beta3 integrin (integrin alphav, integrin beta3), and cathepsin K (CtsK).	Niclosamide	0-11	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	72-77
26792726-6	2016	Niclosamide decreased the expression of the major transcription factors c-Fos and NFATc1, and thereafter abrogated the mRNA expression of osteoclast-specific genes, including TRAP, OSCAR, alphav/beta3 integrin (integrin alphav, integrin beta3), and cathepsin K (CtsK).	Niclosamide	0-11	nuclear factor of activated T cells 1	Homo sapiens	82-88
26792726-6	2016	Niclosamide decreased the expression of the major transcription factors c-Fos and NFATc1, and thereafter abrogated the mRNA expression of osteoclast-specific genes, including TRAP, OSCAR, alphav/beta3 integrin (integrin alphav, integrin beta3), and cathepsin K (CtsK).	Niclosamide	0-11	TRAP	Homo sapiens	175-179
26792726-6	2016	Niclosamide decreased the expression of the major transcription factors c-Fos and NFATc1, and thereafter abrogated the mRNA expression of osteoclast-specific genes, including TRAP, OSCAR, alphav/beta3 integrin (integrin alphav, integrin beta3), and cathepsin K (CtsK).	Niclosamide	0-11	integrin subunit alpha V	Homo sapiens	211-242
26792726-6	2016	Niclosamide decreased the expression of the major transcription factors c-Fos and NFATc1, and thereafter abrogated the mRNA expression of osteoclast-specific genes, including TRAP, OSCAR, alphav/beta3 integrin (integrin alphav, integrin beta3), and cathepsin K (CtsK).	Niclosamide	0-11	cathepsin K	Homo sapiens	249-260
26792726-6	2016	Niclosamide decreased the expression of the major transcription factors c-Fos and NFATc1, and thereafter abrogated the mRNA expression of osteoclast-specific genes, including TRAP, OSCAR, alphav/beta3 integrin (integrin alphav, integrin beta3), and cathepsin K (CtsK).	Niclosamide	0-11	cathepsin K	Homo sapiens	262-266
26643609-0	2016	Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer.	Niclosamide	0-11	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-135
26643609-6	2016	Interestingly, niclosamide reversed epithelial-mesenchymal transition, induced apoptosis and inhibited cell growth by perturbing aberrant signaling pathway activation in lapatinib-resistant human epidermal growth factor receptor 2-positive cells.	Niclosamide	15-26	erb-b2 receptor tyrosine kinase 2	Homo sapiens	196-230
26643609-9	2016	These findings suggest a role of niclosamide or derivatives optimized for more favorable bioavailability not only in reversing lapatinib resistance but also in reducing metastatic potential during the treatment of human epidermal growth factor receptor 2-positive breast cancer.	Niclosamide	33-44	erb-b2 receptor tyrosine kinase 2	Homo sapiens	220-254
26703449-4	2016	N-acetyl-l-cysteine (NAC) pretreatment significantly attenuated niclosamide-induced apoptosis.	Niclosamide	64-75	X-linked Kx blood group	Homo sapiens	21-24
26703449-6	2016	The activation of mitochondrial pathway in niclosamide-treated RA FLS induced the cytochrome C, cleavage of caspase-9 and caspase-3.	Niclosamide	43-54	cytochrome c, somatic	Homo sapiens	82-94
26703449-6	2016	The activation of mitochondrial pathway in niclosamide-treated RA FLS induced the cytochrome C, cleavage of caspase-9 and caspase-3.	Niclosamide	43-54	caspase 9	Homo sapiens	108-117
26703449-6	2016	The activation of mitochondrial pathway in niclosamide-treated RA FLS induced the cytochrome C, cleavage of caspase-9 and caspase-3.	Niclosamide	43-54	caspase 3	Homo sapiens	122-131
26703449-7	2016	Additionally, niclosamide inhibited the phosphorylation of Akt.	Niclosamide	14-25	AKT serine/threonine kinase 1	Homo sapiens	59-62
26703449-8	2016	Collectively, our results reveal that niclosamide inhibits cell proliferation and induces mitochondrial apoptosis of RAFLSs, which is associated with the modulation of Akt signaling pathways.	Niclosamide	38-49	AKT serine/threonine kinase 1	Homo sapiens	168-171
27497986-9	2016	RESULTS: We find that Niclosamide is highly effective on inhibiting cell proliferation, cell migration, and cell cycle progression, and inducing apoptosis in human ovarian cancer cells, possibly by targeting multiple signaling pathways involved in ELK1/SRF, AP-1, MYC/MAX and NFkB.	Niclosamide	22-33	ETS transcription factor ELK1	Homo sapiens	248-252
26784896-8	2016	Further studies revealed that niclosamide blocked acidic pHe, HGF, and epidermal growth factor (EGF)-induced anterograde lysosome redistribution, protease secretion, motility, and invasion of DU145 castrate resistant prostate cancer cells at clinically relevant concentrations.	Niclosamide	30-41	hepatocyte growth factor	Homo sapiens	62-65
27497986-9	2016	RESULTS: We find that Niclosamide is highly effective on inhibiting cell proliferation, cell migration, and cell cycle progression, and inducing apoptosis in human ovarian cancer cells, possibly by targeting multiple signaling pathways involved in ELK1/SRF, AP-1, MYC/MAX and NFkB.	Niclosamide	22-33	serum response factor	Homo sapiens	253-256
27497986-9	2016	RESULTS: We find that Niclosamide is highly effective on inhibiting cell proliferation, cell migration, and cell cycle progression, and inducing apoptosis in human ovarian cancer cells, possibly by targeting multiple signaling pathways involved in ELK1/SRF, AP-1, MYC/MAX and NFkB.	Niclosamide	22-33	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	258-271
27497986-10	2016	Silencing IGF-1R exert a similar but weaker effect than that of Niclosamide"s.	Niclosamide	64-75	insulin like growth factor 1 receptor	Homo sapiens	10-16
27497986-11	2016	However, silencing IGF-1R significantly sensitizes ovarian cancer cells to Niclosamide-induced anti-proliferative and anticancer activities both in vitro and in vivo.	Niclosamide	75-86	insulin like growth factor 1 receptor	Homo sapiens	19-25
26068521-0	2016	Metabolism of the anthelmintic drug niclosamide by cytochrome P450 enzymes and UDP-glucuronosyltransferases: metabolite elucidation and main contributions from CYP1A2 and UGT1A1.	Niclosamide	36-47	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	160-166
26068521-0	2016	Metabolism of the anthelmintic drug niclosamide by cytochrome P450 enzymes and UDP-glucuronosyltransferases: metabolite elucidation and main contributions from CYP1A2 and UGT1A1.	Niclosamide	36-47	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	171-177
26068521-9	2016	The important role of CYP1A2 in niclosamide metabolism was further confirmed by activity correlation analyses as well as inhibition experiments using specific inhibitors.	Niclosamide	32-43	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	22-28
26068521-11	2016	Although seven UGT enzymes were able to catalyze glucuronidation of niclosamide, UGT1A1 and 1A3 were the enzymes showed the highest metabolic activities.	Niclosamide	68-79	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	81-95
26068521-12	2016	Activity correlation analyses demonstrated that UGT1A1 played a predominant role in hepatic glucuronidation of niclosamide, whereas the role of UGT1A3 was negligible.	Niclosamide	111-122	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	48-54
26068521-14	2016	In conclusion, niclosamide was subjected to efficient metabolic reactions hydroxylation and glucuronidation, wherein CYP1A2 and UGT1A1 were the main contributing enzymes, respectively.	Niclosamide	15-26	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	117-123
26068521-14	2016	In conclusion, niclosamide was subjected to efficient metabolic reactions hydroxylation and glucuronidation, wherein CYP1A2 and UGT1A1 were the main contributing enzymes, respectively.	Niclosamide	15-26	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	128-134
26499405-9	2015	Niclosamide also reduced protein expression of VCAM-1 and ICAM1 in HUVECs.Niclosamide significantly inhibited HUVEC proliferation,migration and cord-like structure formation.	Niclosamide	0-11	vascular cell adhesion molecule 1	Homo sapiens	47-53
26499405-9	2015	Niclosamide also reduced protein expression of VCAM-1 and ICAM1 in HUVECs.Niclosamide significantly inhibited HUVEC proliferation,migration and cord-like structure formation.	Niclosamide	0-11	intercellular adhesion molecule 1	Homo sapiens	58-63
26499405-9	2015	Niclosamide also reduced protein expression of VCAM-1 and ICAM1 in HUVECs.Niclosamide significantly inhibited HUVEC proliferation,migration and cord-like structure formation.	Niclosamide	74-85	vascular cell adhesion molecule 1	Homo sapiens	47-53
26499405-10	2015	Niclosamide also suppresses VEGF-induced angiogenesis in vivo.Niclosamide attenuated IKK-mediated activation of NF-kappaB pathway in TNFalpha-induced endothelial cells.	Niclosamide	0-11	vascular endothelial growth factor A	Homo sapiens	28-32
26499405-10	2015	Niclosamide also suppresses VEGF-induced angiogenesis in vivo.Niclosamide attenuated IKK-mediated activation of NF-kappaB pathway in TNFalpha-induced endothelial cells.	Niclosamide	0-11	tumor necrosis factor	Homo sapiens	133-141
26499405-10	2015	Niclosamide also suppresses VEGF-induced angiogenesis in vivo.Niclosamide attenuated IKK-mediated activation of NF-kappaB pathway in TNFalpha-induced endothelial cells.	Niclosamide	62-73	vascular endothelial growth factor A	Homo sapiens	28-32
26499405-10	2015	Niclosamide also suppresses VEGF-induced angiogenesis in vivo.Niclosamide attenuated IKK-mediated activation of NF-kappaB pathway in TNFalpha-induced endothelial cells.	Niclosamide	62-73	tumor necrosis factor	Homo sapiens	133-141
26499405-11	2015	Niclosamide also suppresses VEGF-induced endothelial VEGFR2 activation and downstream P-AKT, P-mTOR and P-p70S6K.	Niclosamide	0-11	vascular endothelial growth factor A	Homo sapiens	28-32
26499405-11	2015	Niclosamide also suppresses VEGF-induced endothelial VEGFR2 activation and downstream P-AKT, P-mTOR and P-p70S6K.	Niclosamide	0-11	kinase insert domain receptor	Homo sapiens	53-59
26788160-0	2015	Niclosamide suppresses migration of hepatocellular carcinoma cells and downregulates matrix metalloproteinase-9 expression.	Niclosamide	0-11	matrix metallopeptidase 9	Homo sapiens	85-111
26788160-7	2015	Compared with the control treatment, treatment with 10 microm niclosamide suppressed the proliferation of the HLF and PRL/PRF/5 cells to 49.9+-3.7 and 17.9+-11.5% (P&lt;0.05), respectively.	Niclosamide	62-73	HLF transcription factor, PAR bZIP family member	Homo sapiens	110-113
26788160-7	2015	Compared with the control treatment, treatment with 10 microm niclosamide suppressed the proliferation of the HLF and PRL/PRF/5 cells to 49.9+-3.7 and 17.9+-11.5% (P&lt;0.05), respectively.	Niclosamide	62-73	prolactin	Homo sapiens	118-121
26788160-8	2015	Furthermore, compared with the control treatment, treatment with 1.0 microM niclosamide downregulated the expression of cyclin D1 to 52.4+-4.4 and 23.9+-5.4% (P&lt;0.05) in the HLF and PRL/PRF/5 cells, respectively.	Niclosamide	76-87	cyclin D1	Homo sapiens	120-129
26788160-8	2015	Furthermore, compared with the control treatment, treatment with 1.0 microM niclosamide downregulated the expression of cyclin D1 to 52.4+-4.4 and 23.9+-5.4% (P&lt;0.05) in the HLF and PRL/PRF/5 cells, respectively.	Niclosamide	76-87	HLF transcription factor, PAR bZIP family member	Homo sapiens	177-180
26788160-8	2015	Furthermore, compared with the control treatment, treatment with 1.0 microM niclosamide downregulated the expression of cyclin D1 to 52.4+-4.4 and 23.9+-5.4% (P&lt;0.05) in the HLF and PRL/PRF/5 cells, respectively.	Niclosamide	76-87	prolactin	Homo sapiens	185-188
26788160-9	2015	In the scratch assay, treatment of the HLF cells with niclosamide (1.0 microm) decreased the distance of the scratched line from the growing edge to 4.6+-1.0 mm compared with the 9.2+-1.4 mm observed with the control treatment (P&lt;0.05).	Niclosamide	54-65	HLF transcription factor, PAR bZIP family member	Homo sapiens	39-42
26788160-10	2015	Similarly, treatment of the PRL/PRF/5 cells with niclosamide (1.0 microm) also decreased the distance of the scratched line from the growing edge to 3.0+-0.8 mm compared with the 5.5+-0.9 mm observed with the control treatment (P&lt;0.05).	Niclosamide	49-60	prolactin	Homo sapiens	28-31
26788160-11	2015	Further, MMP9 expression levels in the HLF cells treated with 1.0 microm niclosamide decreased to 22.4+-1.76% (P&lt;0.05) compared with those in the untreated control HLF cells.	Niclosamide	73-84	matrix metallopeptidase 9	Homo sapiens	9-13
26788160-11	2015	Further, MMP9 expression levels in the HLF cells treated with 1.0 microm niclosamide decreased to 22.4+-1.76% (P&lt;0.05) compared with those in the untreated control HLF cells.	Niclosamide	73-84	HLF transcription factor, PAR bZIP family member	Homo sapiens	39-42
26788160-11	2015	Further, MMP9 expression levels in the HLF cells treated with 1.0 microm niclosamide decreased to 22.4+-1.76% (P&lt;0.05) compared with those in the untreated control HLF cells.	Niclosamide	73-84	HLF transcription factor, PAR bZIP family member	Homo sapiens	167-170
26788160-12	2015	Similarly, expression level of MMP9 in the PRL/PRF/5 cells treated with 1.0 microm niclosamide deceased to 18.7+-10.7% (P&lt;0.05) compared with those in the untreated control PRL/PRF/5 cells.	Niclosamide	83-94	matrix metallopeptidase 9	Homo sapiens	31-35
26788160-12	2015	Similarly, expression level of MMP9 in the PRL/PRF/5 cells treated with 1.0 microm niclosamide deceased to 18.7+-10.7% (P&lt;0.05) compared with those in the untreated control PRL/PRF/5 cells.	Niclosamide	83-94	prolactin	Homo sapiens	43-46
26788160-12	2015	Similarly, expression level of MMP9 in the PRL/PRF/5 cells treated with 1.0 microm niclosamide deceased to 18.7+-10.7% (P&lt;0.05) compared with those in the untreated control PRL/PRF/5 cells.	Niclosamide	83-94	prolactin	Homo sapiens	176-179
26788160-13	2015	Overall, niclosamide downregulated the expression of MMP9 in and suppressed the migration of HCC cells.	Niclosamide	9-20	matrix metallopeptidase 9	Homo sapiens	53-57
26186072-11	2015	Western blot analysis showed decreased expression of Wnt/beta-catenin proteins with niclosamide and analog treatment in a dose-dependent fashion.	Niclosamide	84-95	catenin beta 1	Homo sapiens	57-69
26716739-4	2015	Niclosamide not only inhibits the Wnt/beta-catenin, mTORC1, STAT3, NF-kappaB and Notch signaling pathways, but also targets mitochondria in cancer cells to induce growth inhibition and apoptosis.	Niclosamide	0-11	catenin beta 1	Homo sapiens	38-50
26716739-4	2015	Niclosamide not only inhibits the Wnt/beta-catenin, mTORC1, STAT3, NF-kappaB and Notch signaling pathways, but also targets mitochondria in cancer cells to induce growth inhibition and apoptosis.	Niclosamide	0-11	CREB regulated transcription coactivator 1	Mus musculus	52-58
26716739-4	2015	Niclosamide not only inhibits the Wnt/beta-catenin, mTORC1, STAT3, NF-kappaB and Notch signaling pathways, but also targets mitochondria in cancer cells to induce growth inhibition and apoptosis.	Niclosamide	0-11	signal transducer and activator of transcription 3	Homo sapiens	60-65
26716739-4	2015	Niclosamide not only inhibits the Wnt/beta-catenin, mTORC1, STAT3, NF-kappaB and Notch signaling pathways, but also targets mitochondria in cancer cells to induce growth inhibition and apoptosis.	Niclosamide	0-11	nuclear factor kappa B subunit 1	Homo sapiens	67-76
26234907-7	2015	Our study demonstrated that the combination of niclosamide (1.5 muM) and Pd(II) complex (12.5, 25 and 50 muM) at 48 h has enhanced cytotoxic activity resulted from the induction of apoptosis (indicated by the presence of pyknotic nuclei, increments in M30 and over expression of proapoptotic genes of TNFRSF10A and FAS).	Niclosamide	47-58	latexin	Homo sapiens	64-67
26234907-7	2015	Our study demonstrated that the combination of niclosamide (1.5 muM) and Pd(II) complex (12.5, 25 and 50 muM) at 48 h has enhanced cytotoxic activity resulted from the induction of apoptosis (indicated by the presence of pyknotic nuclei, increments in M30 and over expression of proapoptotic genes of TNFRSF10A and FAS).	Niclosamide	47-58	latexin	Homo sapiens	105-108
26234907-7	2015	Our study demonstrated that the combination of niclosamide (1.5 muM) and Pd(II) complex (12.5, 25 and 50 muM) at 48 h has enhanced cytotoxic activity resulted from the induction of apoptosis (indicated by the presence of pyknotic nuclei, increments in M30 and over expression of proapoptotic genes of TNFRSF10A and FAS).	Niclosamide	47-58	TNF receptor superfamily member 10a	Homo sapiens	301-310
26234907-8	2015	Importantly, the addition of niclosamide resulted in the suppression of autophagy (proved by the decrease in ATG5 gene levels) that might have contributed to the enhanced cytotoxicity.	Niclosamide	29-40	autophagy related 5	Homo sapiens	109-113
26272032-0	2015	Structure-activity studies of Wnt/beta-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure.	Niclosamide	65-76	catenin beta 1	Homo sapiens	34-46
26272032-3	2015	We previously reported the FDA-approved anthelmintic drug Niclosamide inhibits Wnt/beta-catenin signaling and suppresses colon cancer cell growth in vitro and in vivo.	Niclosamide	58-69	catenin beta 1	Homo sapiens	83-95
26272032-4	2015	Niclosamide is a multi-functional drug that possesses important biological activity in addition to inhibition of Wnt/beta-catenin signaling.	Niclosamide	0-11	catenin beta 1	Homo sapiens	117-129
25970160-0	2015	Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition.	Niclosamide	0-11	signal transducer and activator of transcription 3	Homo sapiens	103-108
25970160-8	2015	RESULTS: In the present study, we found niclosamide, a previously identified novel inhibitor of androgen receptor variant (AR-V7), inhibited Stat3 phosphorylation, and expression of downstream target genes.	Niclosamide	40-51	signal transducer and activator of transcription 3	Homo sapiens	141-146
25970160-11	2015	Moreover, niclosamide reversed enzalutamide resistance by down-regulating Stat3 target gene expression Stat3and abrogating recruitment of AR to PSA promoter resulting in PSA inhibition.	Niclosamide	10-21	signal transducer and activator of transcription 3	Homo sapiens	74-79
25970160-13	2015	Niclosamide has the potential to target the IL6-Stat3-AR pathway to overcome enzalutamide resistance and inhibit migration and invasion in advanced prostate cancer.	Niclosamide	0-11	interleukin 6	Homo sapiens	44-47
25970160-13	2015	Niclosamide has the potential to target the IL6-Stat3-AR pathway to overcome enzalutamide resistance and inhibit migration and invasion in advanced prostate cancer.	Niclosamide	0-11	signal transducer and activator of transcription 3	Homo sapiens	48-53
26116531-6	2015	Consistent with niclosamide-mediated Tax degradation, this compound inhibited activities of MAPK/ERK1/2 and IkappaB kinases.	Niclosamide	16-27	mitogen-activated protein kinase 3	Homo sapiens	92-96
26116531-6	2015	Consistent with niclosamide-mediated Tax degradation, this compound inhibited activities of MAPK/ERK1/2 and IkappaB kinases.	Niclosamide	16-27	mitogen-activated protein kinase 3	Homo sapiens	97-103
25174399-0	2015	WNT7A/beta-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer.	Niclosamide	72-83	Wnt family member 7A	Homo sapiens	0-5
25174399-0	2015	WNT7A/beta-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer.	Niclosamide	72-83	catenin beta 1	Homo sapiens	6-18
25174399-8	2015	Niclosamide most efficiently abrogated WNT7A/beta-catenin signaling in our model, inhibited beta-catenin transcriptional activity and cell viability, and increased cell death.	Niclosamide	0-11	Wnt family member 7A	Homo sapiens	39-44
25174399-8	2015	Niclosamide most efficiently abrogated WNT7A/beta-catenin signaling in our model, inhibited beta-catenin transcriptional activity and cell viability, and increased cell death.	Niclosamide	0-11	catenin beta 1	Homo sapiens	45-57
25174399-8	2015	Niclosamide most efficiently abrogated WNT7A/beta-catenin signaling in our model, inhibited beta-catenin transcriptional activity and cell viability, and increased cell death.	Niclosamide	0-11	catenin beta 1	Homo sapiens	92-104
25174399-9	2015	Furthermore, niclosamide decreased cell migration following an increase in E-cadherin subsequent to decreased levels of SLUG.	Niclosamide	13-24	cadherin 1	Homo sapiens	75-85
25174399-9	2015	Furthermore, niclosamide decreased cell migration following an increase in E-cadherin subsequent to decreased levels of SLUG.	Niclosamide	13-24	snail family transcriptional repressor 2	Homo sapiens	120-124
25174399-10	2015	The effects of niclosamide on cell functions were more potent in WNT7A-overexpressing cells.	Niclosamide	15-26	Wnt family member 7A	Homo sapiens	65-70
26434865-5	2015	The signal transducer and activator of transcription (STAT) 3 inhibitors niclosamide and S3I-201 inhibited the STAT3 signal pathway, which is activated by bevacizumab.	Niclosamide	73-84	signal transducer and activator of transcription 3	Homo sapiens	111-116
25708600-1	2015	OBJECTIVES: This study evaluated the anti-inflammatory effect of niclosamide in tumor necrosis factor (TNF)-alpha-stimulated human rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) and inhibitory effects on migration and invasion in RA FLS and investigated the signal mechanism, and further explored the treatment activity of niclosamide on collagen-induced arthritis (CIA).	Niclosamide	65-76	tumor necrosis factor	Homo sapiens	80-113
25708600-6	2015	RESULTS: Niclosamide reduced the secretion of IL-1beta, IL-6, IL-8, IL-17A and IFN-gamma from TNF-alpha-induced RA FLS in a dose-dependent manner.	Niclosamide	9-20	interleukin 1 beta	Homo sapiens	46-54
25708600-6	2015	RESULTS: Niclosamide reduced the secretion of IL-1beta, IL-6, IL-8, IL-17A and IFN-gamma from TNF-alpha-induced RA FLS in a dose-dependent manner.	Niclosamide	9-20	interleukin 6	Homo sapiens	56-60
25708600-6	2015	RESULTS: Niclosamide reduced the secretion of IL-1beta, IL-6, IL-8, IL-17A and IFN-gamma from TNF-alpha-induced RA FLS in a dose-dependent manner.	Niclosamide	9-20	C-X-C motif chemokine ligand 8	Homo sapiens	62-66
25708600-6	2015	RESULTS: Niclosamide reduced the secretion of IL-1beta, IL-6, IL-8, IL-17A and IFN-gamma from TNF-alpha-induced RA FLS in a dose-dependent manner.	Niclosamide	9-20	interleukin 17A	Homo sapiens	68-74
25708600-6	2015	RESULTS: Niclosamide reduced the secretion of IL-1beta, IL-6, IL-8, IL-17A and IFN-gamma from TNF-alpha-induced RA FLS in a dose-dependent manner.	Niclosamide	9-20	interferon gamma	Homo sapiens	79-88
25708600-6	2015	RESULTS: Niclosamide reduced the secretion of IL-1beta, IL-6, IL-8, IL-17A and IFN-gamma from TNF-alpha-induced RA FLS in a dose-dependent manner.	Niclosamide	9-20	tumor necrosis factor	Homo sapiens	94-103
25708600-8	2015	Niclosamide decreased the phosphorylation of c-Jun N-terminal kinase and ERK in TNF-alpha-stimulated RA FLS and blocked TNF-alpha-induced IKK, IkappaBalpha phosphorylation and translocation of p65.	Niclosamide	0-11	mitogen-activated protein kinase 1	Homo sapiens	73-76
25708600-8	2015	Niclosamide decreased the phosphorylation of c-Jun N-terminal kinase and ERK in TNF-alpha-stimulated RA FLS and blocked TNF-alpha-induced IKK, IkappaBalpha phosphorylation and translocation of p65.	Niclosamide	0-11	tumor necrosis factor	Homo sapiens	80-89
25708600-8	2015	Niclosamide decreased the phosphorylation of c-Jun N-terminal kinase and ERK in TNF-alpha-stimulated RA FLS and blocked TNF-alpha-induced IKK, IkappaBalpha phosphorylation and translocation of p65.	Niclosamide	0-11	tumor necrosis factor	Homo sapiens	120-129
25708600-8	2015	Niclosamide decreased the phosphorylation of c-Jun N-terminal kinase and ERK in TNF-alpha-stimulated RA FLS and blocked TNF-alpha-induced IKK, IkappaBalpha phosphorylation and translocation of p65.	Niclosamide	0-11	NFKB inhibitor alpha	Homo sapiens	143-155
25708600-8	2015	Niclosamide decreased the phosphorylation of c-Jun N-terminal kinase and ERK in TNF-alpha-stimulated RA FLS and blocked TNF-alpha-induced IKK, IkappaBalpha phosphorylation and translocation of p65.	Niclosamide	0-11	RELA proto-oncogene, NF-kB subunit	Homo sapiens	193-196
26118906-10	2015	Analysis of niclosamide"s effect on 11 cancer-related signal pathway reporters reveals that three of them, the E2F1, AP1, and c-Myc-responsive reporters, are significantly inhibited.	Niclosamide	12-23	E2F transcription factor 1	Homo sapiens	111-115
26118906-10	2015	Analysis of niclosamide"s effect on 11 cancer-related signal pathway reporters reveals that three of them, the E2F1, AP1, and c-Myc-responsive reporters, are significantly inhibited.	Niclosamide	12-23	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	117-120
26118906-10	2015	Analysis of niclosamide"s effect on 11 cancer-related signal pathway reporters reveals that three of them, the E2F1, AP1, and c-Myc-responsive reporters, are significantly inhibited.	Niclosamide	12-23	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	126-131
26118906-13	2015	E2F1, and c-Myc in OS cells is effectively inhibited by niclosamide.	Niclosamide	56-67	E2F transcription factor 1 L homeolog	Xenopus laevis	0-4
26118906-13	2015	E2F1, and c-Myc in OS cells is effectively inhibited by niclosamide.	Niclosamide	56-67	MYC proto-oncogene, bHLH transcription factor L homeolog	Xenopus laevis	10-15
25093354-1	2014	Structural studies have been carried out of two solid forms of niclosamide [5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide, NCL], a widely used anthelmintic drug, namely niclosamide methanol monosolvate, C13H8Cl2N2O4 CH3OH or NCL MeOH, and niclosamide monohydrate, denoted HA.	Niclosamide	63-74	nucleolin	Homo sapiens	132-135
25093354-1	2014	Structural studies have been carried out of two solid forms of niclosamide [5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide, NCL], a widely used anthelmintic drug, namely niclosamide methanol monosolvate, C13H8Cl2N2O4 CH3OH or NCL MeOH, and niclosamide monohydrate, denoted HA.	Niclosamide	63-74	nucleolin	Homo sapiens	234-237
24740322-0	2014	Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.	Niclosamide	0-11	androgen receptor	Homo sapiens	21-38
24732808-4	2014	Niclosamide not only inhibits the Wnt/beta-catenin, mTORC1, STAT3, NF-kappaB and Notch signaling pathways, but also targets mitochondria in cancer cells to induce cell cycle arrest, growth inhibition and apoptosis.	Niclosamide	0-11	catenin beta 1	Homo sapiens	38-50
24732808-4	2014	Niclosamide not only inhibits the Wnt/beta-catenin, mTORC1, STAT3, NF-kappaB and Notch signaling pathways, but also targets mitochondria in cancer cells to induce cell cycle arrest, growth inhibition and apoptosis.	Niclosamide	0-11	CREB regulated transcription coactivator 1	Mus musculus	52-58
24732808-4	2014	Niclosamide not only inhibits the Wnt/beta-catenin, mTORC1, STAT3, NF-kappaB and Notch signaling pathways, but also targets mitochondria in cancer cells to induce cell cycle arrest, growth inhibition and apoptosis.	Niclosamide	0-11	signal transducer and activator of transcription 3	Homo sapiens	60-65
24732808-4	2014	Niclosamide not only inhibits the Wnt/beta-catenin, mTORC1, STAT3, NF-kappaB and Notch signaling pathways, but also targets mitochondria in cancer cells to induce cell cycle arrest, growth inhibition and apoptosis.	Niclosamide	0-11	nuclear factor kappa B subunit 1	Homo sapiens	67-76
24736023-0	2014	Inhibition of Wnt/beta-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.	Niclosamide	42-53	catenin beta 1	Homo sapiens	18-30
24736023-3	2014	Niclosamide, an FDA approved salicyclamide derivative used for the treatment of tapeworm infections, targets the Wnt/beta-catenin pathway.	Niclosamide	0-11	catenin beta 1	Homo sapiens	117-129
24736023-18	2014	This study demonstrates that niclosamide is a potent Wnt/beta-catenin inhibitor.	Niclosamide	29-40	catenin beta 1	Homo sapiens	57-69
24945434-5	2014	Treatment with STAT3 inhibitors, Stattic and Niclosamide, enhanced motor neuron differentiation only in FGF2-primed hNSCs, as shown by increased homeobox gene Hb9 mRNA levels as well as HB9+ and microtubule-associated protein 2 (MAP2)+ co-labeled cells.	Niclosamide	45-56	signal transducer and activator of transcription 3	Homo sapiens	15-20
24945434-5	2014	Treatment with STAT3 inhibitors, Stattic and Niclosamide, enhanced motor neuron differentiation only in FGF2-primed hNSCs, as shown by increased homeobox gene Hb9 mRNA levels as well as HB9+ and microtubule-associated protein 2 (MAP2)+ co-labeled cells.	Niclosamide	45-56	fibroblast growth factor 2	Homo sapiens	104-108
24945434-5	2014	Treatment with STAT3 inhibitors, Stattic and Niclosamide, enhanced motor neuron differentiation only in FGF2-primed hNSCs, as shown by increased homeobox gene Hb9 mRNA levels as well as HB9+ and microtubule-associated protein 2 (MAP2)+ co-labeled cells.	Niclosamide	45-56	motor neuron and pancreas homeobox 1	Homo sapiens	159-162
24945434-5	2014	Treatment with STAT3 inhibitors, Stattic and Niclosamide, enhanced motor neuron differentiation only in FGF2-primed hNSCs, as shown by increased homeobox gene Hb9 mRNA levels as well as HB9+ and microtubule-associated protein 2 (MAP2)+ co-labeled cells.	Niclosamide	45-56	motor neuron and pancreas homeobox 1	Homo sapiens	186-189
24945434-5	2014	Treatment with STAT3 inhibitors, Stattic and Niclosamide, enhanced motor neuron differentiation only in FGF2-primed hNSCs, as shown by increased homeobox gene Hb9 mRNA levels as well as HB9+ and microtubule-associated protein 2 (MAP2)+ co-labeled cells.	Niclosamide	45-56	microtubule associated protein 2	Homo sapiens	195-227
24945434-5	2014	Treatment with STAT3 inhibitors, Stattic and Niclosamide, enhanced motor neuron differentiation only in FGF2-primed hNSCs, as shown by increased homeobox gene Hb9 mRNA levels as well as HB9+ and microtubule-associated protein 2 (MAP2)+ co-labeled cells.	Niclosamide	45-56	microtubule associated protein 2	Homo sapiens	229-233
24945434-7	2014	Interestingly, Stattic and Niclosamide did not affect the level of STAT3 phosphorylation; rather, they perturbed the nuclear translocation of phosphorylated STAT3.	Niclosamide	27-38	signal transducer and activator of transcription 3	Homo sapiens	157-162
24740322-12	2014	CONCLUSIONS: Niclosamide was identified as a novel inhibitor of AR variants.	Niclosamide	13-24	androgen receptor	Homo sapiens	64-66
24740322-13	2014	Our findings offer preclinical validation of niclosamide as a promising inhibitor of AR variants to treat, either alone or in combination with current antiandrogen therapies, patients with advanced prostate cancer, especially those resistant to enzalutamide.	Niclosamide	45-56	androgen receptor	Homo sapiens	85-87
24750999-0	2014	Niclosamide enhances ROS-mediated cell death through c-Jun activation.	Niclosamide	0-11	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	53-58
24750999-6	2014	The combined treatment induced significantly more phosphorylation of p38 MAPK and c-Jun in H1299 cells than IR or niclosamide alone.	Niclosamide	114-125	mitogen-activated protein kinase 14	Homo sapiens	69-72
24750999-8	2014	Niclosamide pretreatment also induced c-Jun and its phosphorylation in the presence of H2O2, thereby enhancing apoptosis.	Niclosamide	0-11	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	38-43
24750999-10	2014	Knockdown of c-Jun also decreased PARP cleavage and clonogenic cell survival in niclosamide- and IR-treated H1299 cells.	Niclosamide	80-91	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	13-18
24750999-10	2014	Knockdown of c-Jun also decreased PARP cleavage and clonogenic cell survival in niclosamide- and IR-treated H1299 cells.	Niclosamide	80-91	collagen type XI alpha 2 chain	Homo sapiens	34-38
24750999-11	2014	Our findings suggest that niclosamide could be a promising radiosensitizer in lung cancer patients through activation of the p38 MAPK-c-Jun axis.	Niclosamide	26-37	mitogen-activated protein kinase 14	Homo sapiens	125-128
24750999-11	2014	Our findings suggest that niclosamide could be a promising radiosensitizer in lung cancer patients through activation of the p38 MAPK-c-Jun axis.	Niclosamide	26-37	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	134-139
24362463-0	2014	Disruption of STAT3 by niclosamide reverses radioresistance of human lung cancer.	Niclosamide	23-34	signal transducer and activator of transcription 3	Homo sapiens	14-19
24552774-5	2014	Niclosamide has been shown to inhibit the Wnt/beta-catenin signaling pathway by causing degradation of LRP6.	Niclosamide	0-11	catenin beta 1	Homo sapiens	46-58
24552774-5	2014	Niclosamide has been shown to inhibit the Wnt/beta-catenin signaling pathway by causing degradation of LRP6.	Niclosamide	0-11	LDL receptor related protein 6	Homo sapiens	103-107
24552774-11	2014	Niclosamide treatment produced reduced levels of LRP6 and beta-catenin, which is a downstream Wnt/beta-catenin signaling protein.	Niclosamide	0-11	LDL receptor related protein 6	Homo sapiens	49-53
24552774-11	2014	Niclosamide treatment produced reduced levels of LRP6 and beta-catenin, which is a downstream Wnt/beta-catenin signaling protein.	Niclosamide	0-11	catenin beta 1	Homo sapiens	58-70
24552774-11	2014	Niclosamide treatment produced reduced levels of LRP6 and beta-catenin, which is a downstream Wnt/beta-catenin signaling protein.	Niclosamide	0-11	catenin beta 1	Homo sapiens	98-110
24552774-12	2014	The combination of TRA-8 and niclosamide produced additive cytotoxicity and a reduction in Wnt/beta-catenin activity.	Niclosamide	29-40	catenin beta 1	Homo sapiens	95-107
24561310-3	2014	In this study, the effect of niclosamide, a Food and Drug Administration-approved antihelminthic drug, on the activation of lipopolysaccharide (LPS)-stimulated murine bone marrow-derived DCs was examined.	Niclosamide	29-40	toll-like receptor 4	Mus musculus	144-147
24561310-4	2014	Our experimental results show that niclosamide reduced the pro-inflammatory cytokine and chemokine expression of LPS-activated DCs.	Niclosamide	35-46	toll-like receptor 4	Mus musculus	113-116
24561310-6	2014	Therefore, in mixed cell cultures composed of syngeneic OVA-specific T cells and DCs, niclosamide-treated DCs showed a decreased ability to stimulate T cell proliferation and IFN-gamma production.	Niclosamide	86-97	interferon gamma	Mus musculus	175-184
24561310-8	2014	Blocking the LPS-induced activation of MAPK-ERK, JNK and NF-kappaB may contribute to the inhibitory effect of niclosamide on DC activation.	Niclosamide	110-121	toll-like receptor 4	Mus musculus	13-16
24561310-8	2014	Blocking the LPS-induced activation of MAPK-ERK, JNK and NF-kappaB may contribute to the inhibitory effect of niclosamide on DC activation.	Niclosamide	110-121	mitogen-activated protein kinase 8	Mus musculus	49-52
24561310-8	2014	Blocking the LPS-induced activation of MAPK-ERK, JNK and NF-kappaB may contribute to the inhibitory effect of niclosamide on DC activation.	Niclosamide	110-121	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	57-66
24362463-7	2014	Niclosamide, a potent STAT3 inhibitor, can reduce STAT3 nuclear localization in radioresistant lung cancer cells.	Niclosamide	0-11	signal transducer and activator of transcription 3	Homo sapiens	22-27
24362463-7	2014	Niclosamide, a potent STAT3 inhibitor, can reduce STAT3 nuclear localization in radioresistant lung cancer cells.	Niclosamide	0-11	signal transducer and activator of transcription 3	Homo sapiens	50-55
24362463-8	2014	Intriguingly, either inhibition of STAT3 activity by niclosamide or depletion of STAT3 by RNA interference reverses radioresistance in vitro.	Niclosamide	53-64	signal transducer and activator of transcription 3	Homo sapiens	35-40
23956140-0	2013	CYP1A1 and Cnr nitroreductase bioactivated niclosamide in vitro.	Niclosamide	43-54	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	0-6
24416452-7	2014	Moreover, niclosamide blocked breast cancer cells migration and invasion, and the reduction of phosphorylated STAT3(Tyr705), phosphorylated FAK(Tyr925) and phosphorylated Src(Tyr416) were also observed.	Niclosamide	10-21	signal transducer and activator of transcription 3	Mus musculus	110-115
24416452-7	2014	Moreover, niclosamide blocked breast cancer cells migration and invasion, and the reduction of phosphorylated STAT3(Tyr705), phosphorylated FAK(Tyr925) and phosphorylated Src(Tyr416) were also observed.	Niclosamide	10-21	PTK2 protein tyrosine kinase 2	Mus musculus	140-143
24416452-7	2014	Moreover, niclosamide blocked breast cancer cells migration and invasion, and the reduction of phosphorylated STAT3(Tyr705), phosphorylated FAK(Tyr925) and phosphorylated Src(Tyr416) were also observed.	Niclosamide	10-21	Rous sarcoma oncogene	Mus musculus	171-174
24273411-0	2013	Niclosamide suppresses Hepatoma cell proliferation via the Wnt pathway.	Niclosamide	0-11	Wnt family member 3A	Homo sapiens	59-62
24273411-2	2013	We analyzed the association of the Wnt pathway with the proliferation of hepatoma cells using Wnt3a and niclosamide, a drug used to treat tapeworm infection.	Niclosamide	104-115	Wnt family member 3A	Homo sapiens	35-38
24273411-11	2013	Cyclin D1 was upregulated in the presence of Wnt3a and downregulated with addition of niclosamide.	Niclosamide	86-97	cyclin D1	Homo sapiens	0-9
23894143-0	2013	Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.	Niclosamide	0-11	signal transducer and activator of transcription 3	Homo sapiens	78-83
23894143-7	2013	Both blockage of Tyr705 phosphorylation of STAT3 by niclosamide and depletion of STAT3 by RNA interference in HCC827/ER cells reverse erlotinib resistance.	Niclosamide	52-63	signal transducer and activator of transcription 3	Homo sapiens	43-48
24019973-0	2013	Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer.	Niclosamide	23-34	signal transducer and activator of transcription 3	Homo sapiens	14-19
24019973-6	2013	Pharmacological inhibition of STAT3 by niclosamide not only blocked erlotinib-stimulated STAT3 phosphorylation but also synergistically repressed head and neck cancer growth in vitro and in vivo.	Niclosamide	39-50	signal transducer and activator of transcription 3	Homo sapiens	30-35
24019973-6	2013	Pharmacological inhibition of STAT3 by niclosamide not only blocked erlotinib-stimulated STAT3 phosphorylation but also synergistically repressed head and neck cancer growth in vitro and in vivo.	Niclosamide	39-50	signal transducer and activator of transcription 3	Homo sapiens	89-94
24019973-7	2013	Combined inhibition of EGFR and STAT3 by erlotinib and niclosamide more effectively induced apoptosis in tumor tissues without toxicity for normal tissues.	Niclosamide	55-66	epidermal growth factor receptor	Homo sapiens	23-27
24019973-7	2013	Combined inhibition of EGFR and STAT3 by erlotinib and niclosamide more effectively induced apoptosis in tumor tissues without toxicity for normal tissues.	Niclosamide	55-66	signal transducer and activator of transcription 3	Homo sapiens	32-37
23908450-6	2013	Mechanism of action analysis revealed that niclosamide simultaneously inhibited intracellular WNT/CTNNB1-, NOTCH-, mTOR-, and NF-kappaB signaling cascades.	Niclosamide	43-54	catenin beta 1	Homo sapiens	98-104
23956140-6	2013	The incubation of niclosamide with CYP1A1 Supersomes  increased the number of revertants, suggesting that CYP1A1 is responsible for the bioactivation of niclosamide.	Niclosamide	18-29	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	35-41
23956140-6	2013	The incubation of niclosamide with CYP1A1 Supersomes  increased the number of revertants, suggesting that CYP1A1 is responsible for the bioactivation of niclosamide.	Niclosamide	18-29	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	106-112
23956140-6	2013	The incubation of niclosamide with CYP1A1 Supersomes  increased the number of revertants, suggesting that CYP1A1 is responsible for the bioactivation of niclosamide.	Niclosamide	153-164	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	35-41
23956140-6	2013	The incubation of niclosamide with CYP1A1 Supersomes  increased the number of revertants, suggesting that CYP1A1 is responsible for the bioactivation of niclosamide.	Niclosamide	153-164	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	106-112
23956140-8	2013	Our findings indicated that a metabolite, derived from the action of CYP1A1 and a nitroreduction-reaction process, has a key role in the bioactivation of niclosamide.	Niclosamide	154-165	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	69-75
23908450-6	2013	Mechanism of action analysis revealed that niclosamide simultaneously inhibited intracellular WNT/CTNNB1-, NOTCH-, mTOR-, and NF-kappaB signaling cascades.	Niclosamide	43-54	mechanistic target of rapamycin kinase	Homo sapiens	115-119
23908450-7	2013	Furthermore, combinatorial drug testing established that a heterozygous deletion of the NFKBIA locus in glioblastoma samples could serve as a genomic biomarker for predicting a synergistic activity of niclosamide with temozolomide, the current standard in glioblastoma therapy.	Niclosamide	201-212	NFKB inhibitor alpha	Homo sapiens	88-94
23453073-3	2013	Recently, we reported the FDA-approved anthelmintic drug Niclosamide inhibits Wnt/beta-catenin signaling by a unique mechanism, though the target responsible remains unknown.	Niclosamide	57-68	catenin beta 1	Homo sapiens	82-94
23453073-6	2013	Overall, these findings support efforts to identify the target of Niclosamide inhibition of Wnt/beta-catenin signaling and the discovery of potent and selective modulators to treat human disease.	Niclosamide	66-77	catenin beta 1	Homo sapiens	96-108
23459613-1	2013	Niclosamide has been identified to potently inhibit the activation, nuclear translocation, and transactivation of STAT3.	Niclosamide	0-11	signal transducer and activator of transcription 3	Homo sapiens	114-119
23333246-11	2013	Inhibiting this pathway by treatment with anti-IL-6 antibody (1 mug/ml) or niclosamide (0.5-2 muM)/LLL12 (5-10 muM) effectively prevented OCT-4 gene expression.	Niclosamide	75-86	POU class 5 homeobox 1	Homo sapiens	138-143
22474287-0	2012	Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling.	Niclosamide	31-42	CREB regulated transcription coactivator 1	Mus musculus	140-146
22474287-3	2012	We have recently identified niclosamide (a Food and Drug Administration-approved antihelminthic drug) as an inhibitor of mTORC1 signaling.	Niclosamide	28-39	CREB regulated transcription coactivator 1	Mus musculus	121-127
22474287-4	2012	In the present study, we explored possible mechanisms by which niclosamide may inhibit mTORC1 signaling.	Niclosamide	63-74	CREB regulated transcription coactivator 1	Mus musculus	87-93
22474287-5	2012	We tested whether niclosamide interferes with signaling cascades upstream of mTORC1, the catalytic activity of mTOR, or mTORC1 assembly.	Niclosamide	18-29	CREB regulated transcription coactivator 1	Mus musculus	77-83
22474287-5	2012	We tested whether niclosamide interferes with signaling cascades upstream of mTORC1, the catalytic activity of mTOR, or mTORC1 assembly.	Niclosamide	18-29	mechanistic target of rapamycin kinase	Homo sapiens	77-81
22474287-12	2012	Notably, analysis of five niclosamide analogs revealed that the structural features of niclosamide required for protonophoric activity are also essential for mTORC1 inhibition.	Niclosamide	26-37	CREB regulated transcription coactivator 1	Mus musculus	158-164
22474287-12	2012	Notably, analysis of five niclosamide analogs revealed that the structural features of niclosamide required for protonophoric activity are also essential for mTORC1 inhibition.	Niclosamide	87-98	CREB regulated transcription coactivator 1	Mus musculus	158-164
22474287-13	2012	Furthermore, lowering cytoplasmic pH by means other than niclosamide treatment (e.g. incubation with propionic acid or bicarbonate withdrawal) recapitulated the inhibitory effects of niclosamide on mTORC1 signaling, lending support to a possible role for cytoplasmic pH in the control of mTORC1.	Niclosamide	183-194	CREB regulated transcription coactivator 1	Mus musculus	198-204
22474287-13	2012	Furthermore, lowering cytoplasmic pH by means other than niclosamide treatment (e.g. incubation with propionic acid or bicarbonate withdrawal) recapitulated the inhibitory effects of niclosamide on mTORC1 signaling, lending support to a possible role for cytoplasmic pH in the control of mTORC1.	Niclosamide	183-194	CREB regulated transcription coactivator 1	Mus musculus	288-294
22237038-4	2012	Evidence supports that niclosamide targets multiple signaling pathways (NF-kappaB, Wnt/beta-catenin, Notch, ROS, mTORC1, and Stat3), most of which are closely involved with cancer stem cells.	Niclosamide	23-34	nuclear factor kappa B subunit 1	Homo sapiens	72-81
22237038-4	2012	Evidence supports that niclosamide targets multiple signaling pathways (NF-kappaB, Wnt/beta-catenin, Notch, ROS, mTORC1, and Stat3), most of which are closely involved with cancer stem cells.	Niclosamide	23-34	catenin beta 1	Homo sapiens	87-99
22237038-4	2012	Evidence supports that niclosamide targets multiple signaling pathways (NF-kappaB, Wnt/beta-catenin, Notch, ROS, mTORC1, and Stat3), most of which are closely involved with cancer stem cells.	Niclosamide	23-34	CREB regulated transcription coactivator 1	Mus musculus	113-119
22237038-4	2012	Evidence supports that niclosamide targets multiple signaling pathways (NF-kappaB, Wnt/beta-catenin, Notch, ROS, mTORC1, and Stat3), most of which are closely involved with cancer stem cells.	Niclosamide	23-34	signal transducer and activator of transcription 3	Homo sapiens	125-130
22799185-0	2012	[Effect of snail control of niclosamide by soil mixing and spraying methods in high dam of terrace].	Niclosamide	28-39	snail family transcriptional repressor 1	Homo sapiens	11-16
22799185-1	2012	The snail control efffect of niclosamide by soil mixing and spraying method were compared, and the results showed that the effects of the two methods were similar.	Niclosamide	29-40	snail family transcriptional repressor 1	Homo sapiens	4-9
22171093-7	2012	The antipsychotic drug loxapine and the anthelmintic drug niclosamide were both found to activate Slack channels, which was confirmed by using manual patch-clamp analyses (EC(50) = 4.4 muM and EC(50) = 2.9 muM, respectively).	Niclosamide	58-69	potassium sodium-activated channel subfamily T member 1	Homo sapiens	98-103
22171093-7	2012	The antipsychotic drug loxapine and the anthelmintic drug niclosamide were both found to activate Slack channels, which was confirmed by using manual patch-clamp analyses (EC(50) = 4.4 muM and EC(50) = 2.9 muM, respectively).	Niclosamide	58-69	latexin	Homo sapiens	185-188
22171093-7	2012	The antipsychotic drug loxapine and the anthelmintic drug niclosamide were both found to activate Slack channels, which was confirmed by using manual patch-clamp analyses (EC(50) = 4.4 muM and EC(50) = 2.9 muM, respectively).	Niclosamide	58-69	latexin	Homo sapiens	206-209
21752808-1	2012	Currently schistosomiasis transmission has been suppressed to low levels in many historically endemic areas of China by widespread use of praziquantel in human and bovine populations and application of niclosamide for snail control.	Niclosamide	202-213	snail family transcriptional repressor 1	Homo sapiens	218-223
21871175-3	2011	Niclosamide promoted mitochondrial fragmentation but this was blocked by down-regulation of Drp1.	Niclosamide	0-11	collapsin response mediator protein 1	Homo sapiens	92-96
22829072-8	2011	Niclosamide also modulated the nuclear factor-kappaB and STAT3 pathways in MM cells.	Niclosamide	0-11	signal transducer and activator of transcription 3	Homo sapiens	57-62
21871175-5	2011	Moreover, niclosamide led to apoptotic cell death by caspase-3 activation.	Niclosamide	10-21	caspase 3	Homo sapiens	53-62
21203451-9	2010	Niclosamide also precludes the accumulation of poly-ubiquitinated proteins and of p62 upon proteasome inhibition.	Niclosamide	0-11	nucleoporin 62	Homo sapiens	82-85
21685359-0	2011	Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer.	Niclosamide	31-42	S100 calcium binding protein A4	Mus musculus	46-52
21685359-9	2011	RESULTS: Reduced S100A4 mRNA and protein expression, and inhibited cell migration, invasion, proliferation, and colony formation were observed in niclosamide-treated colon cancer cells in vitro.	Niclosamide	146-157	S100 calcium binding protein A4	Mus musculus	17-23
21685359-12	2011	CONCLUSION: Niclosamide inhibits S100A4-induced metastasis formation in a mouse model of colon cancer and has therapeutic potential.	Niclosamide	12-23	S100 calcium binding protein A4	Mus musculus	33-39
21531761-2	2011	The antihelminth compound niclosamide downregulates components of the Wnt pathway, specifically Dishevelled-2 (Dvl2) expression, resulting in diminished downstream beta-catenin signaling.	Niclosamide	26-37	dishevelled segment polarity protein 2	Homo sapiens	96-109
21531761-2	2011	The antihelminth compound niclosamide downregulates components of the Wnt pathway, specifically Dishevelled-2 (Dvl2) expression, resulting in diminished downstream beta-catenin signaling.	Niclosamide	26-37	dishevelled segment polarity protein 2	Homo sapiens	111-115
21531761-2	2011	The antihelminth compound niclosamide downregulates components of the Wnt pathway, specifically Dishevelled-2 (Dvl2) expression, resulting in diminished downstream beta-catenin signaling.	Niclosamide	26-37	catenin beta 1	Homo sapiens	164-176
21531761-3	2011	In this study, we determined whether niclosamide could inhibit the Wnt/beta-catenin pathway in human CRCs and whether its inhibition might elicit antitumor effects in the presence of APC mutations.	Niclosamide	37-48	catenin beta 1	Homo sapiens	71-83
21531761-4	2011	We found that niclosamide inhibited Wnt/beta-catenin pathway activation, downregulated Dvl2, decreased downstream beta-catenin signaling, and exerted antiproliferative effects in human colon cancer cell lines and CRC cells isolated by surgical resection of metastatic disease, regardless of mutations in APC.	Niclosamide	14-25	catenin beta 1	Homo sapiens	40-52
21531761-4	2011	We found that niclosamide inhibited Wnt/beta-catenin pathway activation, downregulated Dvl2, decreased downstream beta-catenin signaling, and exerted antiproliferative effects in human colon cancer cell lines and CRC cells isolated by surgical resection of metastatic disease, regardless of mutations in APC.	Niclosamide	14-25	dishevelled segment polarity protein 2	Homo sapiens	87-91
21531761-4	2011	We found that niclosamide inhibited Wnt/beta-catenin pathway activation, downregulated Dvl2, decreased downstream beta-catenin signaling, and exerted antiproliferative effects in human colon cancer cell lines and CRC cells isolated by surgical resection of metastatic disease, regardless of mutations in APC.	Niclosamide	14-25	catenin beta 1	Homo sapiens	114-126
22195040-0	2011	Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/beta-catenin pathway.	Niclosamide	0-11	LDL receptor related protein 6	Homo sapiens	70-74
22195040-0	2011	Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/beta-catenin pathway.	Niclosamide	0-11	catenin beta 1	Homo sapiens	110-122
22195040-3	2011	Recently, the antihelminthic drug, niclosamide was found to inhibit Wnt/beta-catenin signaling, although the mechanism was not well defined.	Niclosamide	35-46	catenin beta 1	Homo sapiens	72-84
22195040-4	2011	We found that niclosamide was able to suppress LRP6 expression and phosphorylation, block Wnt3A-induced beta-catenin accumulation, and inhibit Wnt/beta-catenin signaling in HEK293 cells.	Niclosamide	14-25	LDL receptor related protein 6	Homo sapiens	47-51
22195040-4	2011	We found that niclosamide was able to suppress LRP6 expression and phosphorylation, block Wnt3A-induced beta-catenin accumulation, and inhibit Wnt/beta-catenin signaling in HEK293 cells.	Niclosamide	14-25	Wnt family member 3A	Homo sapiens	90-95
22195040-4	2011	We found that niclosamide was able to suppress LRP6 expression and phosphorylation, block Wnt3A-induced beta-catenin accumulation, and inhibit Wnt/beta-catenin signaling in HEK293 cells.	Niclosamide	14-25	catenin beta 1	Homo sapiens	104-116
22195040-4	2011	We found that niclosamide was able to suppress LRP6 expression and phosphorylation, block Wnt3A-induced beta-catenin accumulation, and inhibit Wnt/beta-catenin signaling in HEK293 cells.	Niclosamide	14-25	catenin beta 1	Homo sapiens	147-159
22195040-5	2011	Furthermore, the inhibitory effects of niclosamide on LRP6 expression/phosphorylation and Wnt/beta-catenin signaling were conformed in human prostate PC-3 and DU145 and breast MDA-MB-231 and T-47D cancer cells.	Niclosamide	39-50	LDL receptor related protein 6	Homo sapiens	54-58
22195040-6	2011	Moreover, we showed that the mechanism by which niclosamide suppressed LRP6 resulted from increased degradation as evident by a shorter half-life.	Niclosamide	48-59	LDL receptor related protein 6	Homo sapiens	71-75
22195040-9	2011	Our data indicate that niclosamide is a unique small molecule Wnt/beta-catenin signaling inhibitor targeting the Wnt co-receptor LRP6 on the cell surface, and that niclosamide has a potential to be developed a novel chemopreventive or therapeutic agent for human prostate and breast cancer.	Niclosamide	23-34	catenin beta 1	Homo sapiens	66-78
22195040-9	2011	Our data indicate that niclosamide is a unique small molecule Wnt/beta-catenin signaling inhibitor targeting the Wnt co-receptor LRP6 on the cell surface, and that niclosamide has a potential to be developed a novel chemopreventive or therapeutic agent for human prostate and breast cancer.	Niclosamide	23-34	LDL receptor related protein 6	Homo sapiens	129-133
21058733-9	2010	Surprisingly, a few of the compounds, carbazochrome and niclosamide, appeared to augment Abeta formation.	Niclosamide	56-67	amyloid beta precursor protein	Homo sapiens	89-94
24900231-0	2010	Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway.	Niclosamide	18-29	signal transducer and activator of transcription 3	Homo sapiens	71-76
24900231-2	2010	In this study, we report the identification of niclosamide, an FDA-approved anthelmintic drug, as a new small-molecule inhibitor of the STAT3 signaling pathway.	Niclosamide	47-58	signal transducer and activator of transcription 3	Homo sapiens	136-141
20215516-5	2010	Niclosamide inhibited the steps TAK1--&gt;IkappaB kinase (IKK) and IKK--&gt;IkappaBalpha.	Niclosamide	0-11	NFKB inhibitor alpha	Homo sapiens	76-88